NZ734084B2 - Heterocyclic compound and pharmaceutical composition comprising same - Google Patents
Heterocyclic compound and pharmaceutical composition comprising same Download PDFInfo
- Publication number
- NZ734084B2 NZ734084B2 NZ734084A NZ73408416A NZ734084B2 NZ 734084 B2 NZ734084 B2 NZ 734084B2 NZ 734084 A NZ734084 A NZ 734084A NZ 73408416 A NZ73408416 A NZ 73408416A NZ 734084 B2 NZ734084 B2 NZ 734084B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino
- bipyridin
- fluoro
- pyrimidinyl
- preparation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims abstract description 23
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims abstract description 23
- 208000014644 Brain disease Diseases 0.000 claims abstract description 11
- 230000003412 degenerative effect Effects 0.000 claims abstract description 11
- -1 hydroxy, amino Chemical group 0.000 claims description 560
- 150000001875 compounds Chemical class 0.000 claims description 478
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 229960004964 temozolomide Drugs 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Chemical group 0.000 claims description 11
- 150000002367 halogens Chemical group 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
- 108010069236 Goserelin Proteins 0.000 claims description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229960002833 aflibercept Drugs 0.000 claims description 2
- 108010081667 aflibercept Proteins 0.000 claims description 2
- 229960005310 aldesleukin Drugs 0.000 claims description 2
- 108700025316 aldesleukin Proteins 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003982 apatinib Drugs 0.000 claims description 2
- 229960003005 axitinib Drugs 0.000 claims description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002707 bendamustine Drugs 0.000 claims description 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 2
- 229960001081 benzatropine Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960003736 bosutinib Drugs 0.000 claims description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 2
- 229960002802 bromocriptine Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960001602 ceritinib Drugs 0.000 claims description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960005061 crizotinib Drugs 0.000 claims description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 2
- 229960003337 entacapone Drugs 0.000 claims description 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 2
- 229960003649 eribulin Drugs 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 229960003980 galantamine Drugs 0.000 claims description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960002913 goserelin Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 229960004502 levodopa Drugs 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 229960001786 megestrol Drugs 0.000 claims description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004640 memantine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims description 2
- 229960000513 necitumumab Drugs 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960003347 obinutuzumab Drugs 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 229960003278 osimertinib Drugs 0.000 claims description 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960004390 palbociclib Drugs 0.000 claims description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 229960001131 ponatinib Drugs 0.000 claims description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 2
- 229960003089 pramipexole Drugs 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 229960005253 procyclidine Drugs 0.000 claims description 2
- 229960002633 ramucirumab Drugs 0.000 claims description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 2
- 229960000245 rasagiline Drugs 0.000 claims description 2
- 229960004836 regorafenib Drugs 0.000 claims description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 229960001879 ropinirole Drugs 0.000 claims description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 2
- 229960003179 rotigotine Drugs 0.000 claims description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 2
- 229960003946 selegiline Drugs 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960000235 temsirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
- 229960005333 tetrabenazine Drugs 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002952 tipiracil Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229960003962 trifluridine Drugs 0.000 claims description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 362
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 323
- 239000000243 solution Substances 0.000 description 267
- 239000007787 solid Substances 0.000 description 154
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 126
- 238000000034 method Methods 0.000 description 117
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 111
- 235000019439 ethyl acetate Nutrition 0.000 description 109
- 229940093499 ethyl acetate Drugs 0.000 description 105
- 238000006243 chemical reaction Methods 0.000 description 100
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 80
- 230000002829 reductive effect Effects 0.000 description 69
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 67
- 239000003960 organic solvent Substances 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 60
- 239000012141 concentrate Substances 0.000 description 58
- 239000000203 mixture Substances 0.000 description 58
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 54
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 50
- 238000010898 silica gel chromatography Methods 0.000 description 49
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 238000010992 reflux Methods 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000012153 distilled water Substances 0.000 description 33
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 23
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical group [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 20
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 17
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 17
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 17
- 230000022131 cell cycle Effects 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 230000004614 tumor growth Effects 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 16
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 15
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 15
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 13
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 13
- 229960004132 diethyl ether Drugs 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetic acid ester Natural products CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 9
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 9
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 9
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229960000789 guanidine hydrochloride Drugs 0.000 description 9
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 9
- 102000013498 tau Proteins Human genes 0.000 description 9
- 108010026424 tau Proteins Proteins 0.000 description 9
- BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- MLOPJPKEWAYLTG-UHFFFAOYSA-N 1-piperidin-1-ium-1-ylethanone;chloride Chemical compound Cl.CC(=O)N1CCCCC1 MLOPJPKEWAYLTG-UHFFFAOYSA-N 0.000 description 7
- KOMBMTNSAYBOBS-UHFFFAOYSA-N 3,5-bis(2-aminopyrimidin-4-yl)-1H-pyrazin-2-one Chemical compound NC1=NC=CC(=N1)C=1C(=NC=C(N=1)C1=NC(=NC=C1)N)O KOMBMTNSAYBOBS-UHFFFAOYSA-N 0.000 description 7
- VOXVQOIOEDYHIY-UHFFFAOYSA-N 3,5-bis(2-aminopyrimidin-4-yl)-1H-pyridin-2-one Chemical compound NC1=NC=CC(=N1)C=1C(=NC=C(C=1)C1=NC(=NC=C1)N)O VOXVQOIOEDYHIY-UHFFFAOYSA-N 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- PIBWDIRYSTUYLL-UHFFFAOYSA-N tert-butyl N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C1=NC=CC(=C1F)B1OC(C(O1)(C)C)(C)C PIBWDIRYSTUYLL-UHFFFAOYSA-N 0.000 description 7
- SSUJUUNLZQVZMO-UHFFFAOYSA-N 1,2,3,4,8,9,10,10a-octahydropyrimido[1,2-a]azepine Chemical compound C1CCC=CN2CCCNC21 SSUJUUNLZQVZMO-UHFFFAOYSA-N 0.000 description 6
- IQQRAVYLUAZUGX-UHFFFAOYSA-N 1-butyl-3-methylimidazolium Chemical compound CCCCN1C=C[N+](C)=C1 IQQRAVYLUAZUGX-UHFFFAOYSA-N 0.000 description 6
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 6
- VOMMPWVMVDGZEM-UHFFFAOYSA-N 6-bromo-1h-pyridin-2-one Chemical compound OC1=CC=CC(Br)=N1 VOMMPWVMVDGZEM-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 6
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- UCIDOGOHQAWWND-UHFFFAOYSA-N NC1=CC=CC(=N1)C1=NC=CC(=C1O)C1=NC(=NC=C1)N Chemical compound NC1=CC=CC(=N1)C1=NC=CC(=C1O)C1=NC(=NC=C1)N UCIDOGOHQAWWND-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- HYCXTOBEOJOJRJ-UHFFFAOYSA-N 1-(2-acetyl-5-methoxypyridin-4-yl)ethanone Chemical compound COC=1C(=CC(=NC=1)C(C)=O)C(C)=O HYCXTOBEOJOJRJ-UHFFFAOYSA-N 0.000 description 5
- XPEYPWCAHZHXCY-UHFFFAOYSA-N 1-(6-acetyl-5-methoxypyrazin-2-yl)ethanone Chemical compound COC=1C(=NC(=CN=1)C(C)=O)C(C)=O XPEYPWCAHZHXCY-UHFFFAOYSA-N 0.000 description 5
- QAZVYTPODHCIBB-UHFFFAOYSA-N 1-(6-acetyl-5-methoxypyridin-2-yl)ethanone Chemical compound COC=1C(=NC(=CC=1)C(C)=O)C(C)=O QAZVYTPODHCIBB-UHFFFAOYSA-N 0.000 description 5
- WAPBWMNFSOOTGB-UHFFFAOYSA-N 1-piperidin-1-ylpropan-2-one Chemical compound CC(=O)CN1CCCCC1 WAPBWMNFSOOTGB-UHFFFAOYSA-N 0.000 description 5
- XTVFTOVNAKNVQK-UHFFFAOYSA-N 3-hydroxypyridine-2-carbonitrile Chemical compound OC1=CC=CN=C1C#N XTVFTOVNAKNVQK-UHFFFAOYSA-N 0.000 description 5
- UREMOXFNMQZKHW-UHFFFAOYSA-N 4,6-dibromo-3-hydroxypyridine-2-carbonitrile Chemical compound BrC1=C(C(=NC(=C1)Br)C#N)O UREMOXFNMQZKHW-UHFFFAOYSA-N 0.000 description 5
- JIBQBBIDFPMXLE-UHFFFAOYSA-N 6-(bromomethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(OCBr)=N1 JIBQBBIDFPMXLE-UHFFFAOYSA-N 0.000 description 5
- URQDSJADXDTJNN-UHFFFAOYSA-N 6-bromo-N,5-dimethoxy-N-methylpyridine-2-carboxamide Chemical compound BrC1=C(C=CC(=N1)C(=O)N(C)OC)OC URQDSJADXDTJNN-UHFFFAOYSA-N 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 5
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 5
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 5
- 230000004668 G2/M phase Effects 0.000 description 5
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- VHHPDZDTKZOHTB-UHFFFAOYSA-M [Br-].[Mg+]C.C1CCOC1 Chemical compound [Br-].[Mg+]C.C1CCOC1 VHHPDZDTKZOHTB-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 5
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- JJFAXQMDKIUTID-UHFFFAOYSA-N 1-(1-methylpiperidin-2-yl)ethanone Chemical compound CN1CCCCC1C(C)=O JJFAXQMDKIUTID-UHFFFAOYSA-N 0.000 description 4
- KDISMIMTGUMORD-UHFFFAOYSA-N 1-acetylpiperidine Chemical compound CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 4
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- SWANGJKVFWUKPO-UHFFFAOYSA-N 4-[2-(2-aminopyrimidin-4-yl)-5-methoxypyridin-4-yl]pyrimidin-2-amine Chemical compound COC=1C(=CC(=NC=1)C1=NC(=NC=C1)N)C1=NC(=NC=C1)N SWANGJKVFWUKPO-UHFFFAOYSA-N 0.000 description 4
- TYSWHTXRYNHCSZ-UHFFFAOYSA-N 4-[6-(2-aminopyrimidin-4-yl)-5-methoxypyrazin-2-yl]pyrimidin-2-amine Chemical compound COC=1C(=NC(=CN=1)C1=NC(=NC=C1)N)C1=NC(=NC=C1)N TYSWHTXRYNHCSZ-UHFFFAOYSA-N 0.000 description 4
- CIIXITNFSKVRMJ-UHFFFAOYSA-N 4-[6-(2-aminopyrimidin-4-yl)-5-methoxypyridin-2-yl]pyrimidin-2-amine Chemical compound COC=1C(=NC(=CC=1)C1=NC(=NC=C1)N)C1=NC(=NC=C1)N CIIXITNFSKVRMJ-UHFFFAOYSA-N 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- BKJLEYGSIVRWDG-UHFFFAOYSA-N ClCOC1=CC=NC(OCCl)=N1 Chemical compound ClCOC1=CC=NC(OCCl)=N1 BKJLEYGSIVRWDG-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 102000006947 Histones Human genes 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- TYHJMEIBGDDCPA-UHFFFAOYSA-N N-Methylpelletierine Chemical compound CN1CCCCC1CC(C)=O TYHJMEIBGDDCPA-UHFFFAOYSA-N 0.000 description 4
- NLMZIHYIBAEQQT-UHFFFAOYSA-N OC1(CBr)NC=CC=C1 Chemical compound OC1(CBr)NC=CC=C1 NLMZIHYIBAEQQT-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 4
- MHKKUZDJUGIOBC-UHFFFAOYSA-N methyl 3-hydroxypyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1O MHKKUZDJUGIOBC-UHFFFAOYSA-N 0.000 description 4
- UGFPNFKMYRHGBG-UHFFFAOYSA-N methyl 6-bromo-3-hydroxypyridine-2-carboxylate Chemical compound COC(=O)C1=NC(Br)=CC=C1O UGFPNFKMYRHGBG-UHFFFAOYSA-N 0.000 description 4
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 102200082402 rs751610198 Human genes 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- SAAGMIHGVLKZBC-UHFFFAOYSA-N tert-butyl n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC(C)(C)C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 SAAGMIHGVLKZBC-UHFFFAOYSA-N 0.000 description 4
- 229940053867 xeloda Drugs 0.000 description 4
- IEKKJXBNKVUQLJ-UHFFFAOYSA-N 1-(4,6-dibromo-3-hydroxypyridin-2-yl)ethanone Chemical compound BrC1=C(C(=NC(=C1)Br)C(C)=O)O IEKKJXBNKVUQLJ-UHFFFAOYSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 3
- YLUXVJLSOLVQSK-UHFFFAOYSA-N 4-[5-(2-aminopyrimidin-4-yl)-6-methoxypyridin-3-yl]pyrimidin-2-amine Chemical compound COC1=NC=C(C=C1C1=NC(=NC=C1)N)C1=NC(=NC=C1)N YLUXVJLSOLVQSK-UHFFFAOYSA-N 0.000 description 3
- KDBBKFWKXHVPKZ-UHFFFAOYSA-N 4-piperidin-1-ylpyrimidin-2-amine Chemical compound NC1=NC=CC(N2CCCCC2)=N1 KDBBKFWKXHVPKZ-UHFFFAOYSA-N 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
- UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N methylguanidine Chemical compound CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 2
- LVNKZMOQKBGRDX-UHFFFAOYSA-N 1-(6-bromo-3-hydroxypyridin-2-yl)ethanone Chemical compound CC(=O)C1=NC(Br)=CC=C1O LVNKZMOQKBGRDX-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- VFIKPDSQDNROGM-UHFFFAOYSA-N 2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C1=CC(OC)=CC=C1B1OC(C)(C)C(C)(C)O1 VFIKPDSQDNROGM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- HTWIZMNMTWYQRN-UHFFFAOYSA-N 2-methyl-1,3-dioxolane Chemical compound CC1OCCO1 HTWIZMNMTWYQRN-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 2
- MYDKGRAWYIGOGE-UHFFFAOYSA-N 4-n,4-n-dimethylpyrimidine-2,4-diamine Chemical compound CN(C)C1=CC=NC(N)=N1 MYDKGRAWYIGOGE-UHFFFAOYSA-N 0.000 description 2
- UOBVFHWGKOPJQM-UHFFFAOYSA-N 6-(2-aminopyrimidin-4-yl)-2-[6-(methylamino)pyridin-2-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=CC=C(C(=N1)C1=NC(=CC=C1)NC)O UOBVFHWGKOPJQM-UHFFFAOYSA-N 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- LBUCAVGFSDCKGK-UHFFFAOYSA-N 6-bromo-3-hydroxypyridine-2-carbonitrile Chemical compound OC1=CC=C(Br)N=C1C#N LBUCAVGFSDCKGK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000020584 Polyploidy Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000004036 acetal group Chemical group 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000002608 ionic liquid Substances 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OYVXVLSZQHSNDK-UHFFFAOYSA-N n-methoxy-n-methylacetamide Chemical compound CON(C)C(C)=O OYVXVLSZQHSNDK-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- HBPFYUJYVZKPRQ-UHFFFAOYSA-N tert-butyl 4-butanoylpiperidine-1-carboxylate Chemical compound CCCC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 HBPFYUJYVZKPRQ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 2
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- POJLCQLDAGLUSH-UHFFFAOYSA-N 1-(oxan-2-yl)ethanone Chemical compound CC(=O)C1CCCCO1 POJLCQLDAGLUSH-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- DMKREZLZDOSDQU-UHFFFAOYSA-N 2-(3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 DMKREZLZDOSDQU-UHFFFAOYSA-N 0.000 description 1
- SVEMSRNKBCBDRI-UHFFFAOYSA-N 2-(bromomethoxy)pyridine Chemical compound BrCOC1=CC=CC=N1 SVEMSRNKBCBDRI-UHFFFAOYSA-N 0.000 description 1
- WSLKGSKMHNGLJY-UHFFFAOYSA-N 2-[3-(fluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound FCOC=1C=C(C=CC=1)B1OC(C(O1)(C)C)(C)C WSLKGSKMHNGLJY-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- BFGYEELOTIPRDF-UHFFFAOYSA-N 2-chloro-N-methyl-1,3-thiazol-4-amine Chemical compound ClC=1SC=C(N=1)NC BFGYEELOTIPRDF-UHFFFAOYSA-N 0.000 description 1
- XEMDFESAXKSEGI-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CN=C1 XEMDFESAXKSEGI-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DCYKWKYBNWRLLZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC(N)=C1 DCYKWKYBNWRLLZ-UHFFFAOYSA-N 0.000 description 1
- NLTIETZTDSJANS-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC=C1 NLTIETZTDSJANS-UHFFFAOYSA-N 0.000 description 1
- GNJKJKBURMCLOR-UHFFFAOYSA-N 4-chloro-2-fluoropyridine Chemical compound FC1=CC(Cl)=CC=N1 GNJKJKBURMCLOR-UHFFFAOYSA-N 0.000 description 1
- LNKODIBGKHYUKU-UHFFFAOYSA-N 4-chloro-3-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC(Cl)=C1F LNKODIBGKHYUKU-UHFFFAOYSA-N 0.000 description 1
- UMUSFEOPXQLLAG-UHFFFAOYSA-N 4-morpholin-4-ylpyrimidin-2-amine Chemical compound NC1=NC=CC(N2CCOCC2)=N1 UMUSFEOPXQLLAG-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UPFGHTKSBBCMBW-UHFFFAOYSA-N CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C1=NC=CC(=C1O)B1OC(C(O1)(C)C)(C)C Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C1=NC=CC(=C1O)B1OC(C(O1)(C)C)(C)C UPFGHTKSBBCMBW-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LUECSWUDJNBRAD-UHFFFAOYSA-N ClC1=C(C(=NC=C1)C(=O)O)F.C(C)(C)(C)OC(NC1=NC=CC(=C1F)Cl)=O Chemical compound ClC1=C(C(=NC=C1)C(=O)O)F.C(C)(C)(C)OC(NC1=NC=CC(=C1F)Cl)=O LUECSWUDJNBRAD-UHFFFAOYSA-N 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 101150085091 lat-2 gene Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- YSMZEMQBSONIMJ-UHFFFAOYSA-M magnesium;2-methanidylpropane;chloride Chemical compound [Mg+2].[Cl-].CC(C)[CH2-] YSMZEMQBSONIMJ-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- PKAUVIXBZJUYRV-UHFFFAOYSA-N methane;hydroiodide Chemical compound C.I PKAUVIXBZJUYRV-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 125000005402 stannate group Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BYYHZPIPLAIBOA-UHFFFAOYSA-N tert-butyl 2-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate Chemical compound CON(C)C(=O)C1CCCCN1C(=O)OC(C)(C)C BYYHZPIPLAIBOA-UHFFFAOYSA-N 0.000 description 1
- HNVBBNZWMSTMAZ-UHFFFAOYSA-N tert-butyl 4-acetylpiperidine-1-carboxylate Chemical compound CC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 HNVBBNZWMSTMAZ-UHFFFAOYSA-N 0.000 description 1
- VKWKEJQTFWNTNI-UHFFFAOYSA-N tert-butyl N-(4-chloro-3-fluoropyridin-2-yl)carbamate Chemical compound ClC1=C(C(=NC=C1)NC(OC(C)(C)C)=O)F VKWKEJQTFWNTNI-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-M vanillate Chemical compound COC1=CC(C([O-])=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-M 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
The present invention relates to a novel heterocyclic compound capable of suppressing activity of cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an active ingredient. The heterocyclic compound according to the present invention and a pharmaceutically acceptable salt thereof can be effectively used in treatment or prevention of cancers, degenerative brain diseases, etc.
Description
?DESCRIPTION? ?Invention Title? Heterocyclic compound and pharmaceutical composition comprising the same ?Technical Field? The present invention relates to a novel heterocyclic compound inhibiting the activity of a cyclin-dependent kinase(CDK) and a pharmaceutical composition comprising the same as an effective ingredient.
?Background Art? A cyclin-dependent kinase (CDK) is a serine/threonine kinase and binds to a cyclin to form a complex which has kinase activity and substrate specificity. A CDK is known as a kinase regulating the cell cycle through an interaction with various cyclins. Further, a CDK is also involved in transcription regulation, epigenetic regulation, metabolism regulation, stem cell self-renewal, neuronal function, etc. (Lim S, et al., Development, 2013, 140(15): 3079-93).
There are 16 CDK isotypes and they play an important role in the cell cycle regulation or transcription regulation depending on the isotype. In particular, CDK1 and CDK2 among CDKs regulating the cell cycle play an important role in a mitosis. CDK2 induces DNA synthesis in S phase and the progression through the cell cycle. CDK1 is involved in the formation of many factors to drive M phase. Accordingly, abnormality of a CDK may cause various cancers. An anticancer agent targeted to CDK abnormality will be effective in treating blood cancers including acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM), Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, and solid cancers including non- small cell lung cancer, small cell lung cancer, gastric cancer, pancreas cancer, glioma, colon cancer, breast cancer, head and neck squamous cell cancer, liver cancer, melanoma, uterine cancer, prostate cancer, ovarian cancer, thyroid cancer, biliary tract cancer, gallbladder cancer, bladder cancer, kidney cancer, esophageal cancer, etc. (Pitts TM, et al., Pharmacol Ther., 2014, 142(2): 58-69).
CDK5, which is not involved in the regulation of the cell cycle or a transcription, is mostly distributed in a brain, and is activated by binding to p25 which is stable in a cell, resulting in continuous activity and thus various degenerative brain diseases. A substance inhibiting CDK5 activity will be useful for treating Alzheimer’s disease, Parkinson’s disease, and Huntington’s chorea. In particular, Alzheimer’s disease is caused by the neurodegeneration which is the result of the formation of neurofibrillary tangles (NFT) and amyloid plaques, and CDK5 is important for their formation. CDK5 phosphorylates the serin or threonine residues at Thr181, Ser199, Ser202, Thr212, Ser214, Thr231, Ser235, Ser396, and Ser404 of tau protein and tau protein hyperphosphorylated by CDK5 forms a neurofibrillary tangle (NFT). Amyloid plaque is formed by accumulation of A ß(amyloid beta protein) which is produced by degradation of Amyloid precursor protein (APP) by the aspartic proteases, ß-secretase and ?-secretase, in a brain. In this regard, CDK5 phosphorylates Thr668 residue of APP so that APP can be degraded by ß-secretase. Therefore, it is necessary to develop a compound which can inhibit CDK5 activity and thus prevent and treat degenerative brain diseases such as Alzheimer’s disease cuased by excessive action of CDK5 (Cruz JC, et al., Trends Mol Med., 2004, 10(9): 452-8).
?Disclosure? ?Technical Problem? The present inventors have extensively studied to develop a novel CDK inhibitor. As a result, they discovered that a heterocyclic compound of the following formula (I) shows an excellent CDK inhibitory effect in an in vitro experiment and an animal model experiment and thus can be used for the prevention and treatment of cancers, degenerative brain diseases, etc.
An object of the present invention is, therefore, to provide a compound of the following formula (I) having an excellent CDK inhibitory effect or pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide a pharmaceutical composition comprising the compound of the above formula (I) or pharmaceutically acceptable salt thereof.
?Technical Solution? One aspect of the present invention relates to a compound of the following formula (I) or pharmaceutically acceptable salt thereof. wherein, X, Y and Z are each independently carbon, nitrogen, oxygen or sulfur; R is aryl; R is hydrogen or C -C alkyl; and 2 1 6 R is aryl.
The term "C -C alkyl" as used herein means a straight or branched hydrocarbon having 1 to 6 carbon atoms, which includes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, n-hexyl, etc. but is not limited thereto.
The term "aryl" as used herein includes all of aromatic group, heteroaromatic group and partially reduced derivatives thereof. The aromatic group means a 5 to 15-membered simple or fused ring. The heteroaromatic group means an aromatic group containing at least one atom selected from oxygen, sulfur and nitrogen. Examples of the aryl include phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, furanyl, thiophenyl, pyrrolyl, indolyl, quinolinyl, imidazolinyl, oxazolyl, thiazolyl, triazolyl, tetrahydronaphthyl, etc., but are not limited thereto.
The term "C -C cycloalkyl" as used herein means a simple or fused cyclic hydrocarbon having 3 to 10 carbon atoms, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. but is not limited thereto.
The term "C -C heterocycloalkyl" as used herein means a simple or fused cyclic hydrocarbon having 3 to 10 carbon atoms wherein one or more cyclic carbon atoms are substituted with oxygen, sulfur or nitrogen, which includes tetrahydropyranyl, piperidinyl, morpholino, piperazinyl, etc,, but are not limited thereto.
One or more hydrogens of the C -C alkyl, C -C cycloalkyl, C -C heterocycloalkyl 1 6 3 10 3 10 and aryl may be substituted with C -C alkyl, C -C alkenyl, C -C alkynyl, C -C cycloalkyl, 1 6 2 6 2 6 3 10 C -C heterocycloalkyl, C -C heterocycloalkyloxy, C -C haloalkyl, C -C alkoxy, C -C 3 10 3 10 1 6 1 6 1 6 thioalkoxy, aryl, acyl, hydroxy, thio, halogen, amino, C -C alkylamino, alkoxycarbonyl, carboxy, carbamoyl, cyano, nitro, etc.
In one embodiment of the present invention, the compound has formula (I) wherein, X, Y and Z are each independently carbon or nitrogen; R is 5- or 6-membered aromatic or heteroaromatic group substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C 1 6 3 10 cycloalkyl, C -C heterocycloalkyl, hydroxy, C -C alkoxy, amino, C -C alkylamino, halogen 3 10 1 6 1 6 and nitro; R is hydrogen or C -C alkyl; and 2 1 6 R is 5- or 6-membered aromatic or heteroaromatic group substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C 1 6 3 10 cycloalkyl, C -C heterocycloalkyl, hydroxy, C -C alkoxy, amino, C -C alkylamino, halogen 3 10 1 6 1 6 and nitro.
In one embodiment of the present invention, the compound has formula (I) wherein, X, Y and Z are each independently carbon or nitrogen; R is 5- or 6-membered aromatic or heteroaromatic group substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C 1 6 3 10 cycloalkyl, C -C heterocycloalkyl, hydroxy, C -C alkoxy, amino, C -C alkylamino, halogen 3 10 1 6 1 6 and nitro; R is hydrogen or C -C alkyl; and 2 1 6 R is 5- or 6-membered heteroaromatic group substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C cycloalkyl, C -C 1 6 3 10 3 10 heterocycloalkyl, hydroxy, C -C alkoxy, amino, C -C alkylamino, halogen and nitro. 1 6 1 6 In one embodiment of the present invention, the compound has formula (I) wherein, X, Y and Z are each independently carbon or nitrogen; R is phenyl, pyridine, or pyrimidine substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C cycloalkyl, C -C 1 6 3 10 3 10 heterocycloalkyl, hydroxy, C -C alkoxy, amino, C -C alkylamino, halogen and nitro; 1 6 1 6 R is hydrogen; and R is pyridine, pyrimidine or thiazol substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C cycloalkyl, C -C 1 6 3 10 3 10 heterocycloalkyl, hydroxy, C -C alkoxy, amino, C -C alkylamino, halogen and nitro. 1 6 1 6 In one embodiment of the present invention, the compound has formula (I) wherein, X, Y and Z are each independently carbon or nitrogen; R is phenyl, pyridine, or pyrimidine substituted or unsubstituted with one or more substituents selected from the group consisting of hydroxy, amino and halogen; R is hydrogen; and R is pyrimidine substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, C -C heterocycloalkyl, amino, C -C alkylamino and 1 6 3 10 1 6 halogen.
In one embodiment of the present invention, the compound has formula (I) wherein, X is nitrogen; and Y and Z are carbon.
In one embodiment of the present invention, the compound has formula (I) wherein, Y is nitrogen; and X and Z are carbon.
In one embodiment of the present invention, the compound has formula (I) wherein, Z is nitrogen; and X and Y are carbon.
In one embodiment of the present invention, the compound has formula (I) wherein, X and Y are nitrogen; and Z is carbon.
In one embodiment of the present invention, the compound has formula (I) wherein, X and Z are nitrogen; and Y is carbon.
The pharmaceutically acceptable salt of the present invention may include salts of nontoxic inorganic acid and organic acid such as hydrochloride, phosphate, sulfate, nitrate, stannate, methanesulfonate, p-toluensulfonate, acetate, trifluoroacetate, citrate, maleate, succinate, oxalate, benzoate, tartrate, fumarate, mandelate, propionate, lactate, glycolate, gluconate, galacturonate, glutamate, glutarate, glucuronate, aspartate, ascorbate, carbonate, vanillate, hydroiodate, malate, malonate, etc.
The representative compounds according to the present invention are selected from the following group. 2,6-bis(2-aminopyrimidinyl)pyridinol; 3,5-bis(2-aminopyrimidinyl)pyrazinol; 4,6-bis(2-aminopyrimidinyl)pyridinol; 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]ol; 2'-amino(2-aminopyridinyl)-[4,4'-bipyrimidin]ol; 3,5-bis(2-aminopyrimidinyl)pyridinol; 6'-amino(2-aminopyrimidinyl)-[2,2'-bipyridin]ol; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2-(2-aminopyrimidinyl)(4-hydroxyphenyl)pyridinol; 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]ol; 6-(2-aminopyrimidinyl)-[2,3'-bipyridin]ol; 6-(2-aminopyrimidinyl)-[2,4'-bipyridin]ol; 2-(2-aminopyrimidinyl)(3-hydroxyphenyl)pyridinol; 6-(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 6-(4-aminofluorophenyl)(2-aminopyrimidinyl)pyridinol; 6-(3-aminophenyl)(2-aminopyrimidinyl)pyridinol; 2-(2-aminopyrimidinyl)(2-fluorohydroxyphenyl)pyridinol; 6-(3-aminofluorophenyl)(2-aminopyrimidinyl)pyridinol; 2-(2-aminopyrimidinyl)(3-fluorohydroxyphenyl)pyridinol; 2-(2-aminopyrimidinyl)(2,3-difluorohydroxyphenyl)pyridinol; 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]-3',5-diol; 6-(2-aminopyrimidinyl)(4-(methylamino)thiazolyl)pyridinol; 6-(2-aminopyrimidinyl)-6'-(methylamino)-[2,2'-bipyridin]ol; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 6-(2-aminomethylpyrimidinyl)-[2,4'-bipyridin]ol; 6-(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4’-bipyridin]ol; 2-(2-aminomethylpyrimidinyl)(4-hydroxyphenyl)pyridinol; 2-(2-aminomethylpyrimidinyl)(2,3-difluorohydroxyphenyl)pyridinol; 2-(2-aminomethylpyrimidinyl)(2-fluorohydroxyphenyl)pyridinol; 2-(2-aminomethylpyrimidinyl)(3-aminophenyl)pyridinol; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(tetrahydro-2H-pyranyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(piperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- -ol; 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- -ol; 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-amino(1-ethylpiperidinyl)methylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-aminoethyl(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)propylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-aminomorpholinopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(dimethylamino)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(4-methylpiperazinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 6-(2-aminochloropyrimidinyl)-[2,4'-bipyridin]ol; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-aminoethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-aminopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino-3'-fluoro(2-(methylamino)(1-methylpiperidinyl)pyrimidinyl)-[2,4'- bipyridin]ol; 2'-amino(2-amino-5,6-dimethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2,6-bis(2-aminopyrimidinyl)pyridinol 3hydrochloride; 2,6-bis(2-aminopyrimidinyl)pyridinol oxalate; 2,6-bis(2-aminopyrimidinyl)pyridinol malonate; 2,6-bis(2-aminopyrimidinyl)pyridinol sulfate; 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]ol oxalate; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol oxalate; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 2malonate; 2-(2-aminopyrimidinyl)(2-fluorohydroxyphenyl)pyridinol 2hydrochloride; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminomorpholinopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomorpholinopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate; 2'-amino(2-amino(dimethylamino)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-amino(4-methylpiperazinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 5hydrochloride; 2'-amino(2-amino(4-methylpiperazinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol acetate; 2'-amino(2-amino-(6-(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 2acetate; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol oxalate; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol malonate; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 2acetate; 2'-amino(2-amino(piperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-amino(piperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate; 2'-amino(2-amino(tetrahydro-2H-pyranyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 3hydrochloride; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- -ol 4hydrochloride; 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- -ol 4hydrochloride; 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-ethylpiperidinyl)methylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-amino-5,6-dimethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoethyl(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; and 2'-amino(2-amino(1-isopropylpiperidinyl)propylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride.
The processes for preparing the compounds according to the present invention are depicted in the following Reaction Schemes 1 to 10. However, those illustrated in the following Reaction Schemes represent only typical processes used in the present invention.
The manipulation order, reagents, reaction conditions, etc. may be changed without limit.
[Reaction Scheme 1] Reaction Scheme 1 shows a process of six steps for preparing the compound (VII) using commercially available pyridine alcohol (I) as a starting material.
In step 1, 1 to 5 equivalents of bromine is added to an aqueous solution of 1 to 5 equivalents of inorganic bases such as KOH, NaOH, etc. and then the compound (I) is added to the mixture to react at 0 ? to room temperature to give the compound (II). 10 to 30% of the aqueous solution of inorganic bases is used.
In step 2, the compound (II) obtained in step 1 is reacted with 1 to 5 equivalents of iodomethane (CH I) in an organic solvent in the presence of a base such as potassium carbonate (K CO ), sodium carbonate (Na CO ), sodium hydrogen carbonate (NaHCO ), etc. to give the 2 3 2 3 3 compound (III). The organic solvent may be acetone, acetonitrile, dichloromethane, chloroform, tetrahydrofuran, N,N-dimethylformamide, etc. The base may be used in an amount of 1 to 3 equivalents relative to the compound (I) and the reaction of the base with the compound (I) may be conducted at room temperature to reflux temperature.
In step 3, the compound (III) obtained in step 2, palladium catalyst, and 1,3- bis(diphenylphosphino)propane(DPPP) are stirred with reflux in an organic solvent or an ionic liquid in the presence of butyl vinyl ether and triethylamine to give the compound (IV). The solvent may be ethylene glycol, or an ionic liquid such as 1-butylmethylimidazolium tetrafluoroborate ([bmim][BF ]), the palladium catalyst is 0.1 to 1 mol% of palladium (II) acetate (Pd(OAc) ), and the ligand may be 0.1 to 1 mol% of 1,3-bis(diphenylphosphino)propane.
In step 4, the compound (IV) obtained in step 3 is stirred with reflux in the presence of 2 to 30 equivalents of N,N-Dimethylformamide dimethyl acetal (DMFDMA) to give the compound (V).
In step 5, the compound (V) obtained in step 4 is reacted with 1 to 3 equivalents of guanidine hydrochloride in an organic solvent in the presence of 4 to 12 equivalents of a base to give the compound (VI). The base may be sodium methoxide (NaOMe), sodium ethoxide (NaOEt), potassium hydroxide (KOH), etc. and the solvent may be methanol, ethanol, etc.
In step 6, the compound (VI) obtained in step 5 is reacted with 5 to 30 equivalents of pyridine hydrochloride to give the compound (VII). The reaction temperature is 150? to 200?.
[Reaction Scheme 2] Reaction Scheme 2 shows a process of six steps for preparing the compound (XIV) using a commercially available aminopyrazine (VIII) as a starting material.
In step 1, aminopyrazine (VIII) is reacted with 2 to 4 equivalents of N- bromosuccinimide (NBS) at 0? to room temperature to give the compound (IX). A reaction solvent such as a mixture of water and dimethylsulfoxide (DMSO), acetonitrile, dichloromethane or chloroform may be used for the reaction.
In step 2, 1.5 to 5 equivalents of isoamylnitrite is used in methanol solvent to give the compound (X).
In step 3, the compound (XI) is prepared in accordance with the same procedure as the step 3 of Reaction Scheme 1. In step 4, the compound (XII) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 5, the compound (XIII) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 6, the compound (XIV) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 3] Reaction Scheme 3 shows a process of eight steps for preparing the compound (XXIII) using a commercially available 6-bromo-pyridinol (XV) as a starting material.
In step 1, 6-bromo-pyridinol (XV) is reacted with 4-toluenesulfonyl chloride (TsCl) in an organic solvent in the presence of 1 to 3 equivalents of a base such as triethylamine to give the compound (XVI). The organic solvent may be dichloromethane, chloroform, etc. and 4- toluenesulfonyl chloride is used in an amount of 1 to 2 equivalents.
In step 2, the compound (XVI) obtained in step 1 is dissolved in an organic solvent and then 1 to 4 equivalents of a base such as lithium diisopropylamide (LDA), n-butyllithium (n- BuLi), etc and 1.5 to 5 equivalents of N-methoxy-N-methyl acetamide are used to give the compound (XVII). The organic solvent may be tetrahydrofuran, diethylester, etc.
In step 3, the compound (XVII) obtained in step 2 is dissolved in an organic solvent, and then 1 to 4 equivalents of a base is used to give the compound (XVIII). The organic solvent is a mixture of tetrahydrofuran, methanol and water and the base may be lithium hydroxide (LiOH), sodium hydroxide (NaOH), potassium hydroxide (KOH), etc.
In step 4, the compound (XIX) is prepared in accordance with the same procedure as the step 2 of Reaction Scheme 1. In step 5, the compound (XX) is prepared in accordance with the same procedure as the step 3 of Reaction Scheme 1. In step 6, the compound (XXI) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 7, the compound (XXII) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 8, the compound (XXIII) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 4] Reaction Scheme 4 shows a process of four steps for preparing the compound (XXVIII) using the compound (XIX) prepared in step 4 of Reaction Scheme 3 as a starting material.
In step 1, the compound (XXV) is prepared through Suzuki reaction using the compound (XIX) obtained in step 4 of Reaction Scheme 3, 0.5 to 3 equivalents of boronate compound (XXIV) which is commercially available or easily produced, and 1 to 5 mol% of a palladium catalyst. The palladium catalyst is tetrakis(triphenylphosphine)palladium(0) and the reaction solvent is a mixture of ethylene glycol dimethylester and water.
In step 2, the compound (XXVI) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 3, the compound (XXVII) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 4, the compound (XXVIII) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 5] Reaction Scheme 5 shows a process of five steps for preparing the compound (XXXIV) using a commercially available 2,4-dichloromethoxypyrimidine (XXIX) as a starting material.
In step 1, the compound (XXX) is prepared in accordance with the same procedure as the step 1 of Reaction Scheme 4. In step 2, the compound (XXXI) is prepared in accordance with the same procedure as the step 3 of Reaction Scheme 1. In step 3, the compound (XXXII) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 4, the compound (XXXIII) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 5, the compound (XXXIV) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 6] Reaction Scheme 6 shows a process of seven steps for preparing the compound (XXXXII) using a commercially available 3,5-bromomethoxypyridine (XXXV) as a starting material.
In step 1, the compound (XXXVI) is prepared in accordance with the same procedure as the step 3 of Reaction Scheme 1. In step 2, the compound (XXXVII) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 3, the compound (XXXVIII) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 4, the compound (XXXIX) is prepared in accordance with the same procedure as the step 3 of Reaction Scheme 1. In step 5, the compound (XXXX) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 6, the compound (XXXXI) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 7, the compound (XXXXII) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 7] Reaction Scheme 7 shows a process of twelve steps for preparing the compound (LV) using a commercially available 5-hydroxymethylpyridine (XXXXIII) as a starting material.
In step 1, 5-hydroxymethylpyridine (XXXXIII) is reacted with 0.5 to 3 equivalents of bromine in pyridine solvent to give the compound (XXXXIV).
In step 2, the compound (XXXXV) is prepared in accordance with the same procedure as the step 2 of Reaction Scheme 1.
In step 3, the compound (XXXXV) obtained in step 2 is dissolved in water and then 2 to equivalents of potassium permanganate (KMnO ) is used to give the compound (XXXXVI).
In step 4, the compound (XXXXVI) obtained in step 3 is dissolved in an organic solvent and then it is subjected to 1-ethyl(3-dimethylaminopropyl)carbodiimide (EDC) coupling reaction with N,O-dimethylhydroxyamine hydrochloride to give the compound (XXXXVII).
The organic solvent may be dichloromethane, N,N-dimethylformamide, etc.
In step 5, the compound (XXXXVII) obtained in step 4 is dissolved in an organic solvent and then 1 to 3 equivalents of methylmagnesium bromide is used to give the compound (XXXXVIII). The organic solvent may be tetrahydrofuran, diethylester, etc.
In step 6, the compound (XXXXVIII) obtained in step 5 is dissolved in an oraganic solvent and then an acetyl group is converted to an acetal group using an excess amount of ethylene glycol and 0.1 to 0.5 equivalents of p-toluenesulfonic acid to give the compound (XXXXIX). The organic solvent may be benzene, toluene, etc.
In step 7, the compound (XXXXIX) obtained in step 6 is dissolved in an oraganic solvent and then 2 to 3 equivalents of triisopropyl borate is used to give boronic acid (L). The organic solvent may be diethylester, tetrahydrofuran, etc.
In step 8, the compound (LI) is prepared in accordance with the same procedure as the step 1 of Reaction Scheme 4.
In step 9, the compound (LI) obtained in step 8 is dissolved in a mixture of water and acetone and then it is reacted with 0.1 to 0.7 equivalents of pyridimium p-toluenesulfonate to remove the acetal group to give the compound (LII).
In step 10, the compound (LIII) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 11, the compound (LIV) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 12, the compound (LV) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 8] Reaction Scheme 8 shows a process of seven steps for preparing the compound (LXIII) using a commercially available 2-cyanohydroxypyridine (LVI) as a starting material.
In step 1, 2-cyanohydroxypyridine (LVI) is dissolved in distilled water and then 0.5 to 2 equivalents of N-Bromosuccinimide (NBS) is added to the resulting solution to give the compound (LVII) through a bromination reaction.
In step 2, the compound (LVII) obtained in step 1 is dissolved in an organic solvent and then 1 to 4 equivalents of alkylmagnesium bromide or alkylmagnesium chloride is used to introduce alkylcarbonyl group to give the compound (LVIII). The organic solvent may be tetrahydrofuran, diethylester, etc.
In step 3, the compound (LIX) is prepared in accordance with the same procedure as the step 2 of Reaction Scheme 1. In step 4, the compound (LX) is prepared in accordance with the same procedure as the step 4 of Reaction Scheme 1. In step 5, the compound (LXI) is prepared in accordance with the same procedure as the step 5 of Reaction Scheme 1. In step 6, the compound (LXII) is prepared in accordance with the same procedure as the step 1 of Reaction Scheme 4. In step 7, the compound (LXIII) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 9] Reaction Scheme 9 shows a process of seven steps for preparing the compound (LXXI) using a commercially available 3-hydroxypicolinic acid (LXIV) as a starting material.
In step 1, 3-hydroxypicolinic acid (LXIV) is dissolved in methanol and then 0.5mL/1g to 2mL/1g of sulfuric acid is added to the resulting solution to give the compound (LXV) by esterification.
In step 2, the compound (LXVI) is prepared in accordance with the same procedure as the step 1 of Reaction Scheme 1. In step 3, the compound (LXVII) is prepared in accordance with the same procedure as the step 2 of Reaction Scheme 1.
In step 4, the compound (LXVII) obtained in step 3 is dissolved in an organic solvent, and then diketone is introduced using 1 to 3 equivalents of alkyl ketone to give the compound (LXVIII). The organic solvent may be tetrahydrofuran, diethylester, etc.
In step 5, the compound (LXVIII) obtained in step 4 is reacted with 1 to 3 equivalents of guanidine carbonate in an organic solvent in the presence of 0 to 4 equivalents of a base to give the compound (LXIX). The base may be potassium carbonate (K CO ), sodium carbonate (Na CO ), sodium methoxide (NaOMe), sodium ethoxide (NaOEt), potassium hydroxide (KOH), etc. and the solvent may be methanol, ethanol, etc.
In step 6, the compound (LXX) is prepared in accordance with the same procedure as the step 1 of Reaction Scheme 4. In step 7, the compound (LXXI) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
[Reaction Scheme 10] Reaction Scheme 10 shows a process of five steps for preparing the compound (LXXVI) using the compound (LXVII) obtained in step 3 of Reaction Scheme 9 as a starting material.
In step 1, the compound (LXVII) obtained in step 3 of Reaction Scheme 9 is dissolved in ethylacetate and then a base is used to give diketone. The base may be potassium t-butoxide (t- BuOK), lithium bis(trimethylsilyl)amide (LiHMDS), lithium diisopropylamine (LDA), etc.
In step 2, the compound (LXXII) obtained in step 1 is dissolved in an organic solvent, and then reacted with 1 to 4 equivalents of guanidine carbonate to give the compound (LXXIII).
The solvent may be methanol, ethanol, isopropanol, etc.
In step 3, the compound (LXXIII) obtained in step 2 is dissolved in an organic solvent and then 1 to 4 equivalents of (benzotriazolyloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and 1 to 4 equivalents of 1,8-diazabicyclo[5,4,0]undecene (DBU) are added dropwise to the resulting solution and then an amine compound is added to the solution to give the compound (LXXIV). The solvent may be acetonitrile, tetrahydrofuran, etc. and amine may be morpholine, piperidine, piperazine, etc.
In step 4, the compound (LXXV) is prepared in accordance with the same procedure as the step 1 of Reaction Scheme 4. In step 5, the compound (LXXVI) is prepared in accordance with the same procedure as the step 6 of Reaction Scheme 1.
The compounds according to the present invention prepared as described above may be prepared as a pharmaceutically acceptable salt in accordance with a conventional method in the In one embodiment of the present invention, a useful pharmaceutically acceptable salt may be an acid addition salt formed by a free acid. An acid addition salt may be prepared by a conventional method in the art. For example, a compound is dissolved in an excess amount of aqueous solution of an acid at room temperature or with heat, and the resulting salt is precipitated with a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Or the mixture is evaporated to dry and recrystallized to give a salt.
One aspect of the present invention relates to a pharmaceutical composition for inhibiting a cyclin-dependent kinase (CDK) comprising the compound of the above formula (I) or pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier, in particular, a pharmaceutical composition for prevention or treatment of cancers or degenerative brain diseases.
In one embodiment of the present invention, the compound of the above formula (I) or pharmaceutically acceptable salt thereof induces anticancer effect through regulation of the cell cycle by inhibiting a CDK and therefore can be used for treating blood cancers including Acute lymphoblastic leukemia (ALL), Chronic lymphoblastic leukemia (CLL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), multiple myeloma (MM), Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, and solid cancers including non-small cell lung cancer, small cell lung cancer, gastric cancer, pancreas cancer, glioma, colon cancer, breast cancer, head and neck squamous cell cancer, liver cancer, melanoma, uterine cancer, prostate cancer, ovarian cancer, thyroid cancer, biliary tract cancer, gallbladder cancer, bladder cancer, kidney cancer, esophageal cancer, etc.
Further, the compound of the above formula (I) or pharmaceutically acceptable salt thereof can pass through blood brain barrier (BBB) and therefore can be used for treating glioma such as astrocytoma, anaplastic astrocytoma, and glioblastoma, brain tumor such as pituitary adenoma, medulloblastoma, and meningioma, or metastatic brain tumor metastasized from lung cancer, breast cancer, melanoma, etc.
In one embodiment of the present invention, the compound of the above formula (I) or pharmaceutically acceptable salt thereof inhibits a phosphorylation of tau protein and a generation of A ß, which are causes of Alzheimer disease, by CDK5 inhibition. Therefore, the compound of the above formula (I) or pharmaceutically acceptable salt thereof can be used for treating Alzheimer’s disease, Huntington’s chorea, Parkinson’s disease, etc.
The pharmaceutical composition according to the present invention can be administered orally, e.g., ingestion or inhalation; or parenterally, e.g., injection, deposition, implantation or suppositories. The injection can be, for example, intravenous, subcutaneous, intramuscular or intraperitoneal. Depending on the route of administration, the pharmaceutical composition of the present invention may be formulated as tablets, capsules, granules, fine subtilae, powders, sublingual tablets, suppositories, ointments, injection solutions, emulsions, suspensions, syrups, aerosols, etc. The above various forms of the pharmaceutical composition of the present invention can be prepared in a manner well known in the art using a pharmaceutically acceptable carrier(s) which are usually used for each form. Examples of the pharmaceutically acceptable carriers include excipient, binder, disintegrating agent, lubricant, preservative, antioxidant, isotonic agent, buffer, coating agent, sweetening agent, dissolvent, base, dispersing agent, wetting agent, suspending agent, stabilizer, colorant, etc.
The pharmaceutical composition according to the present invention contains 0.01 to 95 wt% of the compound of the above formula (I) or pharmaceutically acceptable salt thereof depending on the form thereof.
The specific dosage of the present pharmaceutical composition can be varied with species of mammals including a human-being, body weight, gender, severity of disease, judgment of doctor, etc. It is preferable that 0.01 to 50 mg of the active ingredient is administered per kg of body weight a day for oral use, while 0.01 to 10 mg of the active ingredient is administered per kg of body weight a day for parenteral use. The total daily dosage can be administered once or over several times depending on the severity of disease, judgment of doctor, etc.
In one embodiment of the present invention, the compound of the above formula (I) or pharmaceutically acceptable salt thereof may be administered in combination with one or more anticancer agents selected from the group consisting of capecitabine, 5-fluorouracil, thioguanine, chlorambucil, oxaliplatin, cisplatin, carboplatin, paclitaxel, docetaxel, irinotecan, doxorubicin, vinorelbin, gemcitabine, pemetrexed, etoposide, vincristine, citarabine, cyclophosphamide, iphosphamide, tamoxifen, anastrozole, retrozole, exemestane, fulvestrant, temozolomide, camustine, lomustine, epirubicine, eribulin, toremifene, goserelin, megestrol, vinblastine, bendamustine, thiotepa, bleomycin, topotecan, leucovorin, trifluridine, tipiracil, mitomycin C, aldesleukin, temsirolimus, everolimus, mitoxantrone, mecloretamine, methotrexate, trastuzumab, bevacizumab, cetuximab, aflibercept, pertuzumab, ramucirumab, panitumumab, nivolumab, necitumumab, pembrolizumab, obinutuzumab, ofatumumab, erlotinib, gefitinib, sorafenib, lapatinib, palbociclib, regorafenib, imatinib, sunitinib, axitinib, pazopanib, apatinib, ceritinib, crizotinib, osimertinib, bosutinib, dasatinib, nilotinib, ponatinib, hydroxyurea, and procarbazine, or one or more drugs for treating a degenerative brain disease selected from the group consisting of levodopa, bromocriptine, ropinirole, pramipexole, rotigotine, trihexyphenidyl, benztropine, procyclidine, entacapone, selegiline, rasagiline, amantadine, tetrabenazine, donepezil, rivastigmine, galantamine and memantine, in particular, temozolomide, to improve treatment.
The specific dosage and administration time can be varied depending on a combined drug.
?Advantageous Effects? The compound of the above formula (I) of the present invention or pharmaceutically acceptable salt thereof can be used in a pharmaceutical composition for preventing or treating cancers or degenerative brain diseases, etc., since it has an effect of inhibiting CDK activity.
?Brief Description of Figures? Fig. 1 shows changes in the cell cycle caused by the compound according to the present invention in a cancer cell and a normal cell.
Fig. 2 is a graph showing a tumor growth inhibitory effect of the compound according to the present invention in an animal model.
Fig. 3 is a graph showing a tumor growth inhibitory effect of the compound according to the present invention combined with a conventional anticancer drug in an animal model.
Fig. 4 shows an inhibitory effect of the compound according to the present invention on the phosphorylation of Tau protein.
Fig. 5 shows an inhibitory effect of the compound according to the present invention on the phosphorylation of APP protein.
Fig. 6 shows an inhibitory effect of the compound according to the present invention on the generation of A ß.
?Best Mode? The present invention is further illustrated by the following examples, which are not to be construed to limit the scope of the invention.
Example 1 : Preparation of 2,6-bis(2-aminopyrimidinyl)pyridinol (VII) Example 1-1 : Preparation of 2,6-dibromomethoxypyridine (III) Bromine (1.62 mL, 63.09 mmole) was slowly added dropwise to 25 mL of 20% sodium hydroxide (NaOH) aqueous solution at 0? and the mixture was stirred at 0? for 15 min. Then, 3-hydroxypyridine (I) (2.0 g, 21.03 mmole) dissolved in 20% sodium hydroxide (NaOH) aqueous solution was slowly added dropwise thereto at 0?, and the mixture was stirred at 0? for 2 hours and then at room temperature for 12 hours. The mixture was filtered to remove floating matter and to the resulting solution was slowly added dropwise 2N hydrochloric acid (HCl) to adjust pH to 1~2. The resulting solid was filtered and dried to provide a white solid.
The solid was dissolved in 60 ml of acetone and potassium carbonate (K CO ) (2.64 g, 19.13 mmol) and methaneiodide (CH I) (893.03 uL, 14.34 mmole) were added dropwise thereto and the solution was stirred with reflux for 3 hrs. The resulting solution was evaporated under reduced pressure to concentrate, diluted with ethylacetate (EA), and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and then evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 5/1) to give the title compound (1.04 g, 19%).
H NMR (400 MHz, CDCl ) d 7.38 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 3.91 (s, Example 1-2 : Preparation of 1,1'-(3-methoxypyridin-2,6-diyl)diethanone (IV) 2,6-Dibromomethoxypyridine (III) (450 mg, 1.69 mmole), palladium (II) acetate (Pd(OAc) ) (15.14 mg, 67.44 umole), and 1,3-bis(diphenylphosphino)propane (DPPP) (55.63 mg, 134.87 umole) were dissolved in 3mL of ethylene glycol. To the resulting reaction mixture butyl vinyl ether (1.09 mL, 8.43 mmole) and triethylamine (TEA) (704.94 uL, 50.6 mmole) were slowly added dropwise. The resulting mixture was stirred at 125? for 24 hrs and cooled to room temperature. 2N hydrochloric acid (HCl) was slowly added dropwise thereto to adjust pH to 1~2 and the mixture was stirred for 30 min and neutralized. The resulting solution was diluted with dichloromethane and washed with water. Then, the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (120mg, 37%).
H NMR (400 MHz, CDCl ) d 8.20 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 3.98 (s, 3H), 2.73 (s, 3H), 2.71 (s, 3H).
Example 1-3 : Preparation of 4,4'-(3-methoxypyridin-2,6-diyl)bis(pyrimidin amine) (VI) 1,1'-(3-Methoxypyridin-2,6-diyl)diethanone (IV) (80 mg, 414.08 umole) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (831.6 uL, 6.21 mmole) and the resulting solution was stirred with reflux for 24 hrs. The resulting solution was cooled and evaporated and concentrated under reduced pressure to give a yellow solid. The solid was dissolved in methanol (MeOH) (1 mL), and 25% sodium methoxide (NaOMe) (757.4 uL, 3.31 mmole) and guanidine hydrochloride (118.67 mg, 1.24 mmole) were added dropwise thereto.
And then, the resulting reaction mixture was stirred with reflux for 24 hrs and cooled. The resulting solution was diluted with ethylacetate (EA), washed with water, and the organic solvent was dried over anhydrous magnesium sulfate (MgSO), filtered, and evaporated and concentrated under reduced pressure to give the title compound (65 mg, 53%).
H NMR (400 MHz, DMSO-d ) d 8.37~8.32 (m, 3H), 7.75 (d, J = 8.8 Hz, 1H), 7.36 (d, J = 4.8 Hz, 1H), 6.84 (d, J = 5.2 Hz, 1H), 6.73 (s, 2H), 6.69 (s, 2H), 3.87 (s, 3H).
Example 1-4 : Preparation of 2,6-bis(2-aminopyrimidinyl)pyridinol (VII) 4,4'-(3-Methoxypyridin-2,6-diyl)bis(pyrimidinamine) (VI) (15mg, 50.80 umole) was mixed with pyridine hydrochloride (Pyridine HCl) (58.70 mg, 507.96 umole) and the mixture was stirred at 170? for 4 hrs. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA). The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (6.4 mg, 45%).
H NMR (400 MHz, DMSO-d ) d 8.52 (d, J = 4.8 Hz, 1H), 8.37 (d, J = 5.2 Hz, 1H), 8.32 (d, J = 8.8 Hz, 1H), 7.69 (d, J = 5.2 Hz 1H), 7.55 (d, J = 4.8 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.32 (s, 2H), 6.68 (s, 2H), 3.87 (s, 3H).
Example 2 : Preparation of 3,5-bis(2-aminopyrimidinyl)pyrazinol (XIV) Example 2-1 : Preparation of 3,5-dibromopyrazinamine (IX) Pyrazinamine (VIII) (1.91 g, 20.08 mmol) was dissolved in dimethylsulfoxide (DMSO) (40 mL) and distlled water (1 mL). To the resulting solution was slowly added dropwise N-Bromosuccinimide (NBS) (8.20 g, 46.07 mmol) at 0? and the solution was stirred at room temperature for 16 hrs. Ice was added to the solution and the solution was stirred to give a yellow solid which was filtered to give the title compound (3.40 mg, 67%).
H NMR (400 MHz, CDCl ) d 8.04 (s, 1H), 5.05 (br, 2H).
Example 2-2 : Preparation of 3,5-dibromomethoxypyrazine (X) 3,5-Dibromopyrazinamine (IX) (1.0 g, 4.0 mmole) was dissolved in methanol (MeOH) (10 mL), and 2.5M HCl/MeOH solution (0.32 mL, 0.80 mmol) and isoamylnitrite (1.5 mL, 12 mmol) were added dropwise to the resulting solution and the solution was stirred with reflux for 2 hrs. The reaction solution was evaporated and concentrated under reduced pressure, diluted with dichloromethane, and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate.
The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 5/1) to give the title compound (500 mg, 47%).
H NMR (400 MHz, CDCl ) d 8.14 (s, 1H), 4.04 (s, 3H).
Example 2-3 : Preparation of 1,1'-(3-methoxypyrazin-2,6-diyl)diethanone (XI) 3,5-Dibromomethoxypyrazine (X) (600 mg, 2.24 mmol), palladium(II) acetate (Pd(OAc) ) (40.22 mg, 179.16 umole), and 1,3-bis(diphenylphosphino)propane (DPPP) (147.80 mg, 358.33 umole) were dissolved in 2.5 mL of 1-butylmethylimidazolium tetrafluoroborate ([bmim][BF4]). To the resulting solution was slowly added dropwise butyl vinyl ether (2.32 mL, 17.92 mmole) and triethylamine (TEA) (1.0 mL, 7.17 mmole). The solution was stirred at 125? for 24 hrs and then cooled to room temperature. 2N hydrochloric acid (HCl) was slowly added dropwise to the solution to adjust pH to 1~2 and then the solution was stirred for 30 min and neutralized. The solution was diluted with dichloromethane and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (65 mg, 15%).
H NMR (400 MHz, CDCl ) d 8.98 (s, 1H), 4.15 (s, 3H), 2.73 (s, 3H), 2.70 (s, 3H).
Example 2-4 : Preparation of 4,4'-(3-methoxypyrazin-2,6-diyl)bis(pyrimidin amine) (XIII) 1,1'-(3-Methoxypyrazin-2,6-diyl)diethanone (XI) (65 mg, 334.72 umole) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (672.23 uL, 5.02 mmole) and the resulting solution was stirred with reflux for 24 hrs. The solution was cooled and evaporated under reduced pressure to concentrate. The resulting yellow solid was dissolved in methanol (MeOH) (1 mL), and 25% sodium methoxide (NaOMe) (612.29 uL, 2.68 mmole) and guanidine hydrochloride (95.93 mg, 1.0 mmole) were added dropwise to the solution. And then, the solution was stirred with reflux for 24 hrs and cooled. The solution was diluted with ethylacetate (EA) and washed with water, and the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (47 mg, 47%).
H NMR (400 MHz, DMSO-d ) d 8.75 (s, 1H), 8.17 (d, J = 5.2 Hz, 1H), 8.12 (d, J = 5.6 Hz, 1H), 7.40 (d, J = 5.2 Hz, 1H), 7.15 (d, J = 5.2 Hz, 1H), 6.39 (s, 2H), 6.32 (s, 2H), 3.17 (s, Example 2-5 : Preparation of 3,5-bis(2-aminopyrimidinyl)pyrazinol (XIV) 4,4'-(3-Methoxypyrazin-2,6-diyl)bis(pyrimidinamine) (XIII) (47 mg, 158.62 umole) was mixed with pyridine hydrochloride (Pyridine HCl) (11.3 mg, 40.03 umole) and the mixture was stirred at 170? for 4 hrs. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA). The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (7.6 mg, 17%).
H NMR (400 MHz, CD OD) d 8.92 (s, 1H), 8.29 (d, J = 5.2 Hz, 1H), 8.18 (d, J = 5.6 Hz, 1H), 7.62 (d, J = 4.8 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H), 6.39 (s, 2H), 6.32 (s, 2H), 3.17 (s, Example 3 : Preparation of 4,6-bis(2-aminopyrimidinyl)pyridinol (XXIII) Example 3-1 : Preparation of toluenesulfonic acid 6-bromo-pyridinyl ester (XVI) 6-Bromopyridinol (XV) (500 mg, 2.87 mmol) was dissolved in dichloromethane (3 mL). Then, triethylamine (TEA) (520 uL, 3.74 mmol) and 4-toluenesulfonyl chloride (TsCl) (657.41 mg, 3.45 mmol) were slowly added dropwise to the resulting solution at 0? and the solution was stirred at room temperature for 12 hrs. The solution was diluted with dichloromethane, washed with water and saturated sodium hydrogen carbonate (NaHCO ). The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (980 mg, 100%).
H NMR (400 MHz, CDCl ) d 7.89 (d, J = 3.2 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.8 Hz, 1H), 7.36-7.33 (m, 3H), 2.47 (s, 3H).
Example 3-2 : Preparation of toluene sulfonic acid 4-acetylbromo-pyridinyl ester (XVII) Toluenesulfonic acid 6-bromo-pyridinyl ester (XVI) (980 mg, 2.99 mmol) was dissolved in tetrahydrofuran (THF) (3 mL) and the resulting solution was cooled to -78?. 2.0M lithium diisopropylamide (LDA) (2.24 mL, 4.48 mmol) dissolved in tetrahydrofuran was slowly added dropwise to the solution and the solution was stirred at -78? for 3 hrs. And then, N-methoxy-N-methyl acetamide (609.77 uL, 5.97 mmol) was slowly added dropwise to the solution and the solution was stirred for 2 hrs. Saturated sodium hydrogen carbonate (NaHCO ) solution was added dropwise to the solution and the solution was diluted with ethylacetate (EA).
Then, the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 4/1) to give the title compound (570 mg, 52%).
H NMR (400 MHz, CDCl ) d 7.97 (s, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.65 (s, 1H), 7.37 (d, J = 8.0 Hz, 2H), 2.58 (s, 3H), 2.49 (s, 3H).
Example 3-3 : Preparation of 1-(2-bromohydroxypyridinyl)ethanone (XVIII) Toluenesulfonic acid 4-acetylbromo-pyridinyl ester (XVII) (1.3 g, 3.51 mmol) was dissolved in a mixture of tetrahydrofuran (THF) (4 mL), methanol (MeOH) (4 mL) and water (H O) (2 mL). To the resulting solution was added dropwise lithium hydroxide (LiOH) (294.68 mg, 7.02 mmol) and the solution was stirred at room temperature for 12 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with ethylacetate (EA).
The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (620 mg, 82%).
H NMR (400 MHz, CDCl ) d 11.34 (s, 1H), 8.30 (s, 1H), 7.55 (s, 1H), 2.68 (s, 3H).
Example 3-4 : Preparation of 1-(2-bromomethoxypyridinyl)ethanone (XIX) 1-(2-Bromohydroxypyridinyl)ethanone (XVIII) (365 mg, 1.69 mmol) was dissolved in 6 mL of acetone, and then potassium carbonate (K CO ) (373.63 mg, 2.70 mmol) and iodomethane (CH I) (126.22 uL, 2.03 mmole) were added dropwise thereto. The resulting solution was stirred with reflux for 3 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with ethylacetate (EA) and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 5/1) to give the title compound (381.0 mg, 98%).
H NMR (400 MHz, CDCl ) d 8.19 (s, 1H), 7.49 (s, 1H), 4.02 (s, 3H), 2.61 (s, 3H).
Example 3-5 : Preparation of 1,1'-(5-methoxypyridin-2,4-diyl)diethanone (XX) 1-(2-Bromomethoxypyridinyl)ethanone (XIX) (260 mg, 1.13 mmol), palladium(II) acetate (Pd(OAc) ) (10.15 mg, 45.20 umole), and 1,3-bis(diphenylphosphino)propane (DPPP) (37.29 mg, 90.41 umole) were dissolved in 1.0 mL of 1-butylmethylimidazolium tetrafluoroborate ([bmim][BF4]), and butyl vinyl ether (731.23 uL, 5.65 mmole) and triethylamine (TEA) (252.03 uL, 1.81 mmole) were slowly added thereto. The resulting solution was stirred 125? for 24 hrs and then cooled to room temperature. 2N hydrochloric acid (HCl) was slowly added dropwise to the solution to adjust pH to 1~2 and the solution was stirred for 30 min and neutralized. The solution was diluted with dichloromethane and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (54 mg, 25%).
H NMR (400 MHz, CDCl ) d 8.47 (s, 1H), 8.23 (s, 1H), 4.11 (s, 3H), 2.69 (s, 3H), 2.62 (s, 3H).
Example 3-6 : Preparation of 4,4'-(5-methoxypyridin-2,4-diyl)bis(pyrimidin amine) (XXII) 1,1'-(5-Methoxypyridin-2,4-diyl)diethanone (XX) (54 mg, 279.50 umole) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (561.33 uL, 4.19 mmole) and the resulting solution was stirred with reflux for 24 hrs. The solution was cooled, and evaporated and concentrated under reduced pressure to provide a yellow solid. The solid was dissolved in methanol (MeOH) (1 mL), and 25% sodium methoxide (NaOMe) (511.28 uL, 2.24 mmole) and guanidine hydrochloride (80.10 mg, 838.51 umole) were added dropwise to the resulting solution.
And then, the solution was stirred with reflux, cooled, diluted with ethylacetate (EA) and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (23 mg, 28%).
H NMR (400 MHz, DMSO-d ) d 8.56 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.46 (s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 7.37 (d, J = 5.6 Hz, 1H), 7.30 (d, J = 5.2 Hz, 1H), 6.72 (s, 2H), 6.66 (s, 2H), 4.03 (s, 3H).
Example 3-7 : Preparation of 4,6-bis(2-aminopyrimidinyl)pyridinol (XXIII) 4,4'-(5-Methoxypyridin-2,4-diyl)bis(pyrimidinamine) (XXII) (23 mg, 778.87 umole) was mixed with pyridine hydrochloride (Pyridine HCl) (90 mg, 7.79 mmole) and the mixture was stirred at 170? for 4 hrs. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA). The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (9.8 mg, 45%).
H NMR (400 MHz, DMSO-d ) d 8.71 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.42 (s, 1H), 8.34 (d, J = 5.2 Hz, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.33 (s, 2H), 7.30 (d, J = 5.2 Hz, 1H), 6.66 (s, Example 4 : Preparation of 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin] ol (XXVIII) Example 4-1 : Preparation of 1-(2'-aminomethoxy-[2,4']bipyridinylyl)- ethanone (XXV) 1-(2-Bromomethoxypyridinyl)ethanone (XIX) (1g, 4.34mmol) obtained in Example 3-4 and [4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)-pyridinyl]-carbamic acid- tert-butyl ester (1.16g, 3.62mmol) were dissolved in ethylene glycol dimethyl ester/distilled water (10ml/2ml) solution. To the resulting solution were added sodium carbonate (1.15g, .86mmol), and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (125.6mg, 0.109mmol) and the solution was stirred with reflux for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the brown title compound (317.2mg, 30.0%).
H NMR (400 MHz, CDCl ) d 8.55 (s, 1H), 8.43 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.80 (dd, J = 8.0, 7.6 Hz, 1H), 7.34 (d, J = 7.6 Hz, 1H), 4.10 (s, 3H), 2.70 (s, 3H).
Example 4-2 : Preparation of 4-(2-amino-pyrimidinyl) methoxy[2,4']bipyridinyl -2'-ylamine (XXVII) 1-(2'-Aminomethoxy-[2,4']bipyridinylyl)-ethanone (XXV) (317mg, 1.303mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (1.7ml, 13.03mmol) and the resulting solution was stirred with reflux for 24 hrs. The reaction solution was cooled and evaporated and concentrated under reduced pressure to give a yellow solid. The solid was dissolved in methanol (MeOH) (1 mL), and to the resulting solution were added 25% sodium methoxide (NaOMe) (186uL, 5.212mmol) and guanidine hydrochloride (498.0mg, 5.212mmol).
And then, the solution was stirred with reflux for 24 hrs and cooled. The solution was diluted with ethylacetate (EA) and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and then evaporated and concentrated under reduced pressure to give the title compound (111.2mg, 29%).
H NMR (400 MHz, DMSO-d ) d 8.70 (s, 1H), 8.53 (d, J = 5.4 Hz, 1H), 8.42 (s, 1H), 8.34 (d, J = 5.4 Hz, 1H), 7.51 (s, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.32 (s, 2H), 7.30 (d, J = 5.2 Hz, 1H), 6.63 (s, 2H).
Example 4-3 : Preparation of 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]- -ol (XXVIII) 4-(2-Amino-pyrimidinyl)methoxy[2,4']bipyridinyl-2'-ylamine(XXVII) (30mg, 0.102mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (100mg, 1.019mmol) and the mixture was stirred at 170? for 4 hrs. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA).
Then, the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and then evaporated and concentrated under reduced pressure to give the title compound (12.8 mg, 45%).
H NMR (400 MHz, DMSO-d ) d 8.71 (s, 1H), 8.51 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.30 (d, J = 5.2 Hz, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.29 (s, 1H), 7.33 (s, 2H), 7.30 (d, J = 5.2 Hz, 1H), 6.66 (s, 2H).
Example 5 : Preparation of 2'-amino(2-aminopyridinyl)-[4,4'-bipyrimidin] ol (XXXIV) Example 5-1 : Preparation of [4-(4-chloromethoxy-pyrimidinyl)-pyridinyl]- carbamic acid-tert-butyl ester (XXX) 2,4-Dichloromethoxypyrimidine (XXIX) (800mg, 4.34mmol) and [4-(4,4,5,5- tetramethyl-[1,3,2]dioxaborolanyl)-pyridinyl]-carbamic acid-tert-butyl ester (XXIV) (1.16g, 3.62mmol) were dissolved in ethylene glycol dimethyl ester/distilled water (10ml/2ml) solution.
Sodium carbonate (1.15g, 10.86mmol) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (125.6mg, 0.109mmol) were added to the resulting solution and then the solution was stirred with reflux for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the brown title compound (302.1mg, 28.0%).
H NMR (400 MHz, CDCl ) d 8.43 (s, 1H), 8.01 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 3.99 (s, 3H), 1.48 (s, 9H).
Example 5-2 : Preparation of 1-[2-(2-amino-pyridinyl)methoxy-pyrimidin yl]-ethanone (XXXI) [4-(4-chloromethoxy-pyrimidinyl)-pyridinyl]-carbamic acid-tert-butyl ester (XXX) (200 mg, 1.13 mmol), palladium(II) acetate (Pd(OAc) ) (10.15 mg, 45.20 umole), and 1,3-bis(diphenylphosphino)propane (DPPP) (37.29 mg, 90.41 umole) were dissolved in 1.0 mL of 1-butylmethylimidazolium tetrafluoroborate ([bmim][BF4]). To the resulting solution were slowly added dropwise butyl vinyl ether (731.23 uL, 5.65 mmole) and triethylamine (TEA) (252.03 uL, 1.81 mmole). The resulting mixture was stirred at 125? for 24 hrs and then cooled to room temperature. 2N hydrochloric acid (HCl) was slowly added dropwise to the mixture to adjust pH to 1~2 and the mixture was stirred for 30 min and neutralized. The resulting solution was diluted with dichloromethane and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and then evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (50 mg, 21%).
H NMR (400 MHz, CDCl ) d 8.42 (s, 1H), 8.03 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 3.99 (s, 3H), 1.72 (s, 3H) Example 5-3 : Preparation of 2'-(2-amino-pyridinyl)-5'-methoxy- [4,4']bipyrimidinylylamine (XXXIII) 1-[2-(2-Amino-pyridinyl)methoxy-pyrimidinyl]-ethanone (XXXI) (200mg, 1.404mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (1.7ml, 14.03mmol) and the resulting solution was stirred with reflux for 24 hrs. The solution was cooled and evaporated and concentrated under reduced pressure to give a yellow solid. The solid was dissolved in methanol (MeOH) (1 mL), and to the resulting solution were added dropwise 25% sodium methoxide (NaOMe) (186uL, 6.212mmol) and guanidine hydrochloride (498.0mg, 6.212mmol). And then, the solution was stirred with reflux for 24 hrs, cooled, diluted with ethylacetate (EA) and washed with water. Then, the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and then evaporated and concentrated under reduced pressure to give the title compound (98.3mg, 19%).
H NMR (600 MHz, DMSO-d ) d 9.90 (s, NH), 8.63 (s, 1H), 8.63 (d, J = 5.4 Hz, 1H), 8.36 (d, J = 4.8 Hz, 1H), 7.82 (s, 1H), 7.56 (d, J = 5.4 Hz, 1H), 7.43 (d, J = 4.8 Hz, 1H), 6.68 (s, NH2), 3.98 (s, 3H).
Example 5-4 : Preparation of 2'-amino(2-aminopyridinyl)-[4,4'-bipyrimidin]- -ol (XXXIV) 2'-(2-Amino-pyridinyl)-5'-methoxy-[4,4']bipyrimidinylylamine (XXXIII) (30mg, 0.111mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (114mg, 1.011mmol) and the mixture was stirred at 170? for 4 hrs. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA).
The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (15.8 mg, 48%).
H NMR (600 MHz, CD OD) d 14.88 (s, OH), 8.69 (s, 1H), 8.34 (s, 1H), 8.32 (d, J = 4.8 Hz, 1H), 7.70 (dd, J = 8.4, 7.8 Hz, 1H), 7.39 (d, J = 4.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 6.81 (s, NH2), 6.65 (s, NHJ2), 6.61 (d, J = 8.4 Hz, 1H).
Example 6 : Preparation of 3,5-bis(2-aminopyrimidinyl)pyridinol (XXXXII) Example 6-1 : Preparation of 1-(5-bromomethoxy-pyridinyl)-ethanone (XXXVI) 3,5-Bromomethoxypyridine (XXXV) (100 mg, 1.13 mmol), palladium(II) acetate (Pd(OAc) ) (5.03 mg, 25.04 umole), and 1,3-bis(diphenylphosphino)propane (DPPP) (14.4 mg, 45.3 umole) were dissolved in 1.0 mL of 1-butylmethylimidazolium tetrafluoroborate ([bmim][BF4]), and butyl vinyl ether (345 uL, 2.56 mmole) and triethylamine (TEA) (125.03 uL, 0.192 mmole) were slowly added dropwise to the resulting solution. The resulting mixture was stirred at 130? for 24 hrs and cooled to room temperature. 2N hydrochloric acid (HCl) was slowly added dropwise to the mixture to adjust pH to 1~2 and the mixture was stirred for 30 min and neutralized. The resulting solution was diluted with dichloromethane, washed with water.
The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (53 mg, 41%).
H NMR (400 MHz, CDCl ) d 7.85 (s, 1H), 7.06 (s, 1H), 3.89 (s, 3H), 2.48 (s, 3H).
Example 6-2 : Preparation of 4-(5-bromomethoxy-pyridinyl)-pyrimidin ylamine (XXXVIII) 1-(5-Bromomethoxy-pyridinyl)ethanone (XXXVI) (200 mg, 1.404mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (1.7ml, 14.03mmol), and the resulting solution was stirred with reflux for 24 hrs. The solution was cooled and evaporated and concentrated under reduced pressure to give a yellow solid. The solid was dissolved in methanol (MeOH) (1 mL) and 25% sodium methoxide (NaOMe) (186uL, 6.212mmol) and guanidin hydrochloride (498.0mg, 6.212mmol) were added dropwise to the resulting solution.
And then, the solution was stirred with reflux for 24 hrs and cooled. The solution was diluted with ethylacetate (EA) and washed with water, and the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (20.3mg, 55%).
H NMR (400 MHz, CDCl ) d 8.50 (s, 1H), 8.43 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 4.07 (s, 3H).
Example 6-3 : Preparation of 1-[5-(2-amino-pyrimidinyl)methoxy-pyridin yl]-ethanone (XXXIX) 4-(5-Bromomethoxy-pyridinyl)-pyrimidinylamine (XXXVIII) (200 mg, 2.22 mmol), palladium(II) acetate (Pd(OAc)) (10.1 mg, 50.22 umole), and 1,3- bis(diphenylphosphino)propane (DPPP) (28.33 mg, 90.5 umole) were dissolved in 1.0 mL of 1- butylmethylimidazolium tetrafluoroborate ([bmim][BF4]). To the resulting solution were slowly added dropwise butyl vinyl ether (801 uL, 5.02 mmole) and triethylamine (TEA) (250.4 uL, 0.383 mmole). The resulting mixture was stirred at 125? for 24 hrs and then cooled to room temperature. 2N hydrochloric acid (HCl) was slowly added dropwise to the mixture to adjust pH to 1~2 and the mixture was stirred for 30 min and neutralized. The resulting solution was diluted with dichloromethane and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (n-Hex/EA = 3/1) to give the title compound (101 mg, 70.2%).
H NMR (400 MHz, CDCl ) d 8.51 (s, 1H), 8.43 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 3.90 (s, 3H) 2.12 (s, 3H).
Example 6-4 : Preparation of 4,4'-(2-methoxypyridin-3,5-diyl)bis(pyrimidin amine) (XXXXI) 1-[5-(2-Amino-pyrimidinyl)methoxy-pyridinyl]-ethanone (XXXIX) (100mg, 0.712mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (DMFDMA) (0.8ml, 7.03mmol) and the resulting solution was stirred with reflux for 24 hrs. The solution was cooled and evaporated and concentrated under reduced pressure to give a yellow solid. The solid was dissolved in methanol (MeOH) (1 mL), and 25% sodium methoxide (NaOMe) (98uL, 3.111mmol) and guanidine hydrochloride (249.2mg, 3.111mmol) were added dropwise to the resulting solution. And then, the solution was stirred with reflux for 24 hrs and cooled. The solution was diluted with ethylacetate (EA) and washed with water, and the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (80mg, 54%).
H NMR (400 MHz, DMSO-d ) d 8.35~8.30 (m, 3H), 7.75 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 4.8 Hz, 1H), 6.84 (d, J = 5.2 Hz, 1H), 6.73 (s, 2H), 6.69 (s, 2H), 4.07 (s, 3H).
Example 6-5 : Preparation of 3,5-bis(2-aminopyrimidinyl)pyridinol (XXXXII) 4,4'-(2-Methoxypyridin-3,5-diyl)bis(pyrimidinamine) (XXXXI) (80mg, 0.333mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (328mg, 3.332mmol) and the mixture was stirred at 170? for 4 hrs. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA). The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated and concentrated under reduced pressure to give the title compound (43.3 mg, 32%).
H NMR (400 MHz, DMSO-d ) d 8.60 (d, J = 4.8 Hz, 1H), 8.33 (s, 1H), 8.32 (d, J = 8.8 Hz, 1H), 7.69 (s, 1H), 7.55 (d, J = 4.8 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.30 (s, 2H), 6.66 (s, 2H), 3.88 (s, 3H).
Example 7 : Preparation of 6'-amino(2-aminopyrimidinyl)-[2,2'-bipyridin] ol (LV) Example 7-1 : Preparation of 2-bromomethylpyridinol (XXXXIV) -Hydroxymethylpyridine (XXXXIII) (1.0 g, 9.16 mmol) was dissolved in 30ml of pyridine. To the resulting solution was slowly added bromine (879 mg, 5.50 mmol) at 0 ? and the solution was stirred at room temperature for 16 hrs. After pyridine was removed, the solution was extracted with 60 ml of ethylacetate (EA) and 60 ml of water. The organic layer was treated with magnesium sulfate (MgSO ), filtered, and concentrated for a next reaction.
Example 7-2 : Preparation of 2-bromomethoxymethylpyridine (XXXXV) To 2-bromomethylpyridinol (XXXXIV) were added 50 ml of acetone, potassium carbonate (K CO ) (2.0 g, 14.66 mmol) and iodomethane (684 ul, 10.99 mmol), and the resulting mixture was stirred with reflux for 2 hrs. After TLC was conducted, the solvent was removed and the mixture was extracted with 60 ml of ethylacetate (EA) and 60 ml of water. The organic layer was treated with magnesium sulfate (MgSO ) and filtered, and the solution was concentrated and purified through silica gel chromatography (normal hexane : ethylacetate = 10 : 1, v/v) to give the title compound as pale yellow crystals (772 mg, 3.82 mmol, 42%).
H NMR (400 MHz, CDCl ) d 7.06 (s, 2H), 3.89 (s, 3H), 2.48 (s, 3H).
Example 7-3 : Preparation of 6-bromomethoxypicolinic acid (XXXXVI) 2-Bromomethoxymethylpyridine (XXXXV) 760 mg (3.76 mmol) was dissolved in ml of water, and to the resulting solution was added potassium permanganate (KMnO ) (1.49g, 9.40mmol) and the mixture was heated at 80 ? for 3 hrs. After TLC was conducted, pH was adjusted to 4 with 10% hydrochloric acid (HCl) and filtration was conducted with celite.
The filtrate was extracted with 50 ml of ethylacetate (EA). The organic layer was treated with magnesium sulfate (MgSO ) and filtered, and the solution was concentrated to give the title compound as a white solid (665 mg, 2.87 mmol, 75%) without purification.
H NMR (400 MHz, DMSO-d ) d 13.22 (s, OH), 8.05 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 4.02 (s, 3H).
Example 7-4 : Preparation of 6-bromo-N,5-dimethoxy-N-methylpicolinamide (XXXXVII) 6-Bromomethoxypicolinic acid (XXXXVI) (665 mg, 2.87 mmol) was dissolved in 10 ml of dichloromethane. N,O-dimethylhydroxyamine hydrochloride (336 mg, 3.44 mmol), 1- ethyl(3-dimethylaminopropyl)carbodiimide (EDCI) (659 mg, 3.44 mmol), 4- dimethylaminopyridine (DMAP) (105 mg, 0.86 mmol), and triethylamine (TEA) (479 ul, 3.44 mmol) were added to the resulting solution and the solution was stirred at room temperature for 16 hrs. And then, the solution was extracted with 30 ml of dichloromethane and 30 ml of water.
The organic layer was treated with magnesium sulfate (MgSO ) and filtered, and the solution was concentrated and purified by silica gel column chromatography (normal hexane : ethylacetate = 3 : 1, v/v) to give the title compound as colorless crystals (515 mg, 1.87 mmol, 65%).
H NMR (400 MHz, CDCl ) d 7.70 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 3.93 (s, 3H), 3.81 (s, 3H), 3.36 (s, 3H).
Example 7-5 : Preparation of 1-(6-bromomethoxypyridinyl)ethanone (XXXXVIII) 6-Bromo-N,5-dimethoxy-N-methylpicolinamide (XXXXVII) (2.29 g, 8.32 mmol) was dissolved in 30 ml of tetrahydrofuran (THF) and the resulting solution was cooled to -78 ?.
To the solution was slowly added methylmagnesium bromide (1.4M) (7.73 ml, 10.82mmol) and the solution was stirred at 0 ? for 1 hr. 60 ml of saturated ammonium chloride solution (Sat.NH Cl) was added to the solution and the solution was extracted with 60 ml of ethylacetate (EA). The organic layer was treated with magnesium sulfate (MgSO ) and filtered, and the resulting solution was concentrated and purified by silica gel column chromatography (normal hexane : ethylacetate = 3 : 1, v/v) to give the title compound as a white solid (1.88 g, 8.17 mmol, 98%).
H NMR (400 MHz, CDCl ) d 8.03 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 3.97 (s, 3H), 2.66 (s, 3H).
Example 7-6 : Preparation of 2-bromomethoxy(2-methyl-1,3-dioxolan yl)pyridine (XXXXIX) 1-(6-Bromomethoxypyridinyl)ethanone (XXXXVIII) (3.22 g, 14.00 mmol) was dissolved in 30 ml of benzene. To the resulting solution were added 3.9 ml of ethylene glycol and p-toluenesulfonic acid (p-TsOH) (799 mg, 4.20 mmol) and the solution was stirred with reflux for 40 hrs. After the reaction was completed, the solvent was concentrated under reduced pressure and extracted with 60 ml of water and 60 ml of ethylacetate. The organic layer was treated with magnesium sulfate (MgSO ), and filtered, and the solution was concentrated and purified by silica gel column chromatography (normal hexane : ethylacetate = : 1, v/v) to give the title compound as a white solid (2.18 g, 7.95 mmol, 57%).
H NMR (400 MHz, CDCl ) d 7.46 (d, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 4.06- 4.10 (m, 2H), 3.92 (s, 3H), 3.86-3.92 (m, 2H), 1.72 (s, 3H).
Example 7-7 : Preparation of (3-methoxy(2-methyl-1,3- dioxolanyl)pyridin yl)boronic acid (L) 2-Bromomethoxy(2-methyl-1,3-dioxolanyl)pyridine (XXXXIX) (300 mg, 1.09 mmol) obtained in step 6 was dissolved in 10 ml of tetrahydrofuran and the resulting solution was cooled to -78 ?. To the solution was added n-butyllithium (n-BuLi) (820 ul, 1.31 mmol) and the solution was stirred at the same temperature for 90 min. Triisopropyl borate (0.302 ml, 2.18 mmol) was added to the solution and the solution was stirred at the same temperature for 5 min and then at room temperature for 90 min. After cooling to 0 ?, 5% sodium hydroxide (NaOH) was added to the solution and the solution was stirred for 10 min and extracted with small amount of water. After removal of the organic layer, aqueous layer was neutralized with 2N hydrochloric acid (HCl) to pH 7 and used for next step.
Example 7-8 : Preparation of tert-butyl-(3-methoxy(2-methyl-1,3-dioxolan yl)pyridinyl)-[2,2'-pyridin]yl)carbamate (LI) To (3-methoxy(2-methyl-1,3-dioxolanyl)pyridinyl)boronic acid (L) solution (1.09 mmol) were added 2-(6-chloropyridinyl)-1,3-bis(1,1-dimethylethyl)ester imidodicarbonic acid (358 mg, 1.09 mmol), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (63 mg, 0.05 mmol), and potassium carbonate (K CO ) (1.0 g, 7.30 mmol). Then, the resulting mixture was refluxed with heat along with 1,4-dioxane for 3 hrs. After the reaction was completed, the solution was extracted 50 ml of water and 50 ml of ethylacetate. The organic layer was treated with magnesium sulfate (MgSO ), and filtered, and the solution was concentrated and purified by silica gel column chromatography (normal hexane : ethylacetate = 1 : 1, v/v) to give the title compound as a white solid (120 mg, 0.25 mmol, 23%).
H NMR (400 MHz, CDCl ) d 8.42 (s, 1H), 8.03 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.77 (dd, J = 8.0, 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 4.02-4.10 (m, 2H), 3.99 (s, 3H), 3.80-3.95 (m, 2H), 1.72 (s, 3H) 1.48 (s, 18H).
Example 7-9 : Preparation of (6'-acetyl-3'methoxy-[2,2']bipyridinylyl)- imidocarbonic acid -1,3-bis(1,1-dimethylethyl)ester (LII) Tert-butyl-(3-methoxy(2-methyl-1,3-dioxolanyl)pyridinyl)-[2,2'-pyridine] yl)carbamate (LI) (82 mg, 0.17 mmol) was dissolved in 3 ml of acetone and 330 ul of water.
Pyridinium p-toluenesulfonate (PPTS) (13 mg, 0.05 mmol) was added to the resulting solution and the solution was refluxed with heat for 20 hrs. The solution was concentrated and purified by silica gel column chromatography (normal hexane : ethylacetate = 3 : 1, v/v) to give the title compound as a white solid (55 mg, 0.12 mmol, 73%).
H NMR (400 MHz, CDCl ) d 8.56 (s, 1H), 8.44 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.79 (dd, J = 8.0, 7.6 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 4.08 (s, 3H), 2.70 (s, 3H), 1.50 (s, 18H).
Example 7-10 : Preparation of [6'-(3-dimethylamino-acryloyl)-3'-methoxy- [2,2']bipyridinylyl-imidocarbonic acid -1,3-bis(1,1-dimethylethyl)ester (LIII) (6'-Acetyl-3'methoxy-[2,2']bipyridinylyl)-imidodicarbonic acid-1,3-bis(1,1- dimethylethyl)ester (LII) (55 mg, 0.12 mmol) was added to 3 ml of N,N-dimethylformamide dimethyl acetal (DMFDMA) and the resulting mixture was stirred with reflux for 20 hrs. And then, the mixture was extracted with 30 ml of water and 30 ml of ethyl acetate. The organic layer was washed with brine two times. The organic layer was treated with magnesium sulfate (MgSO ) and filtered, and the resulting solution was concentrated and purified by silica gel column chromatography (normal hexane : ethylacetate = 1 : 1, v/v) to give the title compound as a solid (38 mg, 0.08 mmol, 67%).
H NMR (400 MHz, CD OD) d 8.60 (s, 1H), 8.40 (s, 1H), 7.87 (d, J = 12.0 Hz, 1H), 7.72-7.82 (m, 2H), 7.20-7.32 (m, 1H), 6.41 (d, J = 12.0 Hz, 1H), 4.08 (s, 3H), 3.16 (brs, 3H), 2.99 (brs, 3H), 1.47 (s, 18H).
Example 7-11 : Preparation of tert-butyl-(6'-(2-amino-pyrimidinyl)-3'-methoxy- [2,2'-bipyridin]yl)carbamate (LIV) [6'-(3-dimethylamino-acryloyl)-3'-methoxy-[2,2']bipyridinylyl-imidodicarbonic acid- 1,3-bis(1,1-dimethylethyl)ester (LIII) (38 mg, 0.08 mmol) was dissolved in 3 ml of methanol, and guanidine hydrochloride (7.6 mg, 0.08 mmol) and 25% sodium methoxide (NaOMe) (18 ul, 0.08 mmol) were added to the resulting solution and the solution was stirred with reflux for 20 hrs. After the reaction was completed, the solvent was concentrated under reduced pressure.
Then, a small amount of water was added and the resulting solution was acidified with 4M hydrochloric acid (HCl) to pH 4. The resulting solid was filtered to give the title compound as a solid (22 mg, 0.06 mmol, 70%) without silica gel column chromatography.
H NMR (600 MHz, DMSO-d ) d 9.89 (s, NH), 8.64 (s, 1H), 8.63 (d, J = 5.4 Hz, 1H), 8.36 (d, J = 4.2 Hz, 1H), 7.84 (dd, J = 5.4, 5.4 Hz, 1H), 7.82 (s, 1H), 7.56 (d, J = 5.4 Hz, 1H), 7.44 (d, J = 4.2 Hz, 1H), 6.66 (s, NH2), 4.04 (s, 3H).
Example 7-12 : Preparation of 6'-amino(2-aminopyrimidinyl)-[2,2'- bipyridin]ol (LV) Tert-butyl-(6'-(2-amino-pyrimidinyl)-3'-methoxy-[2,2'-bipyridin]yl)carbamate (LIV) (22 mg, 0.06 mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (104 mg, 0.90 mmol) in a sealed tube at 170? for 30 min. 2N sodium hydroxide (NaOH) was added to neutralize the resulting mixture to pH 7, and then the mixture was extracted with 30 ml of water and 30 ml of ethylacetate. The organic layer was treated with magnesium sulfate (MgSO ), and filtered, and the resulting solution was concentrated to give the title compound as a yellow solid (6.7 mg, 0.02 mmol, 33%) without silica gel column chromatography.
H NMR (600 MHz, CD OD) d 14.88 (s, OH), 8.69 (s, 1H), 8.34 (s, 1H), 8.32 (d, J = 4.8 Hz, 1H), 7.70 (dd, J = 8.4, 7.8 Hz, 1H), 7.39 (d, J = 4.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 6.81 (s, NH2), 6.65 (s, NHJ2), 6.61 (d, J = 8.4 Hz, 1H).
Preparation Example 1 : Preparation of 2-[3-fluoro(4,4,5,5-tetramethyl- [1,3,2]dioxaborolanyl)pyridinyl]-imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester Preparation Example 1-1 : Preparation of 4-chlorofluoropyridine 4-Chlorofluoropyridine hydrochloride (50g, 0.298mol) was dissolved in distilled water (200ml) and 2N sodium hydroxide (NaOH) aqueous solution was added dropwise to basify the resulting solution (pH=14). And then, the solution was extracted with diethylether, dried over magnesium sulfate (MgSO ), and concentrated under reduced pressure to use in a next reaction without isolation.
Preparation Example 1-2 : Preparation of 4-chlorofluoro-pyridincarboxylic 2,2,6,6,-Tetramethylpiperidine(430ml, 0.357mol) was added dropwise to tetrahydrofuran (THF) (74ml) at -78?, and then 1.6M n-butyllithium hexane solution (220ml, 0.357mol) was added dropwise thereto and the resulting mixture was stirred for 30 min. To the mixture was slowly added dropwise 4-chlorofluoropyridine diethylether solution obtained in Preparation Example 1-1 and the resulting solution was stirred at -78? for 1 hr. Carbon dioxide gas was passed through the solution at -78? for 1 hr, the solution was warmed to room temperature and then stirred for 1 hr. After completion of the reaction by addition of water, the organic layer was separated with diethylether and aqueous layer was acidified to pH 2 using 2N hydrochloric acid aqueous solution. And then, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was recrystallized with hexane/ethylacetate (1/1) to give the white title compound (13.06g, 25.0%).
H NMR (400 MHz, DMSO) d 8.47 (d, J = 3.6 Hz, 1H), 7.95 (m, 1H).
Preparation Example 1-3 : Preparation of (4-chlorofluoro-pyridinyl)- carbamic acid-tert-butyl ester 4-Chlorofluoro-pyridincarboxylic acid (13.06g, 0.074mol) was dissolved in tert- butanol (370ml) and the temperature was lowered to 0?. To the resulting solution was added dropwise triethylamine (15.56ml, 0.112mol). And then, the solution was stirred at room temperature for 40 min and the reaction temperature was lowered to 0?.
Diphenylphosphorylazide (DPPA) (24.09ml, 0.112mol) was added dropwise to the solution and the solution was stirred at room temperature for 1.5 hrs and then with reflux for 18 hrs. After completion of the reaction, the solution was extracted with ethylacetate, washed with distilled water, and then dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 2/1) to give the brown title compound (5.51g, 30.0%).
H NMR (600 MHz, CDCl ) d 9.76 (s, NH), 8.15 (d, J = 6.0 Hz, 1H), 7.51 (m, 1H).
Preparation Example 1-4 : Preparation of 2-(3-fluorochloropyridinyl)- imidocarbonic acid-1,3-bis(1,1-dimethylethyl)ester (4-Chlorofluoro-pyridinyl)-carbamic acid-tert-butyl ester (5.51g 0.022mol) was dissolved in acetonitrile (110ml), and di-t-butyl dicarbonate ((Boc) O) (7.31g, 0.033mol), potassium carbonate (K CO ) (9.62g, 0.67mol), and 4-dimethylaminopyridine(820mg, 0.007mol) were added to the resulting solution. The solution was stirred at room temperature for 18 hrs.
After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 3/1) to give the brown title compound (7.36g, 95.0%).
H NMR (600 MHz, CDCl ) d 8.22 (d, J = 4.2 Hz, 1H), 7.51 (m, 1H), 1.43(m, 18H).
Preparation Example 1-5 : Preparation of 2-[3-fluoro(4,4,5,5-tetramethyl- [1,3,2]dioxaborolanyl)pyridinyl]-imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester 2-(3-Fluorochloropyridinyl)-imidocarbonic acid-1,3-bis(1,1-dimethylethyl)ester (7.36g, 0.021mol) was dissolved in 1,4-dioxane (20ml), and bis(pinacolato)diboron (10.78g, 0.042mol), tris(dibenzylideneacetone)dipalladium(0) (970mg, 1.0mmol), tricyclohexylphosphine (450mg, 1.607mmol), and potassium acetate(8.33g, 0.085mol) were added to the resulting solution. The solution was stirred with reflux for 18 hrs. After completion of the reaction, the solid was removed through celite filter and the solvent was dried under reduced pressure. The resulting residue was isolated and purified by silica gel column chromatography (ethylacetate/methanol = 10/1) to give the brown title compound (2.05g, 22.0%).
H NMR (600 MHz, CDCl ) d 8.28 (d, J = 7.2 Hz, 1H), 7.58 (m, 1H), 1.42(s, 18H), 1.37(s, 12H).
Preparation Example 2 : Preparation of 4-(6-bromomethoxy-pyridinyl)- pyrimidinylamine (LXI) Preparation Example 2-1 : Preparation of 6-bromohydroxy-pyridin carbonitrile and 4,6-dibromohydroxy-pyridincarbonitrile (LVII) 2-Cyanohydroxypyridine (5g, 0.042mol) was dissolved in a mixture of acetonitrile (50ml) and distilled water (10ml) and the resulting solution was cooled to 0?. N- bromosuccinimide (6g, 0.050mol) was slowly added to the solution and the solution was stirred at room temperature for 24 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was washed with small amount of ethylacetate and hexane to give the white title compound (8.28g, 99.9%).
H NMR (400 MHz, CDCl ) d 11.03(s, OH), 7.74 (d, J = 6.0 Hz, 1H), 7.42 (d, J = 6.0 Hz, Preparation Example 2-2 : Preparation of 1-(6-bromohydroxy-pyridinyl)- ethanone and 1-(4,6-dibromohydroxy-pyridinyl)-ethanone (LVIII) 6-Bromohydroxy-pyridincarbonitrile and 4,6-dibromohydroxy-pyridin carbonitrile (8.28g, 0.042mol) were dissolved in tetrahydrofuran (THF) (140ml), and the resulting solution was cooled to 0?. 3M methylmagnesium bromide tetrahydrofuran (THF) solution (40ml) was added to the solution and the solution was stirred at room temperature for 3 hrs. After completion of the reaction by 5N hydrochloric acid aqueous solution (pH=2), aqueous layer was basified with saturated sodium bicarbonate aqueous solution. The solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate/dichloromethane = 10/2/3) to give the white title compound (3.15g, 35.0%).
H NMR (400 MHz, CDCl ) d 11.79(s, OH), 7.54 (m, 1H), 7.42 (d, J = 6.0 Hz, 1H), 2.70 (s, 3H).
Preparation Example 2-3 : Preparation of 1-(6-bromomethoxy-pyridinyl)- ethanone (LVIX) 1-(6-Bromohydroxy-pyridinyl)-ethanone and 1-(4,6-dibromohydroxy-pyridin- 2-yl)-ethanone (3.15g, 0.012mol) were dissolved in acetone (60ml). Potassium carbonate (K CO ) (6.04g, 0.044mol) and iodomethane (CH I) (1.81ml, 0.026mol) were added to the 2 3 3 resulting solution and the solution was stirred with reflux for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the white title compound (3.18g, 95.0%).
H NMR (400 MHz, CDCl ) d 7.77 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 3.30 (s, Preparation Example 2-4 : Preparation of 1-(6-bromomethoxy-pyridinyl) dimethylamino-propenone (LX) 1-(6-Bromomethoxy-pyridinyl)-ethanone (3.18g, 0.014mol) was dissolved in N,N- dimethylformamide dimethyl acetal (DMFDMA) (18.53ml) and the solution was stirred with reflux for 18 hrs. After completion of the reaction, N,N-dimethylformamide dimethyl acetal (DMFDMA) was removed by drying under reduced pressure, and the resulting solution was recrystallized with ethylacetate/hexane to give the brown title compound (3.55g, 90%).
H NMR (400 MHz, CDCl ) d 7.8-7.5(br, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 9.0 Hz, 1H), 5.61(br, 1H), 3.85 (s, 3H).
Preparation Example 2-5 : Preparation of 4-(6-bromomethoxy-pyridinyl)- pyrimidinylamine (LXI) 1-(6-Bromomethoxy-pyridinyl)dimethylamino-propenone (3.55g, 0.012mol) was dissolved in methanol (60ml). 25% Sodium methoxide (8.55ml, 0.037mol) and guanidine hydrochloride (1.79g, 0.019mol) were added to the resulting solution and the solution was stirred with reflux for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the brown title compound (2.98g, 85.0%).
H NMR (400 MHz, DMSO) d 8.31 (d, 1H), 7.66(d, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 9.0 Hz, 1H), 5.61(br, 1H), 3.85 (s, 3H).
Example 8 : Preparation of 2'-amino-6'-(2-aminopyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol (LXIII) Example 8-1 : Preparation of 6-(2-amino-pyrimidinyl)-3'-fluoromethoxy- [2,4']bipyridin-2'-ylamine (LXII) 4-(6-Bromomethoxy-pyridinyl)-pyrimidinylamine (830mg, 2.95mmol) obtained in Preparation Example 2 and 2-[3-fluoro(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl) pyridinyl]-imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester (1.0g, 2.281mmol) obtained in Preparation Example 1 were dissolved in ethylene glycol dimethyl ester/distilled water (10ml/2ml) solution. Sodium carbonate (730mg, 6.887mmol) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (80mg, 0.069mmol) were added to the resulting solution and the solution was stirred with reflux for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the brown title compound (210mg, 30.0%).
H NMR (400 MHz, DMSO) d 8.31 (d, J = 3.2 Hz, 1H), 7.90 (dd, J = 2.4 Hz, J = 3.2Hz, 1H), 7.71 (d, J = 6.0 Hz, 1H), 6.98(m, 1H), 6.82 (d, J = 3.6Hz, 1H), 3.87 (s, 3H).
Example 8-2 : Preparation of 2'-amino-6'-(2-aminopyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol (LXIII) 6-(2-amino-pyrimidinyl)-3'-fluoromethoxy-[2,4']bipyridin-2'-ylamine (LXII) (210mg, 0.672mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (790mg, 6.720mmol) and the mixture was stirred at 170? for 1 hr. The mixture was cooled to room temperature, neutralized with 2N sodium hydroxide (NaOH) solution, and diluted with ethylacetate (EA). Then, the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered and evaporated under reduced pressure to concentrate to give the title compound (170mg, 85%).
H NMR (400 MHz, DMSO) d 8.50 (d, J = 3.6 Hz, 1H), 7.90 (d, J = 5.6Hz, 1H), 7.83 (d, J = 3.2 Hz, 1H), 7.59(dd, J = 3.2 Hz, J = 3.6 Hz, 1H), 7.51 (d, J = 5.6Hz, 1H), 7.31 (br, 2H), 7.12(m, 1H).
Example 9 : Preparation of 2-(2-aminopyrimidinyl)(4- hydroxyphenyl)pyridinol The title compound as a yellow solid (4.6mg) was obtained according to the same procedure as Example 8, except for using 2-(4-methoxy-phenyl)-4,4,5,5-tetramethyl- [1,3,2]dioxaborolane instead of the compound obtained Preparation Example 1.
H NMR (600 MHz, DMSO) d 13.54 (s, 1H), 9.62 (s, 1H), 8.47 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 9.6Hz, 1H), 7.86 (d, J = 12.6 Hz, 1H), 7.64(d, J = 7.8 Hz, 1H), 7.37 (d, J = 12.6Hz, 1H), 7.22 (br, 2H), 6.84(d, J = 9.6 Hz, 1H).
Example 10 : Preparation of 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]- The title compound as a yellow solid (5.3mg) was obtained according to the same procedure as Example 8, except for using 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolaneyl)- pyridinylamine instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO) d 13.56 (s, 1H), 9.66 (s, 1H), 8.49 (d, J = 7.8 Hz, 1H), 7.94 (d, J = 13.2Hz, 1H), 7.88 (d, J = 13.2 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 13.2 Hz, 1H), 7.25 (br, 2H), 6.85 (d, J = 13.2 Hz, 1H).
Example 11 : Preparation of 6-(2-aminopyrimidinyl)-[2,3'-bipyridin]ol The title compound as a yellow solid (8.8mg) was obtained according to the same procedure as Example 8, except for using 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)- pyridine instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO) d 13.81 (s, 1H), 9.29 (s, 1H), 8.58 (d, J = 7.8 Hz, 1H), 8.48(m, 2H). 8.11 (d, J = 12.6Hz, 1H), 7.70 (d, J = 7.2 Hz, 1H), 7.50(m, 2H), 7.29 (br, 2H).
Example 12 : Preparation of 6-(2-aminopyrimidinyl)-[2,4'-bipyridin]ol The title compound as a yellow solid (7.3mg) was obtained according to the same procedure as Example 8, except for using 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)- pyridine instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO) d 13.99 (s, 1H), 8.69 (d, J = 7.2 Hz, 1H), 8.52(d, J = 7.8 Hz, 1H). 8.20 (d, J = 13.2Hz, 1H), 8.15 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 13.2 Hz, 1H), 7.36 (br, 2H).
Example 13 : Preparation of 2-(2-aminopyrimidinyl)(3- hydroxyphenyl)pyridinol The title compound as a yellow solid (11.2mg) was obtained according to the same procedure as Example 8, except for using 2-(3-methoxy-phenyl)-4,4,5,5-tetramethyl- [1,3,2]dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO) d 13.66 (s, 1H), 9.64(s, 1H), 8.50 (d, J = 5.2 Hz, 1H), 7.92(d, J = 8.8 Hz, 1H). 7.65 (d, J = 4.8Hz, 1H), 7.57(s, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 8.8 Hz, 1H), 7.26 (m, 3H), 6.80 (d, J = 8.0 Hz, 1H).
Example 14 : Preparation of 6-(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- The title compound as a yellow solid (10.4mg) was obtained according to the same procedure as Example 8, except for using 3-fluoro(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan yl)-pyridine instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, CD OD) d 8.55 (d, J = 3.6 Hz, 1H), 8.49(d, J = 4.8 Hz, 1H). 8.45 (d, J = 5.4 Hz, 1H), 8.21 (m, 1H), 8.02 (dd, J = 8.4 Hz, J = 9.6 Hz,, 1H), 7.80 (d, J = 5.4 Hz, 1H), 7.47 (d, J = 9.0 Hz, 1H).
Example 15 : Preparation of 6-(4-aminofluorophenyl)(2-aminopyrimidin yl)pyridinol The title compound as a yellow solid (7.9mg) was obtained according to the same procedure as Example 8, except for using N-[3-fluoro(4,4,5,5-tetramethyl- [1,3,2]dioxaborolanyl)-phenyl]phenyl-acetamide instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO) d 13.49 (s, 1H), 8.44 (d, J = 5.2 Hz, 1H), 7.73 (m, 1H), 7.63(d, J = 8.8 Hz, 1H). 7.56 (d, J = 5.2Hz, 1H), 7.34 (d, J = 8.8Hz, 1H), 7.18(br, 2H), 6.47 (d, J = 8.8 Hz, 1H), 6.35 (d, J = 14.8 Hz, 1H), 5.62 (s, 2H).
Example 16 : Preparation of 6-(3-aminophenyl)(2-aminopyrimidinyl)pyridin- The title compound as a yellow solid (5.2mg) was obtained according to the same procedure as Example 8, except for using 2-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan yl)phenyl]-1,3-bis(1,1-dimethylethyl)-ester-imidodicarbonic acid instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO) d 13.62 (s, 1H), 8.50 (d, J = 5.2 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.48 (d, J = 3.2 Hz, 1H). 7.35 (s, 1H), 7.25 (br, 2H), 7.19 (d, J = 7.6Hz, 1H), 7.11 (m, 1H), 6.59 (d, J = 9.2 Hz, 1H), 6.35 (d, J = 14.8 Hz, 1H), 5.16 (s, 2H).
Example 17 : Preparation of 2-(2-aminopyrimidinyl)(2-fluoro hydroxyphenyl)pyridinol The title compound as a yellow solid (27mg) was obtained according to the same procedure as Example 8, except for using 2-(2-fluoromethoxy-phenyl)-4,4,5,5-tetramethyl- [1,3,2]dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO) d 13.63 (s, 1H), 10.11 (s, 1H), 8.48 (d, J = 7.8 Hz, 1H), 7.89 (m, 1H), 7.72 (d, J = 13.2 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 12.6 Hz, 1H). 7.24 (br, 2H), 6.76 (d, J = 12.6Hz, 1H), 6.65 (d, J = 19.8 Hz, 1H).
Example 18 : Preparation of 6-(3-aminofluorophenyl)(2-aminopyrimidin yl)pyridinol The title compound as a yellow solid (26mg) was obtained according to the same procedure as Example 8, except for using 2-fluoro[(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan- 2-yl)phenyl]-1,3-bis(1,1-dimethylethyl)-ester-imidodicarbonic acid instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO) d 13.69 (s, 1H), 8.48 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 13.2 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 13.2 Hz, 1H). 7.25 (br, 2H), 7.07 (m, 1H), 6.97 (m, 1H), 6.80 (m, 1H).
Example 19 : Preparation of 2-(2-aminopyrimidinyl)(3-fluoro hydroxyphenyl)pyridinol The title compound as a yellow solid (50.2mg) was obtained according to the same procedure as Example 8, except for using 2-(3-fluoromethoxy-phenyl)-4,4,5,5-tetramethyl- [1,3,2]dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO) d 13.64 (s, 1H), 10.16(s, 1H), 8.49 (d, J = 3.6 Hz, 1H), 7.94 (d, J = 5.6 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 6.0 Hz, 1H). 7.41 (d, J = 5.6 Hz, 1H), 7.25 (br, 2H), 7.07 (m, 1H).
Example 20 : Preparation of 2-(2-aminopyrimidinyl)(2,3-difluoro hydroxyphenyl)pyridinol The title compound as a yellow solid (12.6mg) was obtained according to the same procedure as Example 8, except for using 2-(2,3-difluoromethoxy-phenyl)-4,4,5,5- tetramethyl-[1,3,2]dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO) d 13.71 (s, 1H), 10.50(br, 1H), 8.49 (d, J = 3.6 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.66 (m, 1H), 7.59 (d, J = 5.2 Hz, 1H). 7.46 (d, J = 8.4 Hz, 1H), 7.28 (br, 2H), 6.92 (m, 1H).
Example 21 : Preparation of 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]- 3',5-diol The title compound as a yellow solid (2.1mg) was obtained according to the same procedure as Example 8, except for using 2-[3-hydroxy(4,4,5,5-tetramethyl- [1,3,2]dioxaborolanyl)pyridinyl]-imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO-d ) d 8.61 (d, J = 5.2 Hz, 1H), 8.28 (d, J = 9.2 Hz, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.51 (d, J = 5.6 Hz, 1H), 7.46 (s, 2H), 7.15 (d, J = 5.2 Hz, 1H), 7.13 (d, J = .6 Hz, 1H), 5.96 (s, 2H).
Example 22 : Preparation of 6-(2-aminopyrimidinyl)(4-(methylamino)thiazol- 2-yl)pyridinol The title compound as a yellow solid (3.2mg) was obtained according to the same procedure as Example 7, except for using (2-chloro-thiazolyl)-methyl-amine instead of 2-(6- chloropyridinyl)-1,3-bis(1,1-dimethylethyl)ester imidodicarbonic acid in Example 7-8.
H NMR (400 MHz, DMSO-d ) d 9.04 (s, 1H), 8.73 (d, J = 3.2 Hz, 1H), 8.38 (d, J = 4.4 Hz, 1H), 7.43 (d, J = 5.2 Hz, 1H), 7.04 (s, 1H), 6.71 (s, 2H), 6.66 (d, J = 5.2 Hz, 1H), 3.70 (s, Example 23 : Preparation of 6-(2-aminopyrimidinyl)-6'-(methylamino)-[2,2'- bipyridin]ol The title compound as a yellow solid (8.4mg) was obtained according to the same procedure as Example 7-12 using the by-product [6'-(2-amino-pyrimidinyl)-3'methoxy- [2,2']bipyridinylyl]-methyl-amine obtained in Example 7-11.
H NMR (600 MHz, CD OD) d 14.88 (s, OH), 8.69 (s, 1H), 8.34 (s, 1H), 8.32 (d, J = 4.8 Hz, 1H), 7.70 (dd, J = 8.4, 7.8 Hz, 1H), 7.39 (d, J = 4.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 6.81 (s, NH2), 6.65 (s, NH2), 6.61 (d, J = 8.4 Hz, 1H), 3.48(s, 1H).
Preparation Example 3 : Preparation of 4-(6-bromomethoxypyridinyl) methylpyrimidinamine (LXIX) Preparation Example 3-1 : Preparation of methyl 3-hydroxypicolinate (LXV) 3-Hydroxypicolinic acid (5.0 g, 35.94 mmol) was dissolved in methanol (120 mL). To the resulting solution was slowly added dropwise sulfuric acid (5.75 mL, 107.83 mmol) at 0? and the solution was refluxed with heat for 24 hrs, cooled to room temperature, and evaporated under reduced pressure. The resulting residue was diluted with dichloromethane and distilled water, neutralized with 6N sodium hydroxide, and extracted with dichloromethane. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the white title compound (4.62 g, 83%).
H NMR (600 MHz, CDCl ) d 8.28 (dd, J = 1.2, 2.4 Hz, 1H), 7.43 (dd, J = 4.2, 4.2 Hz, 1H), 7.38, (dd, J = 1.2, 7.2 Hz, 1H), 4.06 (s, 3H).
Preparation Example 3-2 : Preparation of methyl 6-bromohydroxypicolinate (LXVI) Methyl 3-hydroxypicolinate (4.62 g, 30.17 mmol) was dissolved in distilled water (200 mL). To the resulting solution was slowly added dropwise bromine water (1.7 mL, 33.18 mmol) and the solution was stirred at room temperature for 4 hrs. The solution was diluted with ethylacetate and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 3/1) to give the white title compound (5.07 g, 72%).
H NMR (600 MHz, CDCl ) d 7.55 (d, J = 9.0 Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 4.04 (s, Preparation Example 3-3 : Preparation of methyl 6-bromomethoxypicolinate (LXVII) Methyl 6-bromohydroxypicolinate (5.07 g, 21.85 mmol) was dissolved in acetone (75 mL). To the resulting solution were added dropwise potassium carbonate (K CO ) (4.83 g, 34.96 mmol) and iodomethane (CH I) (1.77 mL, 28.41 mmol) and the solution was refluxed with heat for 3 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with EtOAc, and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 3/1) to give the white title compound (4.18 g, 78%).
H NMR (600 MHz, CDCl ) d 7.57 (d, J = 9.0 Hz, 1H), 7.26 (d, J = 9.0 Hz, 1H), 3.95 (s, 3H), 3.92 (s, 3H).
Preparation Example 3-4 : Preparation of 1-(6-bromomethoxypyridin yl)butan-1,3-dione (LXVIII) Methyl 6-bromomethoxypicolinate (3.79g, 15.40 mmole) was dissolved in tetrahydrofuran (THF). Acetone (1.52g 26.18 mmole) and 30% sodium methoxide (30% NaOMe) (3.81ml, 20.02 mmole) were added to the resulting solution and the solution was stirred at room temperature and evaporated under reduced pressure to concentrate. The resulting residue was diluted with distilled water, acidified with 2N hydrochloric acid (HCl) solution, and extracted with dichloromethane. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the title compound (2.51g, 60%).
H NMR (400 MHz, CDCl ) d 7.52 (dd, J = 6.8 Hz, 1.2 Hz, 1H), 7.25 (dd, J = 6.8 Hz, 1.2 Hz, 1H), 6.43 (s, 1H), 3.92 (s, 3H), 2.18(s, 3H).
Preparation Example 3-5 : Preparation of 4-(6-bromomethoxypyridinyl) methylpyrimidinamine (LXIX) 1-(6-Bromomethoxypyridinyl)butan-1,3-dione (2.51g, 9.22 mmole) and guanidine carbonate (1.83g, 20.28 mmole) were dissolved in ethanol (EtOH). The resulting solution was stirred with reflux for 20 hrs, cooled to room temperature, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (ethylacetate/methanol = 9/1) to give the title compound (680mg, 25%).
H NMR (400 MHz, CDCl ) d 7.48 (d, J = 9.2 Hz, 1H), 7.24 (d, J = 9.2 Hz, 1H), 6.93 (s, 1H), 5.07(s, 2H), 3.85 (s, 3H), 2.39 (s, 3H).
Example 24 : Preparation of 2'-amino(2-aminomethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol (LXXI) Example 24-1 : Preparation of 6-(2-aminomethylpyrimidinyl)-3'-fluoro methoxy-[2,4'-bipyridin]-2'-amine (LXX) 4-(6-Bromomethoxypyridinyl)methylpyrimidinamine (2.34g, 7.93mmol) obtained in Preparation Example 3 and 2-[3-fluoro(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan yl)pyridinyl]-imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester obtained in Preparation Example 1 (5.21g, 11.89mmol) were dissolved in dioxane/distilled water (6ml/4ml) solution.
To the resulting solution were added potassium phosphate (5.48g, 23.78mmol) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh )) (458mg, 0.4mmol) and the reaction solution was stirred with reflux for 24 hrs, cooled to room temperature, and filtered with celite.
The solvent was evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (dimethylchloride/methanol = 9/1) to give the title compound (1.94g, 75%).
H NMR (400 MHz, DMSO-d ) d 7.89 (d, J = 9.0 Hz, 1H), 7.76 (d, J = 5.4 Hz, 1H), 7.69 (d, J = 9.0 Hz, 1H), 6.97 (t, 1H), 6.68 (s, 1H), 6.56 (s, 1H), 6.23 (s, 2H), 3.82 (s, 3H), 2.27 (s, Example 24-2 : Preparation of 2'-amino(2-aminomethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol (LXXI) 6-(2-Aminomethylpyrimidinyl)-3'-fluoromethoxy-[2,4'-bipyridin]-2'-amine (LXX) (1.94g, 5.94mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (10g) and the mixture was stirred at 170? for 1 hr. The mixture was cooled to room temperature, neutralized with 6N sodium hydroxide (NaOH) solution. The resulting solid was filtered and dried to give the title compound (1.67g, 90%).
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 1H), 2.36 (s, Example 25 : Preparation of 6-(2-aminomethylpyrimidinyl)-[2,4'-bipyridin]- The title compound as a yellow solid (15.2mg) was obtained according to the same procedure as Example 24, except for using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan yl)pyridine instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO-d ) d 13.77 (s, 1H), 9.61 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 9.2 Hz, 1H), 7.54 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.12 (s, 2H), 6.84 (d, J = 9.2 Hz, 1H), 2.36 (s, 3H).
Example 26 : Preparation of 6-(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol The title compound as a yellow solid (9.4mg) was obtained according to the same procedure as Example 24, except for using 3-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan yl)pyridine instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO-d ) d 14.14 (s, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.12 (t, 1H), 6.25 (s, 1H), 2.36 (s, 3H).
Example 27 : Preparation of 2-(2-aminomethylpyrimidinyl)(4- hydroxyphenyl)pyridinol The title compound as a yellow solid (6.1mg) was obtained according to the same procedure as Example 24, except for using 2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, DMSO-d ) d 13.77 (s, 1H), 9.61 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 9.2 Hz, 1H), 7.54 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.12 (s, 2H), 6.84 (d, J = 9.2 Hz, 1H), 2.36 (s, 3H).
Example 28 : Preparation of 2-(2-aminomethylpyrimidinyl)(2,3-difluoro hydroxyphenyl)pyridinol The title compound as a yellow solid (6.4mg) was obtained according to the same procedure as Example 24, except for using 2-(2,3-difluoromethoxyphenyl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (400 MHz, CDCl ) d 13.2 (s, 1H), 7.60 (s, 1H), 7.27 (m, 5H), 5.07 (s, 2H), 2.46 (s, 3H).
Example 29 : Preparation of 2-(2-aminomethylpyrimidinyl)(2-fluoro hydroxyphenyl)pyridinol The title compound as a yellow solid (6.4mg) was obtained according to the same procedure as Example 24, except for using 2-(2-fluoromethoxyphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO-d ) d 7.89 (t, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.13 (s, 2H), 6.76 (dd, J = 8.4 Hz, 1.8 Hz, 1H), 6.65 (dd, J = 8.4 Hz, 1.8 Hz, 1H), 2.36 (s, 3H).
Example 30 : Preparation of 2-(2-aminomethylpyrimidinyl)(3- aminophenyl)pyridinol The title compound as a yellow solid (6.4mg) was obtained according to the same procedure as Example 24, except for using 2-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan yl)phenyl]-1,3-bis(1,1-dimethylethyl)-ester-imidodicarbonic acid instead of the compound obtained in Preparation Example 1.
H NMR (600 MHz, DMSO-d ) d 13.83 (s, 1H), 7.80 (d, J= 9.0 Hz, 1H), 7.55 (s, 1H), 7.38 (d, J = 9.0 Hz, 1H), 7.33 (s, 1H), 7.18 (d, J= 7.8 Hz, 1H), 7.11 (s, 2H), 7.09 (t, 1H), 6.58 (d, J= 6.0 Hz, 1H)15.084 (s, 2H), 2.38 (s, 3H).
Preparation Example 4 : Preparation of 4-(6-bromomethoxypyridinyl) isopropylpyrimidinamine (LXIX) The title compound as a yellow solid (1.8g) was obtained according to the same procedure as Preparation Example 3, except for using 3-methylbutanone instead of acetone in Preparation Example 3-4.
H NMR (600 MHz, DMSO-d ) d 8.31 (s, 1H), 7.65 (d, J= 13.8 Hz, 1H), 7.56 (d, J= 12.6 Hz, 1H), 7.23 (br, 2H), 3.76 (s, 3H), 2.37 (m, 1H), 1.02 (d, J= 10.8 Hz, 6H).
Example 31 : Preparation of 2'-amino(2-aminoisopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (8.1mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl) isopropylpyrimidinamine obtained in Preparation Example 4 instead of the compound obtained in Preparation Example 3.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 1H), 2.15 (m, 1H), 0.99 (d, J = 8.4 Hz, 6H).
Preparation Example 5 : Preparation of 4-(6-bromomethoxypyridinyl) (tetrahydro-2H-pyranyl)pyrimidinamine (LXIX) The title compound as a yellow solid (6.4mg) was obtained according to the same procedure as Preparation Example 3, except for using 1-(tetrahydro-2H-pyranyl)ethanone instead of acetone in Preparation Example 3-4.
H NMR (600 MHz, DMSO-d ) d 7.71 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 1H), 3.89 (s, 3H).
Example 32 : Preparation of 2'-amino(2-amino(tetrahydro-2H-pyran yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (8.4mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)(tetrahydro- 2H-pyranyl)pyrimidinamine obtained in Preparation Example 5 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 7.82-7.80 (m, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 5.4 Hz, 1H), 7.03 (s, 1H), 6.82 (br, 2H), 6.25 (br, 2H), 3.70-3.68 (m, 4H), 3.64-3.63 (m, 4H).
Preparation Example 6 : Preparation of 1-(1-methylpiperidinyl)ethanone Preparation Example 6-1 : Preparation of 1-(1-(tert-butoxycarbonyl)piperidine carboxylic acid Isonipecotic acid (5.51g, 0.022mol) was dissolved in dichloromethane (110ml). Di-t- butyl dicarbonate ((Boc) O) (7.31g, 0.033mol) and potassium carbonate (K CO ) (9.62g, 2 2 3 0.67mol) were added to the resulting solution and the solution was stirred at room temperature for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with ethylacetate, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (dichloromethane/methanol, 10/1) to give the white title compound (7.36g, 95.0%).
H NMR (400 MHz, CD OD) d 3.97 (m, 2H), 2.88 (br, 2H), 2.48 (m, 1H), 1.88 (m, 2H), 1.54 (m, 2H), 1.44 (s, 9H) Preparation Example 6-2 : Preparation of tert-butyl (methoxy(methyl)carbamoyl)piperidinecarboxylate 1-(1-(tert-butoxycarbonyl)piperidinecarboxylic acid (6.51g 0.022mol) was dissolved in dichloromethane (50ml). To the resulting solution were added 1,1'-carbonyldiimidazole (CDI) (6.31g, 0.033mol) and N,O-dimethylhydroxylamine hydrochloride (9.62g, 0.67mol) and the solution was stirred at room temperature for 18 hrs. After completion of the reaction by addition of water, the solution was extracted with dichloromethane, washed with distilled water, and dried over magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (dichloromethane/methanol = 10/1) to give the white title compound (5.36g, 95.0%).
H NMR (400 MHz, CDCl ) d 4.14 (m, 2H), 3.71 (s, 3H), 3.13 (s, 3H), 2.79 (m, 5H), 1.42 (s, 9H).
Preparation Example 6-3 : Preparation of tert-butyl 4-acetylpiperidine carboxylate Tert-butyl(methoxy(methyl)carbamoyl)piperidinecarboxylate (2.29 g, 8.32 mmol) was dissolved in 30 ml of tetrahydrofuran (THF) and the resulting solution was cooled to -78 ?.
To the solution was slowly added methylmagnesium bromide (3.0M) (7.73 ml, 10.82mmol) and the solution was stirred at 0 ? for 1 hr. After completion of the reaction by 2N hydrochloric acid aqueous solution, 6N sodium hydroxide solution was added to adjust pH to 10 and then the solution was extracted with dichloromethane. The organic layer was treated with magnesium sulfate (MgSO ) and filtered and the solution was concentrated. The resulting residue was isolated and purified by silica gel column chromatography (dichloromethane/methanol = 10/1) to give the white title compound (6.36g, 94.0%).
H NMR (400 MHz, CDCl ) d 3.90 (m, 2H), 2.98 (s, 2H), 2.51 (s, 1H), 2.15(s, 3H), 1.67 (m, 4H), 1.49 (s, 9H).
Preparation Example 6-4 : Preparation of 1-(piperidinyl)ethanone hydrochloride Tert-butyl 4-acetylpiperidinecarboxylate (3.29 g, 8.32 mmol) was dissolved in 30 ml of methanol. To the resulting solution was slowly added 6N hydrochloric acid aqueous solution and the solution was stirred at room temperature for 18 hrs. After removal of the solvent, acetone was added and the resulting solid was filtered to give the white title compound (4.36g, 95.0%).
H NMR (400 MHz, CDCl ) d 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 2.40 (s, 3H), 1.85 (m, 2H), 1.50 (m, 2H).
Preparation Example 6-5 : Preparation of 1-(1-methylpiperidinyl)ethanone 1-(Piperidinyl)ethanone hydrochloride (4.5 g, 8.32 mmol) was added to 30 ml of formic acid and 30 ml of formaldehyde and the mixture was stirred with reflux for 18 hrs. The solvent was concentrated under reduced pressure and to the solution were added hydrochloric acid and acetone. The resulting solid was filtered to give the white title compound (6.36g, 95.0%).
H NMR (400 MHz, CDCl ) d 2.80 (m, 2H), 2.21 (s, 3H), 2.16 (m, 1H), 2.09 (s, 3H), 1.94 (m, 2H), 1.80 (m, 2H), 1.63 (m, 2H).
Preparation Example 7 : Preparation of 4-(6-bromomethoxypyridinyl) (piperidinyl)pyrimidinamine (LXIX) The title compound as a yellow solid (21mg) was obtained according to the same procedure as Preparation Example 3, except for using 1-(piperidinyl)ethanone obtained in Preparation Example 6-4 instead of acetone in Preparation Example 3-4.
H NMR (600 MHz, DMSO-d ) d 7.70 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H).
Example 33 : Preparation of 2'-amino(2-amino(piperidinyl)pyrimidin yl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (6.8mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)(piperidin yl)pyrimidinamine obtained in Preparation Example 7 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 7.80 (m, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 5.4 Hz, 1H), 7.03 (s, 1H), 6.82 (br, 2H), 6.25 (br, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H).
Preparation Example 8 : Preparation of 4-(6-bromomethoxypyridinyl)(1- methylpiperidinyl)pyrimidinamine (LXIX) The title compound as a yellow solid (21.7mg) was obtained according to the same procedure as Preparation Example 3, except for using 1-(1-methylpiperidinyl)ethanone obtained in Preparation Example 6 instead of acetone in Preparation Example 3-4.
H NMR (600 MHz, DMSO-d ) d 7.71 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.88 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.49 (m, 2H).
Example 34 : Preparation of 2'-amino(2-amino(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (11.5mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)(1- methylpiperidinyl)pyrimidinamine obtained in Preparation Example 8 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 7.74 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H).
Example 35 : Preparation of 2'-amino(2-amino(1-ethylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol Example 35-1 : Preparation of 1-(1-ethylpiperidinyl)ethanone 1-(Piperidinyl)ethanone hydrochloride(6.07 g 21.85 mmol) obtained in Preparation Example 6-4 was dissolved in acetonitrile (75 mL). Potassium carbonate (K CO ) (5.83 g, 34.96 mmol) and iodoethane (CH CH I) (2.77 mL, 28.41 mmol) were added dropwise to the resulting solution and the solution was stirred for 18 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with EtOAc, and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (dimethylchloride/methanol = 10/1) to give the white title compound (5.18 g, 76%).
H NMR (400 MHz, CDCl ) d 2.81 (m, 2H), 2.24 (s, 3H), 2.16 (m, 1H), 2.09 (m, 2H), 1.94 (m, 2H), 1.80 (m, 2H), 1.60 (m, 2H), 1.48 (m, 3H).
Example 35-2 : Preparation of 1-(6-bromomethoxypyridinyl)(1- ethylpiperidinyl)propan-1,3-dione Methyl 6-bromomethoxypicolinate (4.79g, 15.40 mmole) obtained in Preparation Example 3-3 was dissolved in tetrahydrofuran (THF). To the resulting solution were added 1- (1-ethylpiperidinyl)ethanone (5.52g 15.42 mmole) obtained in Example 35-1 and 30% sodium methoxide (30% NaOMe) (4.81ml, 20.02 mmole) and the solution was stirred at room temperature. The solution was evaporated under reduced pressure to concentrate. The resulting residue was diluted with distilled water, acidified with 2N hydrochloric acid (HCl) solution and extracted with dichloromethane. The organic solvent was dried over anhydrous magnesium sulfate (MgSO4), filtered, and evaporated under reduced pressure to concentrate.
The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 1/1) to give the title compound (3.41g, 61%).
H NMR (400 MHz, CDCl ) d 7.52 (d, J = 6.8 Hz, 1H), 7.25 (d, J = 6.8 Hz, 1H), 3.89 (s, 3H), 2.81 (m, 2H), 2.24 (s, 3H), 2.16 (m, 1H), 2.09 (m, 2H), 1.94 (m, 2H), 1.80 (m, 2H), 1.60 (m, 2H), 1.44 (m, 3H).
Example 35-3 : Preparation of 4-(6-bromomethoxypyridinyl)(1- ethylpiperidinyl)pyrimidinamine 1-(6-Bromomethoxypyridinyl)(1-ethylpiperidinyl)propan-1,3-dione (3.41g, 9.22 mmole) and guanidine carbonate (2.75g, 20.28 mmole) were dissolved in ethanol (EtOH) and the resulting solution was stirred with reflux for 20 hrs. The solution was cooled to room temperature and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (ethylacetate/methanol = 10/1) to give the title compound (752mg, 28%).
H NMR (400 MHz, CDCl ) d 7.50 (d, J = 6.8 Hz, 1H), 7.25 (d, J = 6.8 Hz, 1H), 7.24 (s 1H), 6.84 (s 2H), 3.89 (s, 3H), 2.81 (m, 2H), 2.24 (s, 3H), 2.16 (m, 1H), 2.09 (m, 2H), 1.94 (m, 2H), 1.80 (m, 2H), 1.60 (m, 2H), 1.45 (m, 3H).
Example 35-4 : Preparation of 6-(2-amino(1-ethylpiperidinyl)pyrimidin yl)-3'-fluoromethoxy-[2,4'-bipyridin]-2'-amine 4-(6-Bromomethoxypyridinyl)(1-ethylpiperidinyl)pyrimidinamine (2.34g, 7.93mmol) and 2-[3-fluoro(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)pyridinyl]- imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester (5.21g, 11.89mmol) obtained in Preparation Example 1 were dissolved in dioxane/distilled water (6ml/4ml) solution. To the resulting solution were added cesium carbonate (Cs CO) (5.48g, 23.78mmol) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh )) (458mg, 0.4mmol) and the resulting reaction solution was stirred with reflux for 24 hrs. The solution was cooled to room temperature and filtered with celite. The solvent was evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (dimethylchloride/methanol = 9/1) to give the title compound (1.94g, 75%).
H NMR (600 MHz, DMSO-d ) d 7.74 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 3H).
Example 35-5 : Preparation of 2'-amino(2-amino(1-ethylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 6-(2-Amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoromethoxy-[2,4'- bipyridin]-2'-amine (3.88g, 21.88mmol) was mixed with pyridine hydrochloride (Pyridine HCl) (20g) and the mixture was stirred at 170? for 1 hr. The mixture was cooled to room temperature and then neutralized with 6N sodium hydroxide (NaOH) solution. The resulting solid was filtered and dried to give the title compound (3.34g, 89%).
H NMR (600 MHz, DMSO-d ) d 7.74 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 3H).
Example 36 : Preparation of 2'-amino(2-amino(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (14.5mg) was obtained according to the same procedure as Example 35, except for using 1-iodopropane(CH CH CH I) instead of iodoethane 3 2 2 (CH CH I) in Example 35-1.
H NMR (600 MHz, DMSO-d ) d 7.75 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.51 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 3H).
Example 37 : Preparation of 2'-amino(2-amino(1-isopropylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (27.5mg) was obtained according to the same procedure as Example 35, except for using 2-iodopropane(CH CH(I)CH ) instead of iodoethane (CH CH I) in Example 35-1.
H NMR (600 MHz, DMSO-d ) d 7.75 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 6H).
Preparation Example 9 : Preparation of 4-(6-bromomethoxypyridinyl)(1- methylpiperidinyl)-pyrimidinamine (LXIX) The title compound as a yellow solid (45.3mg) was obtained according to the same procedure as Preparation Example 3, except for using 1-(1-methylpiperidinyl)ethanone instead of acetone in Preparation Example 3-4.
H NMR (600 MHz, DMSO-d ) d 7.74 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.14 (s, 2H), 3.88 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.48 (m, 2H).
Example 38 : Preparation of 2'-amino(2-amino(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (12.8mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)(1- methylpiperidinyl)-pyrimidinamine obtained in Preparation Example 9 instead of the compound obtained Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 7.74 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H).
Example 39 : Preparation of 2'-amino(2-amino(1-ethylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (21.8mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)ethanone instead of 1-(piperidin yl)ethanone hydrochloride in Example 35-1.
H NMR (600 MHz, DMSO-d ) d 7.74 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H), 1.21 (m, 3H).
Example 40 : Preparation of 2'-amino(2-amino(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (3.8mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)ethanone and 1- iodopropane(CH CH CH I) instead of 1-(piperidinyl)ethanone hydrochloride and iodoethane 3 2 2 (CH CH I) in Example 35-1.
H NMR (600 MHz, DMSO-d ) d 7.75 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H), 1.20 (m, 3H).
Example 41 : Preparation of 2'-amino(2-amino(1-isopropylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (32.5mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)ethanone and 2- iodopropane(CH CH(I)CH ) instead of 1-(piperidinyl)ethanone hydrochloride and iodoethane (CH CH I) in Example 35-1.
H NMR (600 MHz, DMSO-d ) d 7.75 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.22 (m, 2H), 6.13 (s, 2H), 3.14 (m, 2H), 2.42 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H), 1.20 (m, 9H).
Preparation Example 10 : Preparation of 1-(1-methylpiperidinyl)propanone The title compound as a yellow solid (3.5g) was obtained according to the same procedure as Preparation Example 6, except for using ethylmagnesium bromide instead of methylmagnesium bromide in Preparation Example 6-3.
H NMR (600 MHz, DMSO-d ) d 3.10 (m, 2H), 2.48 (m, 4H), 2.35 (s, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.23 (t, 3H).
Preparation Example 11 : Preparation of 4-(6-bromomethoxypyridinyl) methyl(1-methylpiperidinyl)pyrimidinamine (LXIX) The title compound as a yellow solid (26.2mg) was obtained according to the same procedure as Preparation Example 3, except for using 1-(1-methylpiperidinyl)propanone obtained in Preparation Example 10 instead of acetone in Preparation Example 3-4.
H NMR (400 MHz, DMSO-d ) d 7.84 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.18 (s, 2H), 3.84 (s, 3H), 3.10 (m, 2H), 2.48 (s, 3H), 2.56 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H).
Example 42 : Preparation of 2'-amino(2-aminomethyl(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (11.3mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)methyl(1- methylpiperidinyl)pyrimidinamine obtained in Preparation Example 11 instead of the compound obtained in Preparation Example 3.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 1H), 3.10 (m, 2H), 2.48 (s, 3H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H).
Example 43 : Preparation of 2'-amino(2-amino(1-ethylpiperidinyl) methylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (42.1mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)propanone instead of 1- (piperidinyl)ethanone hydrochloride in Example 35-1.
H NMR (400 MHz, DMSO-d ) d 14.12 (s, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 2H), 3.10 (m, 2H), 3.03 (m, 2H),2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 2.48 (t, 3H).
Example 44 : Preparation of 2'-amino(2-aminomethyl(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (44.8mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)propanone and 1- iodopropane(CH CH CH I) instead of 1-(piperidinyl)ethanone hydrochloride and iodoethane 3 3 3 (CH CH I) in Example 35-1.
H NMR (400 MHz, DMSO-d ) d 14.12 (s, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.80 (d, J = 6.4 Hz, 1H), 7.47 (s, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 2H), 3.82 (m, 2H), 3.10 (m, 2H), 3.03 (m, 2H),2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.45 (t, Example 45 : Preparation of 2'-amino(2-amino(1-isopropylpiperidinyl) methylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (54.1mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)propanone and 2- iodopropane(CH CH(I)CH ) instead of 1-(piperidinyl)ethanone hydrochloride and iodoethane (CH CH I) in Example 35-1.
H NMR (400 MHz, DMSO-d ) d 14.12 (s, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.80 (d, J = 6.4 Hz, 1H), 7.46 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.18 (s, 2H), 7.18 (t, 1H), 6.25 (s, 2H), 3.10 (m, 2H), 2.54 (m, 1H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.15 (d, 6H).
Preparation Example 12 : Preparation of 1-(1-methylpiperidinyl)propanone The title compound as a yellow solid (2.8g) was obtained according to the same procedure as Preparation Example 6, except for using nipecotic acid and ethylmagnesium bromide instead of isonipecotic acid in Preparation Example 6-1 and methylmagnesium bromide in Preparation Example 6-3.
H NMR (600 MHz, DMSO-d ) d 3.11 (m, 2H), 3.24 (m, 2H), 2.48 (m, 3H), 2.35 (s, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.23 (t, 3H).
Preparation Example 13 : Preparation of 4-(6-bromomethoxypyridinyl) methyl(1-methylpiperidinyl)pyrimidinamine (LXIX) The title compound as a yellow solid (1.42g) was obtained according to the same procedure as Preparation Example 3, except for using 1-(1-methylpiperidinyl)propanone obtained in Preparation Example 12 instead of acetone in Preparation Example 3-4.
H NMR (400 MHz, DMSO-d ) d 7.44 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 6.0 Hz, 1H), 7.18 (s, 2H), 3.83 (s, 3H), 3.12 (m, 2H), 2.48 (s, 3H), 2.56 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.28 (m, 2H).
Example 46 : Preparation of 2'-amino(2-aminomethyl(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (33.8mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)methyl(1- methylpiperidinyl)pyrimidinamine obtained in Preparation Example 13 instead of the compound obtained in Preparation Example 3.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 1H), 3.24 (m, 2H), 3.10 (m, 2H), 2.53 (s, 3H), 2.48 (m, 3H), 2.35 (s, 3H), 2.06 (m, 2H), 1.91 (m, 2H).
Example 47 : Preparation of 2'-amino(2-aminomethyl(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (18.2mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)propanone and 1- iodopropane(CH CH CH I) instead of 1-(piperidinyl)ethanone hydrochloride and iodoethane 3 3 3 (CH CH I) in Example 35-1.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.47 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.13 (t, 1H), 6.25 (s, 1H), 3.23 (m, 2H), 2.35 (m, 2H), 3.10 (m, 2H), 2.48 (m, 3H), 2.35 (m, 2H), 2.06 (m, 2H), 1.91 (m, 2H), 1.23 (t, Example 48 : Preparation of 2'-amino(2-amino(1-isopropylpiperidinyl) methylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (32mg) was obtained according to the same procedure as Example 35, except for using 1-(piperidinyl)propanone and 2- iodopropane(CH CH(I)CH ) instead of 1-(piperidinyl)ethanone hydrochloride and iodoethane (CH CH I) in Example 35-1.
H NMR (400 MHz, DMSO-d ) d 14.11 (s, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.13 (t, 1H), 6.25 (s, 1H), 3.14 (m, 2H), 2.54 (m, 1H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.15 (d, 6H).
Preparation Example 14 : Preparation of 1-(1-isopropylpiperidinyl)butanone Preparation Example 14-1 : Preparation of tert-butyl 4-butanoylpiperidine carboxylate The title compound as a yellow solid (10.5g) was obtained according to the same procedure as Preparation Example 6-3, except for using propylmagnesium bromide instead of methylmagnesium bromide in Preparation Example 6-3.
H NMR (400 MHz, CDCl ) d 3.76 (m, 2H), 2.98 (s, 2H), 2.84 (s, 2H), 2.51 (s, 1H), 2.24 (m, 2H), 2.15 (m, 2H), 1.67 (m, 3H), 1.49 (s, 9H).
Preparation Example 14-2 : Preparation of 1-(piperidinyl)butanone hydrochloride The title compound as a yellow solid (5.07g) was obtained according to the same procedure as Preparation Example 6-4, except for using tert-butyl 4-butanoylpiperidine carboxylate instead of tert-butyl 4-acetylpiperidinecarboxylate in Preparation Example 6-4.
H NMR (400 MHz, CDCl ) d 3.86 (m, 2H), 2.78 (s, 2H), 2.84 (s, 2H), 2.51 (s, 1H), 2.24 (m, 4H), 1.45 (m, 3H).
Preparation Example 14-3 : Preparation of 1-(1-isopropylpiperidinyl)butan 1-(Piperidinyl)butanone hydrochloride(2.51 g, 10.9 mmol) obtained in Preparation Example 14-2 was dissolved in acetonitrile (35 mL). To the resulting solution were added dropwise potassium carbonate (K CO ) (2.08 g, 18.9 mmol) and 2-iodopropane (CH CH(I)CH ) 2 3 3 3 (0.99 mL, 14.2 mmol) and the solution was stirred for 18 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with EtOAc, and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate.
The resulting residue was isolated and purified by silica gel column chromatography (dimethylchloride/methanol = 10/1) to give the white title compound (2.09 g, 81%).
H NMR (400 MHz, CDCl ) d 3.88 (m, 2H), 3.79 (m, 2H), 2.84 (m, 2H), 2.51 (m, 3H), 2.31 (m, 1H), 2.24 (m, 4H), 1.45 (m, 3H), 1.24(d, 6H) Example 49 : Preparation of 2'-amino(2-aminoethyl(1-isopropylpiperidin- 4-yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (21.5mg) was obtained according to the same procedure as Example 35, except for using 1-(1-isopropylpiperidinyl)butanone obtained in Preparation Example 14 instead of 1-(1-ethylpiperidinyl)ethanone in Example 35-2.
H NMR (400 MHz, MeOD-d ) d 10.0 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 6.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.26 (m, 1H), 3.08 (m, 2H), 2.93 (m, 3H), 2.74 (m, 1H), 2.24 (m, 2H), 2.00 (m, 2H), 1.62 (m, 2H), 1.25 (t, 3H), 1.04 (d, 6H).
Preparation Example 15 : Preparation of 1-(1-isopropylpiperidinyl)pentanone The title compound as a yellow solid (10.8g) was obtained according to the same procedure as Preparation Example 14, except for using butylmagnesium chloride instead of propylmagnesium bromide in Preparation Example 14-1.
H NMR (400 MHz, MeOD-d ) d, 3.43 (m, 2H), 3.27 (m, 2H), 3.15 (m, 4H), 2.27 (m, 3H), 1.92 (m, 2H), 1.34 (m, 6H), 0.71 (m, 3H).
Example 50 : Preparation of 2'-amino(2-amino(1-isopropylpiperidinyl) propylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (32.1mg) was obtained according to the same procedure as Example 35, except for using 1-(1-isopropylpiperidinyl)pentanone obtained in Preparation Example 15 instead of 1-(1-ethylpiperidinyl)ethanone in Example 35-2.
H NMR (400 MHz, MeOD-d ) d 10.1 (s, 1H), 8.01 (d, J = 9.0 Hz, 1H), 7.84 (d, J = 7.2 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.26 (m, 1H), 3.08 (m, 2H), 2.93 (m, 3H), 2.74 (m, 1H), 2.52 (m, 1H), 2.24 (m, 2H), 2.00 (m, 2H), 1.63 (m, 2H), 1.23 (t, 3H), 1.02 (d, 6H).
Example 51 : Preparation of 2'-amino(2-aminomorpholinopyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol (LXXVI) Example 51-1 : Preparation of ethyl 3-(6-bromomethoxypyridinyl) oxopropanoate (LXXII) Methyl 6-bromomethoxypicolinate (4.18 g, 16.99 mmol) obtained in Preparation Example 3-3 was dissolved in ethanol (85 mL). The resulting solution was cooled to 0? and potassium tert-butoxide (t-BuOK) was added dropwise thereto. The solution was stirred at room temperature for 2 hrs. Distilled water and acetic acid (5 mL) were added dropwise to the solution and the solution was stirred for 10 min. The solution was diluted with ethylacetate and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 2/1) to give the white title compound (3.41 g, 66%).
H NMR (600 MHz, CDCl ) d 7.58 (d, J = 8.4 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 4.05 (s, 2H), 3.93 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H).
Example 51-2 : : Preparation of 2-amino(6-bromomethoxypyridin yl)pyrimidin(1H)-one (LXXIII) Ethyl 3-(6-bromomethoxypyridinyl)oxoproanoate (3.41 g, 11.29 mmol) was dissolved in ethanol (40 mL). To the resulting solution was added dropwise guanidine carbonate (2.64 g, 14.67 mmol) and the solution was refluxed with heat for 24 hrs. The mixture was cooled to room temperature and evaporated under reduced pressure to concentrate. The resulting residue was diluted with distilled water and neutralized with Conc. HCl to provide a solid. The solid was filtered to give the title compound (3.47 g, 100%).
H NMR (600 MHz, DMSO-d ) d 7.71 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 1H), 3.89 (s, 3H).
Example 51-3 : Preparation of 4-(6-bromomethoxypyridinyl) morpholinopyrimidinamine (LXXIV) 2-Amino(6-bromomethoxypyridinyl)pyrimidin(1H)-one (100.0 mg, 336.58 umol) was dissolved in acetonitrile (3.36 mL). To the resulting solution were added dropwise (benzotriazolyloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (193.52 mg, 437.55 umol), 1,8-diazabicyclo[5,4,0]undecene (DBU) (75.5 uL, 504.86 umol) and the resulting mixture was stirred at room temperature for 10 min. Morpholine (44.43 uL, 504.86 umol) was added dropwise to the mixture and the mixture was stirred at room temperature for 24 hrs. The resulting solution was evaporated under reduced pressure to concentrate, diluted with ethylacetate, and washed with distilled water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate.
The resulting residue was isolated and purified by silica gel column chromatography (dichloromethane/methanol = 15/1) to give the title compound (98 mg, 80%).
H NMR (600 MHz, MeOH-d ) d 7.77 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.36 (s, 1H), 4.09 (s, 3H), 3.88 (m, 4H), 3.79 (m, 4H).
Example 51-4 : Preparation of 6-(2-aminomorpholinopyrimidinyl)-3'-fluoro- -methoxy-[2,4'-bipyridin]-2'-amine (LXXV) 4-(6-Bromomethoxypyridinyl)morpholinopyrimidinamine (157.91 mg, 431.21 umol) and 2-[3-fluoro(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)pyridinyl]- imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester (378 mg, 862.42 umol) obtained in Preparation Example 1 were dissolved in dioxane (4 mL). To the resulting solution were added dropwise potassium phosphate (K PO ) (274.6 mg, 1.29 mmol) dissolved in distilled water (2 mL) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (24.94 mg, 21.56 umol). The solution was refluxed with heat for 24 hrs, cooled and evaporated under reduced pressure to concentrate. The solution was diluted with dichloromethane and washed with water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (ethylacetate/hexane, 6/1) to give the title compound (47 mg, 27%).
H NMR (600 MHz, DMSO-d ) d 7.88 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 4.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H) 6.99 (t, J = 6.0 Hz, 1H), 6.23 (m, 5H), 3.85 (s, 3H), 3.65 (m, 4H), 3.53 (m, Example 51-5 : Preparation of 2'-amino(2-aminomorpholinopyrimidinyl)- 3'-fluoro-[2,4'-bipyridin]ol (LXXVI) 6-(2-Aminomorpholinopyrimidinyl)-3'-fluoromethoxy-[2,4'-bipyridin]-2'-amine (120 mg, 301.95 umol) and pyridine hydrochloride (Pyridine HCl) (523.41 mg, 4.53 mmol) were stirred in a sealed tube at 170? for 30 min. The resulting mixture was cooled to room temperature, neutralized with 2N NaOH solution to provide a solid. The solid was filtered, washed with diethylether and dried to give the title compound (72 mg, 62%).
H NMR (600 MHz, DMSO-d ) d 7.82-7.80 (m, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 5.4 Hz, 1H), 7.03 (s, 1H), 6.82 (br, 2H), 6.25 (br, 2H), 3.70-3.68 (m, 4H), 3.64-3.63 (m, 4H).
Example 52 : Preparation of 2'-amino(2-amino(dimethylamino)pyrimidin yl)-3'-fluoro-[2,4'-bipyridin]ol Example 52-1 : Preparation of 6-(6-bromomethoxypyridinyl)-N4,N4- dimethylpyrimidin-2,4-diamine (LXXIV) 2-Amino(6-bromomethoxypyridinyl)pyrimidin-4(1H)-one (400.0 mg, 1.35 mmol) obtained in Example 51-2 was dissolved in acetonitrile (136.5 mL). To the resulting solution were added dropwise (benzotriazoleyloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (774.09 mg, 1.75 mmol) and 1,8-diazabicyclo[5,4,0]undecene (DBU) (604.1 uL, 4.04 mmol) and the solution was stirred at room temperature for 10 min.
Dimethylamine hydrochloride (164.69 mg, 2.02 mmol) was added dropwise to the solution and the solution was stirred at room temperature for 24 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with ethylacetate, and washed with distilled water. The organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting residue was isolated and purified by silica gel column chromatography (dichloromethane/methanol = 15/1) to give the title compound (436 mg, 99%).
H NMR (600 MHz, DMSO-d ) d 7.92 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 9.0 Hz, 1H), 7.16 (s, 1H), 4.04 (s, 3H), 3.31 (s, 6H).
Example 52-2 : Preparation of 6-(2'-amino-3'-fluoromethoxy-[2,4'-bipyridin] yl-N4,N4-dimethylpyrimidin-2,4-diamine (LXXV) 6-(6-Bromomethoxypyridinyl)-N4,N4-dimethylpyrimidin-2,4-diamine (214.49 mg, 661.65 umol) and 2-[3-fluoro(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)pyridinyl]- imidodicarbonic acid-1,3-bis(1,1-dimethylethyl)ester (580 mg, 1.32 mmol) obtained in Preparation Example 1 were dissolved in dioxane (6 mL). To the resulting solution were added dropwise potassium phosphate (K PO ) (421.34 mg, 1.98 mmol) dissolved in distilled water (3 mL) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (38.26 mg, 33.08 umol). The solution was refluxed with heat for 24 hrs, cooled, and evaporated under reduced pressure to concentrate. The solution was diluted with distilled water and dichloromethane and then the resulting solid was filtered, washed with diethylether, and dried to give the title compound (96 mg, 41%).
H NMR (600 MHz, DMSO-d ) d 7.93 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 5.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.03 (t, J = 4.8 Hz, 1H), 6.59 (s, 2H), 6.41 (s, 1H), 6.28 (s, 2H), 3.90 (s, 3H), 3.08 (s, 6H).
Example 52-3 : Preparation of 2'-amino(2-amino(dimethylamino)pyrimidin- 4-yl)-3'-fluoro-[2,4'-bipyridin]ol (LXXVI) 6-(2'-Amino-3'-fluoromethoxy-[2,4'-bipyridin]yl-N4,N4-dimethylpyrimidin-2,4- diamine (96 mg, 270.13 umol) and pyridine hydrochloride (Pyridine HCl) (936.5 mg, 8.10 mmol) were stirred in a sealed tube at 170? for 2 hrs. The resulting mixture was cooled to room temperature and neutralized with 2N NaOH solution to provide a solid. The solid was filtered, washed with diethylether, and dried to give the title compound (22 mg, 24%).
H NMR (600 MHz, DMSO-d ) d 7.82 (d, J = 5.4 Hz, 1H), 7.80 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.12 (t, J = 5.4 Hz, 1H), 6.94 (s, 1H), 6.72 (br, 2H), 6.25 (br, 2H), 3.11 (s, Example 53 : Preparation of 2'-amino(2-amino(4-methylpiperazin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (28mg) was obtained according to the same procedure as Example 52, except for using 4-methylpiperazine instead of dimethylamine hydrochloride in Example 52-1.
H NMR (600 MHz, DMSO-d ) d 7.84-7.82 (m, 2H), 7.44 (d, J = 9.0 Hz, 1H), 7.19 (t, J = 4.8 Hz, 1H), 7.10 (s, 1H), 6.94 (br, 2H), 6.30 (br, 2H), 3.47 (m, 4H), 3.06 (m, 4H), 2.79 (s, 3H).
Example 54 : Preparation of 6-(2-aminochloropyrimidinyl)-[2,4'-bipyridin] Example 54-1 : Preparation of 4-(6-bromomethoxypyridinyl) chloropyrimidinamine 2-Amino(6-bromomethoxypyridinyl)pyrimidin-4(1H)-one (100 mg, 336.58 mol) obtained in Example 51-2 was dissolved in acetonitrile (2 mL). To the resulting solution were added dropwise benzyltriethylammonium chloride (TEBAC) (153.33 mg, 673.15 umol), triethylamine (93.82 uL, 673.15 umol) and phosphoryl chloride (POCl ) (313.72 uL, 3.37 mmol) and the solution was refluxed with heat for 4 hrs and cooled to room temperature. The solution was evaporated under reduced pressure to concentrate and neutralized with 6N sodium hydroxide.
After extraction of the solution with dichloromethane, the organic solvent was dried over anhydrous magnesium sulfate (MgSO ), filtered, and evaporated under reduced pressure to concentrate. The resulting solid was washed with diethylether to give the title compound (26 mg, 24%).
H NMR (600 MHz, DMSO-d ) d 7.72 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.28 (br, 2H), 6.93 (s, 1H).
Example 54-2 : Preparation of 4-chloro(5-methoxy-[2,4'-bipyridin] yl)pyrimidinamine 4-(6-Bromomethoxypyridinyl)chloropyrimidinamine (26 mg, 82.39 umol) and pyridinylboronic acid (12.15 mg, 98.87 umol) were dissolved in dioxane (300 uL). To the resulting solution were added dropwise potassium phosphate (K PO ) (52.47 mg, 247.18 umol) dissolved in distilled water (100 uL) and tetrakis(triphenylphosphine)palladium(0) (Pd(PPh ) ) (4.76 mg, 4.12 umol). The solution was refluxed with heat for 24 hrs, cooled, evaporated under reduced pressure to concentrate, and diluted with distilled water and dichloromethane. The resulting solid was filtered, washed with diethylether, and dried to give the title compound (7.6 mg, 29%).
H NMR (600 MHz, MeOD-d ) d 8.60 (m, 2H), 8.16 (d, J = 9.0 Hz, 1H), 8.10 (m, 2H), 7.74 (d, J = 9.6 Hz, 1H), 7.15 (s, 1H), 3.98 (s, 3H).
Example 54-3 : Preparation of 6-(2-aminochloropyrimidinyl)-[2,4'-bipyridin]- 4-Chloro(5-methoxy-[2,4'-bipyridin]yl)pyrimidinamine (20 mg, 63.74 umol) and pyridine hydrochloride (Pyridine HCl) (73.66 mg, 637.45 mmol) were stirred in a sealed tube at 170? for 3 hrs. The mixture was cooled to room temperature and neutralized with 2N NaOH solution. The resulting solid was filtered, washed with diethylether, and dried to give the title compound (6 mg, 31%).
H NMR (600 MHz, DMSO-d ) d 8.64 (m, 2H), 8.16 (d, J = 5.4 Hz, 2H), 8.05 (d, J = 9.0 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 6.97 (s, 1H).
Preparation Example 16 : Preparation of 4-(6-bromomethoxypyridinyl) methylpyrimidinamine (LXIX) The title compound as a yellow solid (4.1g) was obtained according to the same procedure as Preparation Example 2, except for using 3M ethylmagnesium bromide diethylether solution instead of 3M methylmagnesium bromide tetrahydrofuran (THF) solution in Preparation Example 2-2.
H NMR (600 MHz, MeOH-d ) d 7.77 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.36 (s, 1H), 3.87 (s, 3H), 2.45 (s, 3H).
Example 55 : Preparation of 2'-amino(2-aminomethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (8.4mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl) methylpyrimidinamine obtained in Preparation Example 16 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, CD OD) d 8.32 (s, 1H), 8.01 (d, J= 9.0 Hz, 1H), 7.78 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 9.0 Hz, 1H), 7.41 (t, 1H), 2.64 (s, 3H).
Preparation Example 17 : Preparation of 4-(6-bromomethoxypyridinyl) ethylpyrimidinamine (LXIX) The title compound as a yellow solid (451mg) was obtained according to the same procedure as Preparation Example 2, except for using 3M propylmagnesium bromide diethylether solution instead of 3M methylmagnesium bromide tetrahydrofuran (THF) solution in Preparation Example 2-2.
H NMR (600 MHz, MeOH-d ) d 7.76 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.36 (s, 1H), 3.87 (s, 3H), 2.89 (m, 2H), 0.73 (t, 3H).
Example 56 : Preparation of 2'-amino(2-aminoethylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol The title compound as a yellow solid (18.9mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl) ethylpyrimidinamine obtained in Preparation Example 17 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 8.32 (s, 1H), 7.85 (d, J= 9.0 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H), 7.78 (s, 2H), 6.78 (m, 1H), 6.25 (s, 2H), 2.85 (m, 2H), 1.04(t, 3H).
Preparation Example 18 : Preparation of 4-(6-bromomethoxypyridinyl) propylpyrimidinamine (LXIX) The title compound as a yellow solid (28mg) was obtained according to the same procedure as Preparation Example 2, except for using 3M butylmagnesium chloride diethylether solution instead of 3M methylmagnesium bromide tetrahydrofuran (THF) solution in Preparation Example 2-2.
H NMR (600 MHz, DMSO-d ) d 8.27 (s, 1H), 7.51 (d, J= 9.0 Hz, 1H), 7.42 (d, J = 9.0 Hz, 1H), 3.85 (s, 3H), 2.85 (m, 2H), 1.44 (m, 2H), 1.04(t, 3H) Example 57 : Preparation of 2'-amino(2-aminopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (6.4mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl) propylpyrimidinamine obtained in Preparation Example 18 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 13.93 (s, 1H), 8.27 (s, 1H), 7.51 (d, J= 9.0 Hz, 1H), 7.42 (d, J = 9.0 Hz, 1H), 6.98 (s, 2H), 6.78 (m, 1H), 6.25 (s, 2H), , 2.85 (m, 2H), 1.44 (m, 2H), 1.04(t, 3H).
Preparation Example 19 : Preparation of 4-(6-bromomethoxypyridinyl) isopropylpyrimidinamine (LXIX) The title compound as a yellow solid (120mg) was obtained according to the same procedure as Preparation Example 2, except for using 3M isobutylmagnesium chloride diethylether solution instead of 3M methylmagnesium bromide tetrahydrofuran (THF) solution in Preparation Example 2-2.
H NMR (600 MHz, DMSO-d ) d 8.11 (s, 1H), 7.54 (d, J= 9.0 Hz, 1H), 7.42 (d, J = 9.0 Hz, 1H), 3.27 (m, 2H), 1.04(d, 6H) Example 58 : Preparation of 2'-amino(2-aminoisopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (21.8mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl) isopropylpyrimidinamine obtained in Preparation Example 19 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 13.12 (s, 1H), 8.23 (s, 1H), 7.51 (d, J= 9.0 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 6.98 (s, 2H), 6.78 (m, 1H), 6.25 (s, 2H), , 3.26 (m, 2H), 1.11(d, 6H).
Preparation Example 20: Preparation of 4-(6-bromomethoxypyridinyl)-N- methyl(1-methylpiperidinyl)pyrimidinamine (LXIX) The title compound as a yellow solid (331mg) was obtained according to the same procedure as Preparation Example 3, except for using 1-(1-methylpiperidinyl)ethanone obtained in Preparation Example 6 instead of acetone in Preparation Example 3-4 and using 1- methylguanidine instead of guanidine in Preparation Example 3-5.
H NMR (400 MHz, DMSO-d ) d 7.56 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 6.0 Hz, 1H), 7.38 (s, 2H), 7.32 (t, 1H), 3.48 (s, 3H), 3.10 (m, 2H), 2.48 (s, 3H), 2.42 (s, 3H), 2.35 (m, 3H), 2.14 (m, 2H), 1.28 (m, 2H).
Example 59 : Preparation of 2'-amino-3'-fluoro(2-(methylamino)(1- methylpiperidinyl)pyrimidinyl)-[2,4'-bipyridin]ol The title compound as a yellow solid (29.9mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)-N-methyl(1- methylpiperidinyl)pyrimidinamine obtained in Preparation Example 20 instead of the compound obtained in Preparation Example 3.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 1H), 3.10 (m, 2H), 2.48 (s, 3H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H).
Preparation Example 21: Preparation of 4-(6-bromomethoxypyridinyl)-5,6- dimethylpyrimidinamine Preparation Example 21-1: Preparation of 1-(6-bromomethoxypyridinyl) methylbutan-1,3-dione 1-(6-bromomethoxypyridinyl)butan-1,3-dione(15.41 g, 45.21 mmol) obtained in Preparation Example 3-4 was dissolved in acetonitrile (100 mL). To the resulting solution were added dropwise potassium carbonate (K CO ) (16.88 g, 135.63 mmol) and iodomethane (CH I) 2 3 3 (4.56 mL, 90.42 mmol) and the solution was stirred for 18 hrs. The solution was evaporated under reduced pressure to concentrate, diluted with EtOAc, and washed with water. The washed organic solvent was dried over anhydrous magnesium sulfate (MgSO ) to concentrate.
The resulting residue was isolated and purified by silica gel column chromatography (hexane/ethylacetate = 3/1) to give the white title compound (15.18 g, 67%).
H NMR (600 MHz, CDCl ) d 7.57 (d, J = 9.0 Hz, 1H), 7.26 (d, J = 9.0 Hz, 1H), 3.95 (s, 3H), 2.85 (s, 3H), 2.45 (s, 3H).
Preparation Example 21-2: Preparation of 4-(6-bromomethoxypyridinyl)-5,6- dimethylpyrimidinamine The title compound as a yellow solid (3.12g) was obtained according to the same procedure as Preparation Example 3-5, except for using 1-(6-bromomethoxypyridinyl) methylbutan-1,3-dione obtained in Preparation Example 21-1 instead of the compound obtained in Preparation Example 3-4.
H NMR (600 MHz, DMSO-d ) d 7.80 (d, J= 9.0 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H), 3.95 (s, 3H), 2.85 (s, 3H), 2.45 (s, 3H).
Example 60 : Preparation of 2'-amino(2-amino-5,6-dimethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol The title compound as a yellow solid (34.8mg) was obtained according to the same procedure as Example 24, except for using 4-(6-bromomethoxypyridinyl)-5,6- dimethylpyrimidinamine obtained in Preparation Example 21 instead of the compound obtained in Preparation Example 3.
H NMR (600 MHz, DMSO-d ) d 7.94 (d, J= 9.0 Hz, 1H), 7.90 (d, J= 8.4 Hz, 1H), 7.54 (m, 1H), 7.11 (m, 1H), 6.96 (s, 2H), 6.79 (s, 2H), 2.44 (s, 3H), 2.22 (s, 3H).
Example 61 : Preparation of 2,6-bis(2-aminopyrimidinyl)pyridinol 3hydrochloride The title compound as a yellow solid (4.6mg) was obtained by reacting the compound obtained in Example 1 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 8.56 (d, J = 4.8 Hz, 1H), 8.49 (d, J = 5.2 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 5.2 Hz 1H), 7.79 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 3.97(br, 7H).
Example 62 : Preparation of 2,6-bis(2-aminopyrimidinyl)pyridinol oxalate The title compound as a yellow solid (3.2mg) was obtained by reacting the compound obtained in Example 1 with oxalic acid.
H NMR (400 MHz, DMSO-d ) d 8.57 (d, J = 4.8 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 5.2 Hz 1H), 7.79 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H).
Example 63 : Preparation of 2,6-bis(2-aminopyrimidinyl)pyridinol malonate The title compound as a yellow solid (4.9mg) was obtained by reacting the compound obtained in Example 1 with malonic acid.
H NMR (400 MHz, DMSO-d ) d 8.57 (d, J = 4.8 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 5.2 Hz 1H), 7.79 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 3.17 (s, 2H).
Example 64 : Preparation of 2,6-bis(2-aminopyrimidinyl)pyridinol sulfate The title compound as a yellow solid (3.2mg) was obtained by reacting the compound obtained in Example 1 with sulfuric acid.
H NMR (400 MHz, DMSO-d ) d 8.57 (d, J = 4.8 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 5.2 Hz 1H), 7.79 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H).
Example 65 : Preparation of 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]- -ol oxalate The title compound as a yellow solid (1.9mg) was obtained by reacting the compound obtained in Example 10 with oxalic acid.
H NMR (600 MHz, DMSO) d 13.55 (s, 1H), 9.66 (s, 1H), 8.48 (d, J = 7.8 Hz, 1H), 7.94 (d, J = 13.2Hz, 1H), 7.89 (d, J = 13.2 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 13.2 Hz, 1H), 7.25 (br, 2H), 6.85 (d, J = 13.2 Hz, 1H).
Example 66 : Preparation of 2'-amino-6'-(2-aminopyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 3hydrochloride The title compound as a yellow solid (58mg) was obtained by reacting the compound obtained in Example 8 with hydrochloric acid.
H NMR (600 MHz, DMSO) d 14.10 (s, 1H), 8.55 (d, J = 7.8 Hz, 1H), 8.03 (d, J = 12.6Hz, 1H), 7.88 (d, J = 9.6 Hz, 1H), 7.61 (m, 2H), 7.46 (m, 3H).
Example 67 : Preparation of 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol acetate The title compound as a yellow solid (12.5mg) was obtained by reacting the compound obtained in Example 8 with acetic acid.
H NMR (600 MHz, DMSO) d 14.11 (s, 1H), 8.53 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 12.6Hz, 1H), 7.88 (d, J = 9.6 Hz, 1H), 7.60 (m, 2H), 7.45 (m, 3H), 2.12 (s, 3H).
Example 68 : Preparation of 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol oxalate The title compound as a yellow solid (12.4mg) was obtained by reacting the compound obtained in Example 8 with oxalic acid.
H NMR (600 MHz, DMSO) d 14.10 (s, 1H), 8.53 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 12.6Hz, 1H), 7.88 (d, J = 9.6 Hz, 1H), 7.59 (m, 2H), 7.45 (m, 3H).
Example 69 : Preparation of 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 2malonate The title compound as a yellow solid (9.1mg) was obtained by reacting the compound obtained in Example 8 with malonic acid.
H NMR (600 MHz, DMSO) d 14.11 (s, 1H), 8.53 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 12.6Hz, 1H), 7.88 (d, J = 9.6 Hz, 1H), 7.60 (m, 2H), 7.45 (m, 3H), 3.12 (s, 3H).
Example 70 : Preparation of 2-(2-aminopyrimidinyl)(2-fluoro hydroxyphenyl)pyridinol 2hydrochloride The title compound as a yellow solid (10.1mg) was obtained by reacting the compound obtained in Example 17 with hydrochloric acid.
H NMR (600 MHz, DMSO) d 10.18(s, 1H), 8.05 (s, 1H), 7.89 (m, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.46 (m, 1H), 6.77 (d, J = 7.8Hz, 1H), 6.67 (d, J = 13.2 Hz, 1H).
Example 71 : Preparation of 2'-amino(2-aminomethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (10.1mg) was obtained by reacting the compound obtained in Example 24 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 7.84 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 5.4 Hz, 1H), 7.48 (m, 2H), 7.20 (br, 2H), 7.13 (t, 1H), 6.28 (br, 2H), 2.38 (s, 3H).
Example 72 : Preparation of 2'-amino(2-aminomorpholinopyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (203mg) was obtained by reacting the compound obtained in Example 51 with hydrochloric acid.
H NMR (600 MHz, MeOD-d ) d 8.17 (dd, J = 1.8, 8.4 Hz, 1H), 7.82 (d, J = 7.2 Hz, 1H), 7.77 (t, J = 7.2 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 4.06 (m, 2H), 3.82-3.76 (m, 6H).
Example 73 : Preparation of 2'-amino(2-aminomorpholinopyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol acetate The title compound as a yellow solid (203mg) was obtained by reacting the compound obtained in Example 51 with acetic acid.
H NMR (600 MHz, MeOD-d ) d 7.84 (dd, J = 2.4, 8.4 Hz, 1H), 7.78 (d, J = 5.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.26 (t, J = 5.4 Hz, 1H), 7.23 (s, 1H), 3.78-3.72 (m, 8H), 1.99 (s, 3H).
Example 74 : Preparation of 2'-amino(2-amino(dimethylamino)pyrimidin yl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (242mg) was obtained by reacting the compound obtained in Example 52 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.04 (d, J = 5.4 Hz, 1H), 7.95 (d, J = 7.2 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.12 (t, J = 5.4 Hz, 1H), 6.94 (s, 1H), 6.72 (br, 2H), 6.25 (br, 2H), 3.41 (s, Example 75 : Preparation of 2'-amino(2-amino(4-methylpiperazin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 5hydrochloride The title compound as a yellow solid (48mg) was obtained by reacting the compound obtained in Example 53 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.04 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 6.0 Hz, 1H), 7.73 (m, 1H), 7.63 (m, 1H), 7.34 (s, 1H), 3.72 (m, 4H), 3.56 (m, 2H), 3.13 (m, 2H), 2.81 (s, 3H).
Example 76 : Preparation of 2'-amino(2-amino(4-methylpiperazin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate The title compound as a yellow solid (32mg) was obtained by reacting the compound obtained in Example 53 with acetic acid.
H NMR (600 MHz, MeOD-d ) d 7.94 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 5.4 Hz, 1H), 7.58 (m, 1H), 7.37 (m, 1H), 7.22 (s, 1H), 3.53-3.37 (m, 6H), 3.18 (m, 2H), 2.81 (s, 3H).
Example 77 : Preparation of 2'-amino(2-amino-(6-(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (32mg) was obtained by reacting the compound obtained in Example 34 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.04 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.81 (s, 3H), 2.43 (s, 1H), 1.84 (m, 2H), 1.40 (m, 2H).
Example 78 : Preparation of 2'-amino(2-amino(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 2acetate The title compound as a yellow solid (31mg) was obtained by reacting the compound obtained in Example 34 with acetic acid.
H NMR (600 MHz, DMSO-d ) d 8.05 (d, J = 9.4 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.22 (br, 2H), 6.22 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.98 (s, 2H), 1.85 (m, 2H), 1.49 (m, 2H).
Example 79 : Preparation of 2'-amino(2-amino(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol oxalate The title compound as a yellow solid (21mg) was obtained by reacting the compound obtained in Example 34 with oxalic acid.
H NMR (600 MHz, DMSO-d ) d 8.05 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H).
Example 80 : Preparation of 2'-amino(2-amino(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol malonate The title compound as a yellow solid (19mg) was obtained by reacting the compound obtained in Example 34 with malonic acid.
H NMR (600 MHz, DMSO-d ) d 8.05 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.22 (br, 2H), 6.13 (s, 2H), 4.02 (s, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.53 (m, 2H).
Example 81 : Preparation of 2'-amino(2-aminoisopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (45mg) was obtained by reacting the compound obtained in Example 31 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 6.0 Hz, 1H), 7.56 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.12 (t, 1H), 6.25 (s, 1H), 2.15 (m, 1H), 0.97 (d, J = 8.4 Hz, 6H).
Example 82 : Preparation of 2'-amino(2-aminoisopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 2acetate The title compound as a yellow solid (28.3mg) was obtained by reacting the compound obtained in Example 31 with acetic acid.
H NMR (400 MHz, DMSO-d ) d 14.13 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 6.0 Hz, 1H), 7.54 (s, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.48 (s, 2H), 7.32 (t, 1H), 6.25 (s, 1H), 2.15 (m, 1H), 1.28 (d, J = 8.0 Hz, 6H).
Example 83 : Preparation of 2'-amino(2-amino(piperidinyl)pyrimidin yl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (12.5mg) was obtained by reacting the compound obtained in Example 33 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 7.80 (m, 2H), 8.00 (d, J = 9.0 Hz, 1H), 7.54 (t, J = 5.4 Hz, 1H), 7.32 (s, 1H), 6.99 (br, 2H), 6.25 (br, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 1.85 (m, 2H), 1.51 (m, 2H).
Example 84 : Preparation of 2'-amino(2-amino(piperidinyl)pyrimidin yl)-3'-fluoro-[2,4'-bipyridin]ol acetate The title compound as a yellow solid (9.8mg) was obtained by reacting the compound obtained in Example 33 with acetic acid.
H NMR (600 MHz, DMSO-d ) d 8.02 (m, 2H), 7.59 (d, J = 8.4 Hz, 1H), 7.52 (t, J = 5.4 Hz, 1H), 7.18 (s, 1H), 6.82 (br, 2H), 6.25 (br, 2H), 3.89 (s, 3H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (s, 1H), 1.85 (m, 2H), 1.22 (m, 2H).
Example 85 : Preparation of 2'-amino(2-amino(tetrahydro-2H-pyran yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (8.2mg) was obtained by reacting the compound obtained in Example 32 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.02 (m, 2H), 7.55 (d, J = 8.4 Hz, 1H), 7.44 (t, J = 5.4 Hz, 1H), 7.03 (s, 1H), 6.82 (s, 2H), 6.33 (sr, 2H), 3.70 (m, 4H), 3.65 (m, 4H).
Example 86 : Preparation of 2'-amino(2-amino(1-ethylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (18.6mg) was obtained by reacting the compound obtained in Example 35 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.02 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.81 (br, 2H), 222 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (m, 3H), 2.43 (m, 1H), 1.85 (m, 2H), 1.54 (m, 3H).
Example 87 : Preparation of 2'-amino(2-amino(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (11.8mg) was obtained by reacting the compound obtained in Example 36 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.01 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.51 (br, 2H), 7.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.51 (m, 2H), 2.49 (s, 3H), 2.43 (m, 1H), 1.85 (m, 2H), 1.23 (m, 3H).
Example 88 : Preparation of 2'-amino(2-amino(1-isopropylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (11.4mg) was obtained by reacting the compound obtained in Example 37 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.01 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.54 (br, 2H), 7.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (m, 1H), 1.85 (m, 2H), 1.50 (m, 6H).
Example 89 : Preparation of 2'-amino(2-amino(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (9.8mg) was obtained by reacting the compound obtained in Example 38 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.04 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.55 (br, 2H), 7.13 (br, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.43 (s, 1H), 1.85 (m, 2H), 1.50 (m, 2H).
Example 90 : Preparation of 2'-amino(2-amino(1-ethylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (9.2mg) was obtained by reacting the compound obtained in Example 39 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.02 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.32 (br, 2H), 7.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (m, 1H), 1.85 (m, 2H), 1.50 (m, 2H), 1.21 (t, 3H).
Example 91 : Preparation of 2'-amino(2-amino(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (18.6mg) was obtained by reacting the compound obtained in Example 40 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.03 (d, J = 9.04 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.52 (br, 2H), 7.13 (s, 2H), 3.14 (m, 2H), 2.64 (m, 2H), 2.43 (m, 1H), 1.85 (m, 4H), 1.50 (m, 4H), 1.20 (t, 3H).
Example 92 : Preparation of 2'-amino(2-amino(1-isopropylpiperidin yl)pyrimidinyl)-3'-fluoro[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (25.1mg) was obtained by reacting the compound obtained in Example 41 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.03 (d, J = 9.0 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.62 (m, 2H), 7.13 (s, 2H), 3.14 (m, 2H), 2.42 (s, 1H), 1.85 (m, 4H), 1.50 (m, 4H), 1.20 (m, 9H).
Example 93 : Preparation of 2'-amino(2-aminomethyl(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (28.9mg) was obtained by reacting the compound obtained in Example 42 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 14.00 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 6.4 Hz, 1H), 7.67 (s, 1H), 754 (d, J = 8.4 Hz, 1H), 7.33 (s, 2H), 7.30 (t, 1H), 6.25 (s, 1H), 3.10 (m, 2H), 2.48 (s, 3H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.84 (m, 2H).
Example 94 : Preparation of 2'-amino(2-amino(1-ethylpiperidinyl) methylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (42.1mg) was obtained by reacting the compound obtained in Example 43 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 8.02 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 6.0 Hz, 1H), 7.77 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.32 (s, 2H), 7.12 (t, 1H), 6.25 (s, 2H), 3.10 (m, 2H), 3.03 (m, 2H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.24 (t, 3H).
Example 95 : Preparation of 2'-amino(2-aminomethyl(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (45.9mg) was obtained by reacting the compound obtained in Example 44 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 8.02 (d, J = 6.4 Hz, 1H), 7.80 (d, J = 6.4 Hz, 1H), 7.67 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.35 (s, 2H), 7.12 (t, 1H), 6.65 (s, 2H), 3.82 (m, 2H), 3.10 (m, 2H), 3.03 (m, 2H),2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.45 (t, 3H).
Example 96 : Preparation of 2'-amino(2-amino(1-isopropylpiperidinyl) methylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (84.3mg) was obtained by reacting the compound obtained in Example 45 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) 8.04 (d, J = 6.4 Hz, 1H), 7.54 (d, J = 6.4 Hz, 1H), 7.52 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.38 (s, 2H), 7.18 (t, 1H), 6.35 (s, 2H), 3.10 (m, 2H), 2.54 (m, 1H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.15 (d, 6H).
Example 97 : Preparation of 2'-amino(2-aminomethyl(1-methylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (28.1mg) was obtained by reacting the compound obtained in Example 46 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 8.03 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.56 (s, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.13 (t, 1H), 7.01 (s, 1H), 3.24 (m, 2H), 3.10 (m, 2H), 2.53 (s, 3H), 2.48 (m, 3H), 2.35 (s, 3H), 2.06 (m, 2H), 1.23 (m, 2H).
Example 98 : Preparation of 2'-amino(2-aminomethyl(1-propylpiperidin yl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (33.6mg) was obtained by reacting the compound obtained in Example 47 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 8.03 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.18 (s, 2H), 7.13 (t, 1H), 7.01 (s, 1H), 3.23 (m, 2H), 2.35 (m, 2H), 3.10 (m, 2H), 2.48 (m, 3H), 2.35 (m, 2H), 2.06 (m, 2H), 1.91 (m, 2H), 1.23 (t, 3H).
Example 99 : Preparation of 2'-amino(2-amino(1-isopropylpiperidinyl) methylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (21.4mg) was obtained by reacting the compound obtained in Example 48 with hydrochloric acid.
H NMR (400 MHz, DMSO-d ) d 8.02 (d, J = 9.0 Hz, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.50 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.28 (s, 2H), 7.23 (t, 1H), 7.02 (s, 1H), 3.14 (m, 2H), 2.54 (m, 1H), 2.36 (s, 3H), 2.35 (m, 3H), 2.06 (m, 2H), 1.91 (m, 2H), 1.08 (d, 6H).
Example 100 : Preparation of 2'-amino(2-aminomethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (22.2mg) was obtained by reacting the compound obtained in Example 55 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.02 (s, 1H), 8.01 (d, J= 9.0 Hz, 1H), 7.78 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 9.0 Hz, 1H), 7.41 (t, 1H), 2.45 (s, 3H).
Example 101 : Preparation of 2'-amino(2-amino-5,6-dimethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (18.7mg) was obtained by reacting the compound obtained in Example 60 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.03 (d, J= 9.0 Hz, 1H), 7.90 (d, J= 8.4 Hz, 1H), 7.57 (m, 1H), 7.54 (m, 1H), 7.23 (s, 2H), 7.01 (s, 2H), 2.49 (s, 3H), 2.25 (s, 3H).
Example 102 : Preparation of 2'-amino(2-aminoethylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (13.0mg) was obtained by reacting the compound obtained in Example 56 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 10.0 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 6.8 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.24 (m, 1H), 3.43 (m, 2H), 3.14 (m, 2H), 2.21 (m, 1H), 1.94 (m, 2H), 0.92 (m, 3H).
Example 103 : Preparation of 2'-amino(2-aminopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (28.4mg) was obtained by reacting the compound obtained in Example 57 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 10.0 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 6.8 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.26 (m, 1H), 3.44 (m, 2H), 3.14 (m, 2H), 2.21 (m, 3H), 1.94 (m, 2H), 0.92 (m, 3H).
Example 104 : Preparation of 2'-amino(2-aminoisopropylpyrimidinyl)-3'- fluoro-[2,4'-bipyridin]ol 3hydrochloride The title compound as a yellow solid (22.2mg) was obtained by reacting the compound obtained in Example 58 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 8.62 (s, 1H), 8.04 (d, J = 9.2 Hz, 1H), 8.87 (d, J = 6.0 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.27 (m, 1H), 2.92 (m, 1H), 1.14 (d, J = 6.4 Hz, 6H).
Example 105 : Preparation of 2'-amino(2-aminoethyl(1- isopropylpyrimidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (65.3mg) was obtained by reacting the compound obtained in Example 49 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 9.98 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 6.8 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.26 (m, 1H), 3.43 (m, 2H), 3.27 (m, 2H), 3.15 (m, 4H), 2.27 (m, 3H), 1.92 (m, 2H), 1.34 (d, J = 6.4 Hz, 6H), 0.71 (m, 3H).
Example 106 : Preparation of 2'-amino(2-amino(1-isopropylpiperidinyl) propylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride The title compound as a yellow solid (18.8mg) was obtained by reacting the compound obtained in Example 50 with hydrochloric acid.
H NMR (600 MHz, DMSO-d ) d 10.0 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 6.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.26 (m, 1H), 3.44 (m, 2H), 3.28 (m, 2H), 3.14 (m, 4H), 2.21 (m, 3H), 1.93 (m, 2H), 1.34 (d, J = 6.4 Hz, 6H), 0.95 (m, 3H).
Experimental Example 1 : Analysis for inhibition of CDK enzyme activity The following experiment was conducted to confirm whether the compounds according to the present invention inhibit the activities of CDK1, CDK2, CDK4, CDK5, and CDK6 which are isotypes of a CDK.
Test compounds were prepared by dissolving the compounds obtained in the above Examples in dimethylsulfoxide (DMSO) at a concentration of 10 mM. The test compounds were diluted to 200 nM, 50 nM, 1.5 nM, 3.13 nM, 0.78 nM, and 0.2 nM and used in an enzyme reaction.
CDK enzyme reaction was conducted in a buffer containing 50 mM Tris-HCl (pH 7.5), mM MgCl , 1 mM EGTA, 1 mM EDTA, and 2 mM DTT. CDK1/cyclinB, CDK2/cylcinE, CDK5/p25, and CDK6/cyclinD3 enzymes commercially available from Merck Millipore were used for CDK1, CDK2, CDK5, and CDK6 enzymes, respectively, and CDK4/cyclinD1 enzyme commercially available from Signalchem (US) was used for CDK4. For CDK1, a reaction proceeded by adding 10 nM CDK1/cyclinB and 0.125 mg/ml histone H1 (Merck Millipore) substrate to the buffer and then adding 10 uM ATP thereto. For CDK2, a reaction was proceeded by adding 10 nM CDK2/cyclinE and 0.125 mg/ml histone H1 substrate to the buffer and then adding 10 uM ATP thereto. For CDK5, a reaction was proceeded by adding 10 nM CDK5/p25 and 0.125 mg/ml histone H1 substrate to the buffer and then adding 10 uM ATP thereto. For CDK4, a reaction was proceeded by adding 20 nM CDK4/cyclinD1 and 0.125 mg/ml Rb protein (Merck Millipore) to the buffer and then adding 10 uM ATP thereto. For CDK6, a reaction was proceeded by adding 50 nM CDK6/cyclinD3 and 0.125 mg/ml histone H1 substrate to the buffer and then adding 10 uM ATP thereto. Each enzyme reaction was incubated at 30 ? for 60 min. Then, the amount of ADP produced was measured using Victor X4 instrument (Perkin Elmer) after generating luminescence using ADP-Glo kinase assay kit (Promega, US). An inhibition effect on each enzyme was represented as a percentage of the luminescence value in the presence of the test compounds relative to the luminescence value without the test compounds. IC (nM) is the concentration of the compound to inhibit 50% of the enzyme activity. The results are shown in Table 1 below.
?Table 1? IC (nM) CDK1/cyclin CDK2/cyclinCDK4/cyclinDCDK5/p25 CDK6/cyclin B E D Example 1 1.5 1.5 854.5 2.4 >200 Example 8 2.1 2.1 107.8 0.22 47 Example 9 11.6 6.4 287.1 2.3 44.8 Example 10 3.6 2.6 202.6 1.2 >200 Example 12 12.6 6.6 >200 5.9 50.7 Example 17 30.8 9.4 >200 3.3 65.3 Example 18 26.8 10.7 >200 6.1 180.5 Example 19 19.6 14.6 >200 6.4 128.8 Example 21 6.1 4.5 402.8 1.5 73.6 Example 24 0.6 0.9 341.5 0.7 33.8 Example 31 2.3 0.59 35.9 3.13 61.5 Example 33 17.1 3.7 39.3 9.89 239.8 Example 34 2.1 2.2 31.5 2.2 176.3 Example 51 1.0 4.5 81.3 2.8 35.8 Example 52 0.7 14.6 63.7 1.9 59.6 Example 53 4.0 10.8 >200 2.8 86.8 Example 61 0.4 0.5 0.9 Example 66 0.6 1.0 0.3 Example 71 0.2 0.3 124.9 0.3 29.8 Example 104 1.3 1.6 15.2 0.8 54.1 From Table 1 above, it is shown that the compounds according to the present invention effectively inhibit the activity of a CDK enzyme. Further, it is also shown that the inhibition activity of the compounds according to the present invention is more selective for CDK1, CDK2, and CDK5.
Experimental Example 2 : Analysis for inhibition of cancer cell proliferation The following experiment was conducted to confirm whether the compounds according to the present invention inhibit a cancer cell proliferation and thus exhibit anticancer effect.
A test was conducted to confirm whether the compounds obtained in the above Examples can inhibit proliferation of human colon carcinoma cell line HCT116, glioblastoma cell lines U-87MG and T98G, neuroblastoma cell lines SH-SY5Y and SK-N-SH, and lung cancer cell lines A549 and NCI-H23.
HCT116, U-87MG, SH-SY5Y, SK-N-SH and A549 cells were culured in DMEM medium containing 10% FBS. T98G cells were cultured in MEM medium containing 10% FBS and NCI-H23 cells were cultured in RPMI1664 medium containing 10 % FBS. In order to analyze an inhibition of proliferation, HCT116 cells were dispensed in 2000 cells/well into 96 well plate, and SH-SY5Y, SK-N-SH, U-87MG, T98G, A549, and NCI-H23 cells were dispensed in 3000 cells/well into 96 well plate. And then, the cells were cultured at 5% CO and 37? for 16 hrs to allow the cells to attach to the wells. The compounds of the above Examples were added to each well at a concentration of 0.004, 0.013, 0.04, 0.12, 0.37, 1.1, 3.3, and 10 uM, and the culture volume was adjusted to 100ul. A control group was treated with dimethylsulfoxide (DMSO) at the same concentration, 0.08%, as used to treat the test compounds. Afterwards, cells were cultured at 5% CO and 37? for 72 hrs. And then, 10 ul of the solution of MTT (3- (4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide) dissolved in PBS at 5 mg/ml was added to each well to identify viable cells and the cells were cultured for further 2 hrs. The culture solution was removed, 100 ul of DMSO was added to dissolve the formed formazan and then an absorbance was measured at 535 nm. Based on the absorbance of the control cells not treated with the compounds, the amounts of the viable cells according to the concentration of the compounds were calculated. GI (growth inhibition 50) value which is the concentration of the compound to inhibit cancer cell proliferation by 50% was calculated using Graphpad Prism 5.0 program. The results are shown in Table 2 below.
?Table 2? GI (uM) HCT116 SH- SK-N-SH U-87 MG T98G A549 NCI-H23 Example 1 0.15 0.15 0.28 0.85 Example 3 1.15 0.88 1.43 2.64 Example 5 3.59 Example 6 2.30 Example 7 0.67 Example 8 0.01 0.01 0.01 0.06 0.19 Example 9 0.20 0.09 0.20 0.63 Example 10 0.26 0.11 0.24 0.38 Example 11 6.08 Example 12 0.23 0.24 0.42 0.79 1.83 Example 13 6.97 0.68 7.22 4.60 Example 14 0.59 0.54 1.04 3.41 Example 16 1.33 0.57 2.91 3.60 Example 17 0.61 0.29 0.84 1.70 Example 18 0.34 0.20 0.78 5.86 Example 19 0.46 0.12 0.21 0.44 2.61 Example 20 0.52 0.19 0.39 1.18 4.31 Example 21 0.14 0.11 0.31 0.89 Example 24 0.02 Example 25 0.29 Example 26 1.18 Example 27 0.29 Example 29 1.26 Example 30 0.72 Example 31 0.03 0.18 0.10 Example 32 0.03 0.10 0.11 0.08 0.19 Example 33 0.05 0.15 0.26 0.19 1.71 Example 34 0.02 0.03 0.15 0.04 0.07 Example 35 0.01 0.03 0.21 0.02 0.06 Example 36 0.01 0.01 0.02 0.02 0.05 Example 37 0.01 0.01 0.03 0.02 0.06 Example 38 0.002 0.004 0.02 0.005 0.02 Example 39 0.17 0.39 0.69 0.40 1.79 Example 40 0.01 0.02 0.05 0.01 0.03 Example 41 0.02 0.04 0.11 0.04 0.07 Example 42 0.18 0.27 0.40 0.38 0.89 Example 43 0.23 0.28 0.46 0.46 0.96 Example 44 0.06 0.09 0.13 0.14 0.33 Example 45 0.09 0.10 0.16 0.15 0.40 Example 46 0.14 0.15 0.25 0.21 0.41 Example 47 0.81 1.09 1.41 1.44 2.23 Example 48 2.91 3.82 Example 49 0.02 0.03 0.05 0.05 0.07 Example 50 0.04 0.07 0.13 0.15 0.16 Example 51 0.003 0.01 0.01 0.01 0.01 Example 52 0.01 0.02 0.03 Example 53 0.01 0.03 0.02 0.04 Example 55 0.05 0.11 0.13 0.16 0.18 Example 56 0.03 0.06 0.13 0.08 0.09 Example 57 0.02 0.02 0.06 0.04 0.04 Example 58 0.03 0.06 0.04 0.07 0.06 Example 59 0.04 0.07 0.11 0.07 0.13 Example 60 0.05 0.22 0.26 0.12 0.22 Example 61 0.09 0.21 0.43 Example 62 0.19 Example 63 0.19 Example 64 0.19 Example 65 0.39 Example 66 0.01 0.02 0.03 0.03 0.03 Example 67 0.01 0.01 0.02 0.09 Example 68 0.01 0.01 0.03 0.1 Example 69 0.08 0.004 0.02 0.09 Example 70 0.53 0.16 0.58 1.65 Example 71 0.01 0.01 0.06 0.02 0.04 Example 77 0.003 0.01 0.03 0.01 0.03 Example 78 0.04 Example 79 0.04 Example 80 0.14 Example 81 0.02 0.14 0.07 Example 82 0.02 0.17 0.09 Example 83 0.03 0.09 0.15 0.12 1.18 Example 84 0.06 0.18 0.29 0.22 2.03 Example 85 0.02 0.07 0.09 0.06 0.14 Example 86 0.01 0.03 0.19 0.02 0.05 Example 87 0.003 0.01 0.02 0.01 0.04 Example 88 0.04 0.01 0.02 0.02 0.04 Example 89 0.00 0.00 0.02 0.01 0.02 Example 90 0.04 0.10 0.19 0.11 0.39 Example 91 0.02 0.03 0.07 0.03 0.05 Example 92 0.02 0.03 0.09 0.03 0.05 Example 93 0.07 0.11 0.10 0.10 0.23 Example 94 0.15 0.32 0.48 0.23 0.52 Example 95 0.06 0.10 0.16 0.08 0.15 Example 96 0.06 0.08 0.19 0.13 0.21 Example 97 0.11 0.12 0.16 0.16 0.29 Example 98 0.89 0.97 1.75 1.30 2.06 Example 99 2.03 2.57 3.79 Example 100 0.03 0.06 0.05 0.07 0.07 Example 101 0.06 0.23 0.29 0.12 0.23 Example 102 0.01 0.03 0.02 0.04 0.03 Example 103 0.01 0.01 0.01 0.01 0.02 Example 104 0.03 0.07 0.05 0.08 0.08 Example 105 0.03 0.04 0.06 0.06 0.09 Example 106 0.06 0.09 0.14 0.82 0.17 As shown in Table 2 above, the compounds according to the present invention can effectively inhibit cancer cell proliferation. Since the compounds effectively inhibit neuroblastoma and glioblastoma as well as colon cancer cells and lung cancer cells, the compounds may be effectively used to treat brain tumor.
Experimental Example 3 : Analysis for the cell cycle change The following experiment was conducted to confirm whether the compounds according to the present invention arrest the cell cycle of a cancer cell in G2/M phase.
A human colon carcinoma cell line HCT116 and a human normal lung cell line MRC5 were cultured in DMEM medium containing 10% FBS. Each cultured cells were harvested, placed in 6 well plate at 1 X 10 cells/well, and cultured at 5% CO and 37? for 16 hrs. The compounds of the above Examples at 75 nM and 150 nM in DMEM containing 5% FBS were added to the cells in each well, and after 24 hrs a change in the cell cycle was analyzed using a flow cytometry. Media of treatment groups and a control group were removed, trypsin was added to isolate cells from the plates and the cells were centrifuged at 1000g for 3 min. The isolated cells were washed with a cold phosphate buffer (PBS) two times. Afterwards, 1 ml of 70% ethanol was added to the cells and the cells were maintained at 4 ? for 30 min or more to fix the cells. The fixed cells were centrifuged at 1000g for 3 min to remove ethanol, and washed with phosphate buffer (PBS) two times to remove ethanol completely. The washed cells were suspended in 250 ul of PBS, 6.25 ul of 10 mg/ml RNaseA was added to the suspension and reacted for 15 min at room temperature to degrade all RNA. 12.5 ul of 1 mg/ml propidium iodide (PI, sigma) was added to stain intracellular DNA. The cell cycles of 10,000 stained cells were measured using FACS calibur (Becton-Dickinson, USA) and cell numbers present in G1, S and G2/M phases were calculated as percentage using a cell cycle analysis program. Tables 3 and 4 show the results of cell cycle analysis for the compound obtained in Example 1 in cancer cells and normal cells, respectively.
?Table 3? Sub-G1 G1 S G2/M Polyploidy Control 1.5 54.0 8.0 26.8 10.1 Example 1 - 75 nM 4.9 22.3 5.3 51.5 16.3 Example 1 - 150 nM 5.8 4.3 2.6 54.4 23.3 ?Table 4? Sub-G1 G1 S G2/M Polyploidy Control 5.5 60.4 8.0 20.4 6.0 Example 1 - 75 nM 8.8 50.7 9.1 22.8 8.8 Example 1 - 150 nM 12.8 44.0 6.8 26.6 10.2 The above Tables 3 and 4 and Fig. 1 show that the compounds according to the present invention effectively arrest the cell cycle of a cancer cell in G2/M phase. In particular, while the compound at low concentration of 75 nM arrested the cell cycle of the colon carcinoma cell line HCT116 in G2/M phase, the normal cell line MRC5 showed the cell cycle similar to the control group even at 150 nM of the compound. Therefore, it is expected that the compounds according to the present invention may kill a cancer cell by arresting the cell cycle of the cancer cells in G2/M phase, but may not affect the cell cycle of a normal cell and thus be safe.
Experimental Example 4 : Analysis for tumor growth inhibition in an animal model The following experiment was conducted to confirm whether the compounds according to the present invention inhibit a tumor growth in an animal model injected with cancer cells.
Human colon carcinoma HCT116 cell line of 5 X 10 cells/0.1 ml (Matrigel : PBS = 6:4) was injected subcutaneously into the right flank of a Balb/c nude mouse. When a tumor grew to 220 mm , 5 mice were assigned for each group so that tumor sizes of all groups are consistent and a test compound was orally administered daily for 12 days. Tumor size was measured twice a week using Caliper. The test compound was the one obtained in Example 61 at 1 mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/kg. A vehicle control was 20% propylene glycol (PG) and a positive control was Xeloda at 100 mg/kg. Tumor size (volume) was calculated from the tumor length measured in each animal using the following Equation 1.
[Equation 1] Tumor volume = (length of major axis X length of minor axis )/2 Table 5 below and Fig. 2 show the actual tumor sizes measured over time and the tumor growth inhibition, TGI (%) based on the tumor size for each group compared to the vehicle control group.
?Table 5? Experime Tumor size (mm) tumor growth inhibition ntal group (%) 1 Vehicle control 1842.6 ± 302.4 0 2 Xeloda - 100 mpk 994.7 ± 405.5 46.0 3 Example 61 - 1 mpk 1082.4 ± 994.6 41.3 4 Example 61 - 3 mpk 773.7 ± 253.9 58.0 Example 61 - 10 mpk 647.4 ± 462.1 64.9 6 Example 61 - 30 mpk 403.4 ± 224.1 78.1 As shown in the above Table 5 and Fig. 2, after the end of administration, Xeloda at 100 mg/kg used as a positive control exhibited 46% tumor growth inhibition compared to the tumor size of the vehicle control. However, the compound of Example 61 at 1mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/k exhibited 41.3%, 58.0%, 64.9%, and 78.1% tumor growth inhibition, respectively, and therefore showed a superior tumor growth inhibition effect compared to Xeloda used as a positive control.
Accordingly, it is expected that the compounds according to the present invention may exhibit a superior anticancer effect against various cancers including colon cancer.
Experimental Example 5 : Analysis for tumor growth inhibition by combined administration in an animal model The following experiment was conducted to confirm whether the compounds according to the present invention exhibit synergistic anticancer effect by combined administration in an animal model injected with a tumor cell.
Human glioblastoma U-87MG cell line of 5 X 10 cells/0.1 ml PBS was injected subcutaneously into the right flank of a Balb/c nude mouse. When a tumor grew to 150 mm , 5 mice were assigned for each group so that tumor sizes of all groups are consistent and a test compound was orally administered daily. Tumor size was measured three times a week using Caliper. The test compound was the one obtained in Example 61 at 15 mg/kg and 30 mg/kg.
Temozolomide (TMZ) at 2.5 mg/kg as a positive control was orally administered daily for the first 5 days. Further, in order to analyze the effect of combined administration of TMZ and the compound of Example 61, a tumor growth inhibition test was conducted with the group of TMZ at 2.5 mg/kg combined with the compound of Example 61 at 15 mg/kg and the group of TMZ at 2.5 mg/kg combined with the compound of Example 61 at 30 mg/kg. For the combined administration, TMZ was orally administered daily for the first 5 days. For the single administration, the compound of Example 61 was orally administered daily for 30 days. For the combined administration, the compound of Example 61 was administered orally daily for 34 days. 20% propylene glycol (PG) was used as a vehicle control. Tumor size (volume) was calculated from the tumor length measured in each animal using the following Equation 1.
[Equation 1] Tumor volume = (length of major axis X length of minor axis )/2 Table 6 below and Fig. 3 show the actual tumor sizes measured over time and the tumor growth inhibition, TGI (%) based on the tumor size for each group compared to the vehicle control group.
?Table 6? Experimental Tumor size (mm)Tumor growth group inhibition (%) 1 Vehicle control 4211.7 ± 813.8 0.0 2 Temozolomide - 2.5 mpk 926.7 ± 604.4 78.0 3 Example 61 - 15 mpk 3503.3 ± 674.9 16.8 4 Example 61 - 30 mpk 2015.0 ± 1023 52.2 TMZ 2.5 mpk + Example 61 - 10 62.3 ± 74.6 98.5 6 TMZ 2.5 mpk + Example 61 - 30 5.0 ± 5.0 99.9 As shown in the above Table 6 and Fig. 3, the compound of Example 61 administered alone at 15 mg/kg and 30 mg/kg exhibited 16.8% and 52.2% tumor growth inhibition, respectively, compared to the tumor size of the vehicle control administered for 30 days.
Further, TMZ administered alone at 2.5 mg/kg appeared to diminish the tumor, but the tumor started to grow again after 23 days. The compound of Example 61 administered at 15 mg/kg in combination with TMZ diminished a tumor, but the tumor started to grow again after 32 days.
However, the compound of Example 61 administered at 30 mg/kg in combination with TMZ diminished the tumor and there was no tumor growth until 34 days. Thus, it is confirmed that the compound of Example 61 has an anticancer effect to inhibit tumor growth of glioblastoma.
Further, while temozolomide (TMZ) is used as a medication for treating glioblastoma, it is administered for 5 days only in 28 day cycle administration since its efficacy is weak and it exhibits severe side effects due to cytotoxicity. It is confirmed that the compound of Example 61 combined with TMZ has a synergistic tumor growth inhibitory effect and delays recurrence of cancer cells.
Accordingly, the compounds according to the present invention may be used in combination with various anticancer agents including a molecular targeted agent, a cytotoxic agent or a hormonal agent as well as in a single therapy. Also, it is expected that the compound will exhibit a superior anticancer effect in brain tumor treatment.
Experimental Example 6 : Analysis for blood brain barrier permeation The following experiment was conducted to confirm whether the compounds according to the present invention penetrate the blood brain barrier and migrate into a brain.
Using 9-week-old male ICR mice, the compounds obtained in the above Examples were orally administered once at a dose of 10 mg/kg or 30 mg/kg, and after 1 hr and 4 hrs, the concentrations of the compounds in the blood and brain of the mice were determined. 3 ICR mice were assigned in each group. Plasma was separated from the blood obtained after sacrificing the mice at each time, the brain of the mice was extracted, and the blood was washed with PBS, followed by pulverizing the brain tissue. The blood was placed in a test tube containing heparin to prevent coagulation and then was centrifuged at 12,000 rpm at 4 ? for 3 min to give a supernatant from which plasma was collected. Brain tissue was weighed, and the brain was pulverized using Dounce’s homogenizer after adding 3 times as much volume of PBS as the brain weight. Each of the obtained analytical samples was quantitatively analyzed using a tandem liquid chromatography-mass spectrometer (Tandem LC/MS/MS, API3000 & Agilent 1100 series). Brain permeability of a compound is expressed as a value obtained by dividing the concentration of the compound in the brain by the concentration of the compound in the plasma (B/P ratio), and when the B/P ratio is greater than 1, it means that the concentration in the brain is higher than the one in the blood.
Table 7 below shows B/P ratios for the representative compounds obtained in Examples.
?Table 7? 1 hr 4 hrs Concentration Concentraion B/P ratio Concentration Concentraion B/P in the brain in the plasma in the brain in the plasma ratio (ng/g) (ng/ml) (ng/g) (ng/ml) Example 8 144.4 94.3 1.53 70.9 29.4 2.41 - 30 mg/kg Example 12 71.1 17.3 4.10 9.1 2.6 3.54 - 10 mg/kg Example 10 128.7 82.6 1.56 23.2 8.3 2.78 - 30 mg/kg Example 61 296.4 283.0 1.05 90.3 86.5 1.04 - 10 mg/kg Example 67 55.1 24.9 2.21 15.5 3.9 3.97 - 10 mg/kg Example 61 768.0 278.1 2.76 577.2 128.6 4.49 - 30 mg/kg Example 66 80.5 32.9 2.44 58.9 20.1 2.93 - 10 mg/kg Example 71 3124.0 1380.0 2.26 165.3 52.1 3.18 - 10 mg/kg As shown in Table 7, the compounds according to the present invention exhibit B/P ratio greater than 1. Accordingly, it is confirmed that the compounds according to the present invention may penetrate into a brain through the blood-brain barrier (BBB) after orally adminstrated. Further, in consideration of that the concentrations of the compound in the brain decreases after 4 hrs, it is confirmed that the compounds in a brain do not accumulate but have clearance similar to that in blood.
Accordingly, it is expected that the compounds according to the present invention may penetrate into a brain through the BBB and thus exhibit superior effect in the treatment of brain tumor and degenerative brain diseases such as Alzheimer’s disease.
Experimental Example 7 : Analysis for inhibition of Tau phosphorylation Western blot experiments were carried out as follows to confirm whether the compounds according to the present invention can inhibit phosphorylation of tau protein.
SH-SY5Y cells expressing Tau protein were cultured in DMEM containing 10% FBS. 2.5 X 10 cells were placed in a 6-well plate and incubated at 5% CO and 37? for 16 hrs.
The compounds obtained in the above Examples serially diluted 1/3 from 3 uM to 0.5 nM or the compounds in a concentration of 0.3, 0.1, 0.03, 0.01, 0.003 uM were treated for 4 hrs in DMEM containing 5% FBS. After 4 hrs, the culture solution was removed, washed with PBS, and cells were lysed by adding 100 ul of lysis buffer. The lysis buffer consisted of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDT, 1 mM EGTA, 50 mM NaF, 1 mM PMSF, 1 mM Na VO , 2.5 mM DTT, 1% Triton X-100, and Protease inhibitor (Pierce). The lysed cells were centrifuged at 10,000 rpm and 4? for 10 min and the proteins in the supernatant were quantified. 25 ug of the proteins were electrophoresed on a SDS-PAGE gel and transferred to PVDF (Amersharm) membrane. The PVDF membrane was immersed in T-PBS containing 10% skim milk and shaken for 1 hr at room temperature. The primary antibody, Phosph-Tau[pSer202] (Abcam), diluted 1:1500 in T-PBS solution containing 5% skim milk was reacted with the membrane at room temperature for 2 hrs. The membrane was washed with T-PBS. The secondary antibody, Anti-rabbit IgG HRP, diluted 1:5000 was added to the membrane, reacted at room temperature for 1 hr, and washed. The results obtained by exposing the membrane to ECL (Amersharm) solution are shown in Table 8 below and Fig. 4.
?Table 8? Phosphorylation (%) Concentration 0.012 uM 0.037 uM 0.11 uM 0.33 uM 1 uM 3 uM Example 1 88 92 51 28 30 25 Example 10 101 84 60 39 11 13 Concentration 0.0005 0.0014 uM 0.0041 uM 0.012 uM 0.037 uM 0.11 uM Example 8 40 43 23 0 0 0 Concentration 0.003 uM 0.01 uM 0.03 uM 0.1 uM 0.3 uM Example 34 103 27 13 21 21 Example 71 110 101 35 26 ND As shown in Table 8 and Fig. 4, the compounds according to the present invention exhibited a superior inhibitory effect on the phosphorylation of tau protein.
Accordingly, it is expected that the compounds according to the present invention may inhibit the generation of NFT due to hyperphosphorylation of tau protein and thus will be effective in the prevention and treatment of Alzheimer’s disease caused by NFT.
Experimental Example 8 : Analysis for inhibition of APP phosphorylation and A ß generation The following experiment was conducted to confirm whether the compounds according to the present invention inhibit the phosphorylation of APP (amyloid precursor protein) to prevent A ß (amyloid ß protein) generation.
The APP gene was inserted into B103 cells so that APP could be stably expressed and the resulting B103/APP cells were used to confirm inhibition of APP phosphorylation and A ß generation.
To confirm the effect of APP phosphorylation inhibition by the compounds obtained in the above Examples, 8 X 10 B103/APP cells were cultured in a 6-well plate for 16 hrs in DMEM containing 500ug/ml of G418 and 5% FBS. The compounds serially diluted 1/3 from 3 uM to 0.5 nM or the compounds in a concentration of 0.1, 0.03, 0.01, 0.003, 0.001 uM were treated for 4 hrs in DMEM containing 5% FBS. After 4 hrs, the culture solution was removed, washed with PBS, and cells were lysed by adding 100 ul of lysis buffer. 25 ug of proteins were electrophoresed on SDS-Page gel and transferred to PVDF membrane and westerm blotting experiment was conducted in the same manner as Experimental Example 7. A primary antibody was Phospho-APP[pThr668] (cell signaling technology) diluted 1:1000, and a secondary antibody was Anti-rabbit IgG HRP diluted 1:5000. The results obtained by exposing the membrane to ECL solution are shown in Fig. 5.
Further, to confirm whether A ß generation is reduced due to APP phosphorylation inhibition, 5 X 10 B103/APP cells were cultured in a 6-well plate for 16 hrs. Afterwards, the compounds obtained in the above Examples were added at 100 nM, 75 nM, 50 nM, 25 nM, 12.5 nM to a medium containing 500ug/ml of G418 and 0.5% FBS and incubated for 72 hrs. After 72 hrs, the amount of A ß was quantified using the medium by Human A ß42 ELISA kit (Invitrogen). The results are shown in Table 9 below and Fig. 6.
?Table 9? Inhibition of A ß generation (%) Concentration 0 12.5 nM 25 nM 50 nM 75nM 100 nM Example 66 0 36.6 46.6 75.9 100.0 100.0 Example 71 0.0 37.6 36.2 46.7 76.8 100.0 As shown in Table 9 and Figs. 5 and 6, it was confirmed that the phosphorylation of Threonine 668 residue of APP was effectively inhibited by the compounds according to the present invention and accordingly the generation of A ß was inhibited. The compound according to the present invention will prevent the formation of amyloid plaques by inhibiting the phosphorylation of Threonine 668 residue of APP and accordingly inhibiting the generation of A ß.
Therefore, the compounds according to the present invention are expected to have superior efficacy in the prevention and treatment of Alzheimer’s disease by simultaneously inhibiting the formation of amyloid plaques and the generation of NFT which are the causes of Alzheimer’s disease.
Claims (11)
1. A compound of formula (I) or pharmaceutically acceptable salt thereof: wherein, X is nitrogen, Y and Z are carbon; R is phenyl, pyridine, or pyrimidine substituted or unsubstituted with one or more substituents selected from the group consisting of hydroxy, amino and halogen; R is hydrogen; and R is pyrimidine substituted or unsubstituted with one or more substituents selected from the group consisting of C -C alkyl, tetrahydropyranyl, piperidinyl substituted or unsubstituted with C -C alkyl, morpholino, piperazinyl substituted or unsubstituted with C -C alkyl, amino, 1 6 1 6 C -C alkylamino and halogen.
2. The compound according to claim 1 or pharmaceutically acceptable salt thereof selected from the group consisting of the following compounds: 2,6-bis(2-aminopyrimidinyl)pyridinol; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2-(2-aminopyrimidinyl)(4-hydroxyphenyl)pyridinol; 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]ol; 6-(2-aminopyrimidinyl)-[2,3'-bipyridin]ol; 6-(2-aminopyrimidinyl)-[2,4'-bipyridin]ol; 2-(2-aminopyrimidinyl)(3-hydroxyphenyl)pyridinol; 6-(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 6-(4-aminofluorophenyl)(2-aminopyrimidinyl)pyridinol; 6-(3-aminophenyl)(2-aminopyrimidinyl)pyridinol; 2-(2-aminopyrimidinyl)(2-fluorohydroxyphenyl)pyridinol; 6-(3-aminofluorophenyl)(2-aminopyrimidinyl)pyridinol; 2-(2-aminopyrimidinyl)(3-fluorohydroxyphenyl)pyridinol; 2-(2-aminopyrimidinyl)(2,3-difluorohydroxyphenyl)pyridinol; AH26(26554062_1):RTK 137 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]-3',5-diol; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 6-(2-aminomethylpyrimidinyl)-[2,4'-bipyridin]ol; 6-(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2-(2-aminomethylpyrimidinyl)(4-hydroxyphenyl)pyridinol; 2-(2-aminomethylpyrimidinyl)(2,3-difluorohydroxyphenyl)pyridinol; 2-(2-aminomethylpyrimidinyl)(2-fluorohydroxyphenyl)pyridinol; 2-(2-aminomethylpyrimidinyl)(3-aminophenyl)pyridinol; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(tetrahydro-2H-pyranyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(piperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin] 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin] 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-ethylpiperidinyl)methylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; AH26(26554062_1):RTK 138 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol; 2'-amino(2-aminoethyl(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-amino(1-isopropylpiperidinyl)propylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol; 2'-amino(2-aminomorpholinopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(dimethylamino)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-amino(4-methylpiperazinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol; 6-(2-aminochloropyrimidinyl)-[2,4'-bipyridin]ol; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-aminoethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-aminopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2'-amino-3'-fluoro(2-(methylamino)(1-methylpiperidinyl)pyrimidinyl)-[2,4'- bipyridin]ol; 2'-amino(2-amino-5,6-dimethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol; 2,6-bis(2-aminopyrimidinyl)pyridinol 3hydrochloride; 2,6-bis(2-aminopyrimidinyl)pyridinol oxalate; 2,6-bis(2-aminopyrimidinyl)pyridinol malonate; 2,6-bis(2-aminopyrimidinyl)pyridinol sulfate; 2'-amino(2-aminopyrimidinyl)-[2,4'-bipyridin]ol oxalate; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol oxalate; 2'-amino(2-aminopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 2malonate; 2-(2-aminopyrimidinyl)(2-fluorohydroxyphenyl)pyridinol 2hydrochloride; AH26(26554062_1):RTK 139 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminomorpholinopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomorpholinopyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate; 2'-amino(2-amino(dimethylamino)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-amino(4-methylpiperazinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol 5hydrochloride; 2'-amino(2-amino(4-methylpiperazinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol acetate; 2'-amino(2-amino-(6-(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol 4hydrochloride; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol 2acetate; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol oxalate; 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol malonate; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 2acetate; 2'-amino(2-amino(piperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-amino(piperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol acetate; 2'-amino(2-amino(tetrahydro-2H-pyranyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 3hydrochloride; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin] ol 4hydrochloride; 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; AH26(26554062_1):RTK 140 2'-amino(2-amino(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol 4hydrochloride; 2'-amino(2-amino(1-ethylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin] ol 4hydrochloride; 2'-amino(2-amino(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'-bipyridin]- 5-ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-ethylpiperidinyl)methylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-methylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethyl(1-propylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; 2'-amino(2-amino(1-isopropylpiperidinyl)methylpyrimidinyl)-3'-fluoro- [2,4'-bipyridin]ol 4hydrochloride; 2'-amino(2-aminomethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-amino-5,6-dimethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoethylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoisopropylpyrimidinyl)-3'-fluoro-[2,4'-bipyridin]ol 3hydrochloride; 2'-amino(2-aminoethyl(1-isopropylpiperidinyl)pyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; AH26(26554062_1):RTK 141 2'-amino(2-amino(1-isopropylpiperidinyl)propylpyrimidinyl)-3'-fluoro-[2,4'- bipyridin]ol 4hydrochloride; and pharmaceutically acceptable salts thereof.
3. A pharmaceutical composition comprising the compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
4. Use of the compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting a cyclin-dependent kinase (CDK).
5. Use of the compound according to claim 1 or 2, or a phamaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing cancer.
6. The use according to claim 5, wherein the cancer is acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM), Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, small cell lung cancer, gastric cancer, pancreas cancer, glioma, colon cancer, breast cancer, head and neck squamous cell cancer, liver cancer, melanoma, uterine cancer, prostate cancer, ovarian cancer, thyroid cancer, biliary tract cancer, gallbladder cancer, bladder cancer, kidney cancer, or esophageal cancer.
7. Use of the compound according to claim 1 or 2, or a phamaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing a degenerative brain disease.
8. The use according to claim 7, wherein the degenerative brain disease is Alzheimer’s disease, Huntington’s chorea or Parkinson’s disease.
9. The use according to claim 4, wherein the medicament is formulated for administration in combination with one or more anticancer agents selected from the group consisting of capecitabine, 5-fluorouracil, thioguanine, chlorambucil, oxaliplatin, cisplatin, carboplatin, paclitaxel, docetaxel, irinotecan, doxorubicin, vinorelbin, gemcitabine, pemetrexed, etoposide, vincristine, citarabine, cyclophosphamide, iphosphamide, tamoxifen, anastrozole, retrozole, exemestane, fulvestrant, temozolomide, camustine, lomustine, epirubicine, eribulin, toremifene, goserelin, megestrol, vinblastine, bendamustine, thiotepa, bleomycin, topotecan, leucovorin, AH26(26554062_1):RTK 142 trifluridine, tipiracil, mitomycin C, aldesleukin, temsirolimus, everolimus, mitoxantrone, mecloretamine, methotrexate, trastuzumab, bevacizumab, cetuximab, aflibercept, pertuzumab, ramucirumab, panitumumab, nivolumab, necitumumab, pembrolizumab, obinutuzumab, ofatumumab, erlotinib, gefitinib, sorafenib, lapatinib, palbociclib, regorafenib, imatinib, sunitinib, axitinib, pazopanib, apatinib, ceritinib, crizotinib, osimertinib, bosutinib, dasatinib, nilotinib, ponatinib, hydroxyurea, and procarbazine.
10. The use according to claim 4, wherein the medicament is formulated for administration in combination with one or more drugs for treating a degenerative brain disease selected from the group consisting of levodopa, bromocriptine, ropinirole, pramipexole, rotigotine, trihexyphenidyl, benztropine, procyclidine, entacapone, selegiline, rasagiline, amantadine, tetrabenazine, donepezil, rivastigmine, galantamine and memantine.
11. The use according to claim 4, wherein the medicament is formulated for administration in combination with temozolomide. Beyondbio Inc. By the Attorneys for the Applicant SPRUSON & FERGUSON AH26(26554062_1):RTK 143 ?
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150017339 | 2015-02-04 | ||
PCT/KR2016/001133 WO2016126085A2 (en) | 2015-02-04 | 2016-02-02 | Heterocyclic compound and pharmaceutical composition comprising same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ734084A NZ734084A (en) | 2023-09-29 |
NZ734084B2 true NZ734084B2 (en) | 2024-01-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200190062A1 (en) | Heterocyclic compound and pharmaceutical composition comprising same | |
CA2401241C (en) | 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | |
CA2981530A1 (en) | Substituted quinazoline compounds and methods of use thereof | |
WO2013173254A1 (en) | Bicyclic compounds as kinases inhibitors | |
CN113330009B (en) | Azacyclic compounds, preparation method and application thereof | |
CN110770234B (en) | Substituted aryl ether compound, preparation method thereof, medicinal composition and application thereof | |
CN114163457A (en) | Pyrimido five-membered nitrogen heterocyclic compound and use thereof | |
AU2016333505A1 (en) | New imidazo(4,5-B)pyridine derivatives as dual DYRK1/CLK1 inhibitors | |
ES2709003T3 (en) | 5- (pyridin-2-yl-amino) -pyrazine-2-carbonitrile compounds and their therapeutic use | |
EP3459953B1 (en) | Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative | |
NZ734084B2 (en) | Heterocyclic compound and pharmaceutical composition comprising same | |
CN114555597B (en) | Isocitrate Dehydrogenase (IDH) inhibitors | |
KR20220153581A (en) | Inhibitors of ULK1/2 and methods of use thereof | |
CN111377906B (en) | Substituted pyrazine compounds, their preparation and use | |
KR102333854B1 (en) | Novel pyridinyltriazine derivatives as protein kinase inhibitors and compositions for preventing, improving or treating cancer containing the same | |
EP4332106A1 (en) | Novel compound as protein kinase inhibitor | |
OA18645A (en) | New imidazo[4,5-b]pyridine derivatives as dual DYRK1/CLK1 inhibitors. | |
OA18535A (en) | Heteroramatic Compounds and their use as Dopamine D1 Ligands. |